data_1q71_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1q71 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.32 0 CA-C-O 120.488 -0.062 . . . . 0.0 113.117 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.62 -138.33 4.34 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.183 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.446 ' HA ' ' HB2' ' A' ' 19' ' ' PHE . . . -145.94 141.94 28.25 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.591 0.234 . . . . 0.0 110.415 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.422 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.25 -127.52 1.41 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 121.014 -0.612 . . . . 0.0 111.932 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.462 ' H ' ' C ' ' A' ' 21' ' ' GLY . 45.3 m80 -116.88 -37.16 3.66 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.604 0.24 . . . . 0.0 110.762 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.7 t -88.45 120.18 70.32 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.302 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.07 139.14 45.83 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 122.954 2.436 . . . . 0.0 113.236 -179.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -95.34 -75.57 0.52 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.601 179.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.404 ' O ' ' HA ' ' A' ' 16' ' ' PRO . 27.6 m-85 -107.41 140.58 40.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.073 0.463 . . . . 0.0 111.831 -178.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.431 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.5 m-85 -115.8 147.7 40.69 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.239 -0.891 . . . . 0.0 109.053 178.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.629 HG13 HD11 ' A' ' 17' ' ' ILE . 29.9 m -86.64 -167.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 C-N-CA 120.992 -0.283 . . . . 0.0 110.92 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -57.56 -42.18 93.91 Favored Glycine 0 C--O 1.227 -0.329 0 C-N-CA 121.387 -0.435 . . . . 0.0 113.64 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 17.6 pt -86.75 32.65 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 120.932 0.396 . . . . 0.0 111.964 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.59 29.13 31.45 Favored Glycine 0 CA--C 1.519 0.33 0 CA-C-N 115.666 -0.697 . . . . 0.0 114.051 178.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.434 ' O ' HG23 ' A' ' 11' ' ' VAL . 18.9 m -102.57 120.21 53.68 Favored Pre-proline 0 C--N 1.321 -0.671 0 CA-C-N 117.003 0.401 . . . . 0.0 110.497 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 72.8 Cg_endo -80.2 124.64 5.49 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.269 1.98 . . . . 0.0 112.691 -179.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.629 HD11 HG13 ' A' ' 11' ' ' VAL . 13.0 mt -116.15 39.33 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 122.333 1.063 . . . . 0.0 108.894 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 p -175.92 146.48 0.71 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.451 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.446 ' HB2' ' HA ' ' A' ' 3' ' ' ALA . 56.4 m-85 -131.54 -172.7 2.92 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 10.6 t80 -122.71 -62.66 1.34 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.55 0.691 . . . . 0.0 110.197 -179.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.462 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.442 -0.904 0 CA-C-N 114.596 -1.184 . . . . 0.0 110.233 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.286 0 N-CA-C 113.221 0.048 . . . . 0.0 113.221 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.35 -137.03 3.91 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.112 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.9 138.76 25.8 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.333 -0.247 . . . . 0.0 110.333 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.656 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 173.71 -127.54 1.36 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.255 -179.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -118.64 -37.75 3.23 Favored 'General case' 0 C--N 1.328 -0.363 0 O-C-N 122.827 -0.219 . . . . 0.0 111.248 -179.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.5 t -88.14 115.22 62.49 Favored Pre-proline 0 C--O 1.222 -0.345 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 -179.306 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.718 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 34.8 Cg_exo -62.57 137.55 64.96 Favored 'Trans proline' 0 N--CA 1.473 0.28 0 C-N-CA 123.423 2.749 . . . . 0.0 114.165 -178.692 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.0 mt-10 -97.13 -72.11 0.65 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.257 178.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 27.8 m-85 -116.62 142.53 46.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.667 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -110.73 149.04 31.06 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.84 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 26.9 m -82.87 -167.41 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.688 179.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.78 -42.01 96.25 Favored Glycine 0 C--O 1.227 -0.322 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.588 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.42 HG23 HD11 ' A' ' 13' ' ' ILE . 18.2 pt -87.5 33.83 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.638 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.08 31.28 32.92 Favored Glycine 0 CA--C 1.519 0.335 0 CA-C-N 115.71 -0.677 . . . . 0.0 114.174 178.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 18.0 m -104.77 125.76 33.0 Favored Pre-proline 0 C--N 1.322 -0.588 0 O-C-N 122.539 -0.389 . . . . 0.0 110.135 179.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.718 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 31.3 Cg_endo -65.07 125.77 15.24 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.4 2.067 . . . . 0.0 112.226 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.416 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -115.98 29.09 2.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 122.508 1.147 . . . . 0.0 109.581 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.8 p 179.68 150.08 0.33 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 114.249 -1.341 . . . . 0.0 109.725 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.656 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 14.1 m-85 -140.31 171.38 14.23 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -90.78 -56.41 3.19 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.48 0.657 . . . . 0.0 110.349 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.256 1.492 0 CA-C-O 117.56 -1.689 . . . . 0.0 110.001 -179.841 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.38 0 N-CA-C 113.59 0.196 . . . . 0.0 113.59 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -108.27 -134.68 7.34 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.655 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.38 47.89 1.28 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.031 0.443 . . . . 0.0 111.16 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.622 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . -80.41 -126.06 0.64 Allowed Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.931 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 61.6 m80 -111.47 -44.83 3.46 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -178.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.586 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.8 m -89.42 122.92 67.99 Favored Pre-proline 0 C--O 1.221 -0.431 0 CA-C-O 120.744 0.307 . . . . 0.0 110.962 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.614 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 40.1 Cg_exo -58.27 139.55 90.95 Favored 'Trans proline' 0 N--CA 1.474 0.379 0 C-N-CA 123.32 2.68 . . . . 0.0 114.449 -178.312 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.429 ' HG3' ' C ' ' A' ' 19' ' ' PHE . 94.7 mt-10 -95.26 -72.28 0.63 Allowed 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.675 179.078 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -108.17 144.91 34.94 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.541 -179.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.509 ' CZ ' ' HB2' ' A' ' 7' ' ' PRO . 4.7 m-85 -123.72 141.74 51.73 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.205 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 12' ' ' GLY . 43.8 t -78.2 155.12 5.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.493 ' N ' HG12 ' A' ' 11' ' ' VAL . . . -50.99 -30.52 23.08 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.496 -0.383 . . . . 0.0 113.494 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.2 pt -84.41 30.53 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.847 0.356 . . . . 0.0 111.898 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 55.8 50.09 62.82 Favored Glycine 0 CA--C 1.519 0.283 0 CA-C-N 115.926 -0.579 . . . . 0.0 113.64 178.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.417 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 15.2 m -133.85 118.0 14.18 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 117.142 0.471 . . . . 0.0 111.311 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.614 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 4.6 Cg_exo -77.05 130.97 11.62 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.988 2.459 . . . . 0.0 111.719 179.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.568 HD13 ' H ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -123.88 33.61 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.541 0.686 . . . . 0.0 111.055 179.979 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 p 179.83 152.92 0.47 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.463 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.622 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 8.5 m-85 -144.48 166.92 23.76 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.586 ' HB2' HG23 ' A' ' 6' ' ' VAL . 97.2 m-85 -90.06 -115.72 0.07 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.102 0 CA-C-O 118.123 -1.376 . . . . 0.0 110.633 178.245 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.226 0 CA-C-O 120.555 -0.025 . . . . 0.0 113.077 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.49 -139.14 4.57 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.976 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.62 140.35 30.09 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.649 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.64 -128.94 1.51 Allowed Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.077 -179.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 62.7 m80 -114.65 -43.11 3.18 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 111.59 0.219 . . . . 0.0 111.59 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.605 HG22 ' HB2' ' A' ' 20' ' ' TYR . 3.5 m -89.89 117.82 68.42 Favored Pre-proline 0 C--O 1.223 -0.296 0 CA-C-O 120.825 0.345 . . . . 0.0 110.757 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.445 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 26.8 Cg_exo -63.61 139.61 70.71 Favored 'Trans proline' 0 CA--C 1.53 0.296 0 C-N-CA 123.506 2.804 . . . . 0.0 114.236 -178.301 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.421 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 93.2 mt-10 -91.67 -72.41 0.59 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.425 178.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -112.67 139.93 47.87 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.266 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.522 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 4.5 m-85 -111.41 143.82 41.61 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.192 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.485 HG21 HG22 ' A' ' 17' ' ' ILE . 45.9 t -85.43 151.12 3.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 178.373 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.484 ' N ' HG11 ' A' ' 11' ' ' VAL . . . -53.58 -24.53 24.91 Favored Glycine 0 C--O 1.226 -0.404 0 C-N-CA 121.499 -0.381 . . . . 0.0 113.539 -179.493 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.3 mt -82.22 32.61 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-O 121.182 0.515 . . . . 0.0 111.092 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.0 47.55 54.06 Favored Glycine 0 CA--C 1.52 0.368 0 CA-C-N 115.699 -0.682 . . . . 0.0 114.237 178.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.2 t -150.62 129.58 6.27 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 117.359 0.58 . . . . 0.0 111.43 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 85.5 Cg_endo -85.64 131.63 4.0 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.918 2.412 . . . . 0.0 112.493 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.485 HG22 HG21 ' A' ' 11' ' ' VAL . 34.8 pt -115.47 35.92 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.355 0.598 . . . . 0.0 110.959 179.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.5 p -176.2 148.66 0.8 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.189 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.649 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 11.9 m-85 -141.34 172.13 13.11 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.605 ' HB2' HG22 ' A' ' 6' ' ' VAL . 93.7 m-85 -95.02 -56.79 2.63 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.554 0.692 . . . . 0.0 110.008 179.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -1.006 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.869 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.261 0 CA-C-O 120.313 -0.159 . . . . 0.0 113.305 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.15 -118.0 1.04 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.446 -179.303 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.52 145.09 45.58 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.632 0.253 . . . . 0.0 110.528 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.27 -131.82 1.67 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 121.033 -0.603 . . . . 0.0 111.632 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -123.18 -48.5 1.98 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.069 0.435 . . . . 0.0 110.457 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.473 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 41.8 t -89.96 130.04 44.01 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.253 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.47 ' HD2' HG11 ' A' ' 6' ' ' VAL . 19.6 Cg_endo -60.74 137.98 76.54 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 123.154 2.569 . . . . 0.0 113.798 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.744 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 90.9 mt-10 -89.09 -73.95 0.49 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.622 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -124.43 143.29 50.71 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.022 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.562 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.0 OUTLIER -104.9 148.39 26.73 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.552 179.167 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.448 HG21 ' O ' ' A' ' 15' ' ' THR . 35.9 m -92.46 178.87 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 116.561 -0.29 . . . . 0.0 110.543 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -60.28 -26.2 63.6 Favored Glycine 0 N--CA 1.453 -0.218 0 CA-C-N 116.087 -0.506 . . . . 0.0 113.54 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 9.6 mm -84.06 31.48 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.064 0.459 . . . . 0.0 110.958 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 46.0 43.39 12.84 Favored Glycine 0 N--CA 1.46 0.297 0 CA-C-N 115.575 -0.739 . . . . 0.0 113.782 179.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.448 ' O ' HG21 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -143.23 135.39 13.23 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-O 120.795 0.331 . . . . 0.0 111.287 -179.261 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.562 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 71.7 Cg_endo -84.49 127.35 3.79 Favored 'Trans proline' 0 N--CA 1.454 -0.818 0 C-N-CA 122.562 2.174 . . . . 0.0 112.322 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.6 mt -115.77 39.97 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 122.216 1.007 . . . . 0.0 108.857 179.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.9 p -171.58 144.58 1.91 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.841 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -147.32 173.42 12.61 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.744 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -153.61 169.64 22.76 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.216 0.532 . . . . 0.0 111.398 178.741 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.949 0 CA-C-N 114.648 -1.16 . . . . 0.0 112.529 -179.963 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.244 0 CA-C-O 120.541 -0.033 . . . . 0.0 113.074 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.9 -138.33 4.46 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.988 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.34 140.78 32.22 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.68 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.11 -132.86 2.37 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.459 -179.152 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.468 ' H ' ' C ' ' A' ' 21' ' ' GLY . 23.8 m170 -109.23 -47.34 3.43 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.571 0.224 . . . . 0.0 111.352 -178.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.539 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.45 120.72 69.66 Favored Pre-proline 0 C--O 1.225 -0.233 0 CA-C-O 120.804 0.335 . . . . 0.0 111.206 -179.218 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.556 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 24.7 Cg_exo -64.17 138.98 64.24 Favored 'Trans proline' 0 CA--C 1.529 0.247 0 C-N-CA 123.601 2.868 . . . . 0.0 114.288 -178.584 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.433 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 94.4 mt-10 -91.63 -68.93 0.76 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.568 178.054 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -128.54 142.74 50.97 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.998 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.529 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.5 m-85 -98.07 150.13 21.74 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.369 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 9.1 p -88.89 165.41 2.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.206 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -55.85 -24.21 40.65 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 121.568 -0.348 . . . . 0.0 113.854 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.0 mt -82.41 33.32 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 120.938 0.399 . . . . 0.0 111.333 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 47.5 43.11 20.38 Favored Glycine 0 CA--C 1.521 0.426 0 CA-C-N 115.827 -0.624 . . . . 0.0 114.027 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.92 140.73 15.28 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.902 0.351 . . . . 0.0 111.045 -179.472 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.556 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 35.6 Cg_endo -66.28 126.38 15.57 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.29 1.993 . . . . 0.0 111.824 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.43 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -114.53 31.07 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 122.243 1.021 . . . . 0.0 110.027 -179.606 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 25.2 p 179.63 149.13 0.29 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.12 179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.68 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 11.3 m-85 -142.72 172.0 13.28 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.539 ' HB2' HG23 ' A' ' 6' ' ' VAL . 93.6 m-85 -95.6 -58.35 2.14 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.363 0.601 . . . . 0.0 110.42 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.468 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.253 1.316 0 CA-C-O 117.414 -1.77 . . . . 0.0 110.064 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.301 0 N-CA-C 113.214 0.045 . . . . 0.0 113.214 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.28 -139.29 4.49 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.005 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.91 140.01 29.49 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.651 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.43 -129.24 1.57 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.054 -179.245 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 62.8 m80 -114.6 -43.03 3.2 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.481 0.178 . . . . 0.0 111.481 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.616 HG21 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.71 117.31 68.02 Favored Pre-proline 0 C--N 1.33 -0.274 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.826 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.451 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 24.6 Cg_exo -64.09 140.44 71.93 Favored 'Trans proline' 0 CA--C 1.529 0.271 0 C-N-CA 123.518 2.812 . . . . 0.0 114.258 -178.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.427 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 94.2 mt-10 -91.91 -70.93 0.67 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.447 178.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -116.19 142.4 46.87 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.551 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.52 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 3.7 m-85 -114.06 145.41 41.63 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.405 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.458 ' HB ' HG21 ' A' ' 15' ' ' THR . 42.3 t -82.94 152.92 3.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -54.41 -23.65 27.66 Favored Glycine 0 C--O 1.226 -0.347 0 C-N-CA 121.383 -0.437 . . . . 0.0 113.245 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.2 mt -83.11 32.26 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 CA-C-O 121.209 0.528 . . . . 0.0 111.091 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 51.93 50.14 45.74 Favored Glycine 0 CA--C 1.52 0.348 0 CA-C-N 115.632 -0.713 . . . . 0.0 114.323 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.458 HG21 ' HB ' ' A' ' 11' ' ' VAL . 8.2 t -150.54 129.44 6.23 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 117.437 0.619 . . . . 0.0 111.345 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.52 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 71.7 Cg_endo -80.26 134.8 10.45 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.807 2.338 . . . . 0.0 112.629 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.0 pp -119.14 33.19 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.254 0.549 . . . . 0.0 111.547 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 p -179.22 150.76 0.46 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.094 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.651 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.3 m-85 -140.78 172.17 13.08 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.476 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.616 ' HB2' HG21 ' A' ' 6' ' ' VAL . 95.2 m-85 -95.61 -56.68 2.61 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.509 0.671 . . . . 0.0 110.086 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.978 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.87 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.257 0 CA-C-O 120.475 -0.07 . . . . 0.0 113.108 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.95 -136.15 3.71 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.965 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -144.6 140.75 28.94 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 179.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.685 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.33 -132.67 2.45 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.668 -179.156 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.482 ' H ' ' C ' ' A' ' 21' ' ' GLY . 20.4 m170 -110.03 -43.74 3.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.534 0.207 . . . . 0.0 111.352 -178.703 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 40.7 t -88.2 118.96 70.15 Favored Pre-proline 0 C--O 1.223 -0.334 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.728 -178.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.495 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 31.8 Cg_endo -64.41 138.23 59.29 Favored 'Trans proline' 0 CA--C 1.528 0.225 0 C-N-CA 123.208 2.606 . . . . 0.0 114.234 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.4 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 92.2 mt-10 -95.67 -71.66 0.66 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.516 -0.766 . . . . 0.0 110.372 178.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -117.9 142.35 47.43 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.687 -179.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.455 ' C ' HG21 ' A' ' 11' ' ' VAL . 2.8 m-85 -111.95 136.94 50.61 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.455 HG21 ' C ' ' A' ' 10' ' ' PHE . 43.4 t -145.33 137.69 20.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 120.966 0.412 . . . . 0.0 110.932 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.475 ' O ' HG21 ' A' ' 13' ' ' ILE . . . 111.69 -68.4 0.23 Allowed Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.133 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.475 HG21 ' O ' ' A' ' 12' ' ' GLY . 5.3 pt -156.16 46.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 114.78 -0.71 . . . . 0.0 109.736 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.38 18.23 79.98 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -178.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.431 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 0.7 OUTLIER -89.41 125.81 60.41 Favored Pre-proline 0 N--CA 1.447 -0.595 0 CA-C-N 115.113 -0.544 . . . . 0.0 110.623 179.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.495 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 17.9 Cg_exo -66.66 125.64 14.14 Favored 'Trans proline' 0 N--CA 1.463 -0.28 0 C-N-CA 122.778 2.319 . . . . 0.0 112.33 -179.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.411 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -118.34 27.88 3.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 122.714 1.245 . . . . 0.0 109.376 179.343 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.4 p 179.57 150.28 0.33 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 113.899 -1.5 . . . . 0.0 109.475 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.685 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.5 m-85 -142.18 172.22 12.99 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.4 ' CZ ' ' HG2' ' A' ' 8' ' ' GLU . 93.6 m-85 -92.82 -59.46 2.05 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.461 0.648 . . . . 0.0 110.444 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.482 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.253 1.328 0 CA-C-O 117.244 -1.864 . . . . 0.0 109.987 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.281 0 N-CA-C 112.969 -0.052 . . . . 0.0 112.969 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.93 -141.95 5.62 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.93 -0.652 . . . . 0.0 111.714 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.73 46.24 1.02 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.133 0.492 . . . . 0.0 111.095 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.584 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . -81.83 -127.33 0.94 Allowed Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.668 -0.696 . . . . 0.0 112.815 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.1 m-70 -114.31 -43.37 3.21 Favored 'General case' 0 C--N 1.327 -0.402 0 O-C-N 122.444 -0.445 . . . . 0.0 111.89 -178.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.413 ' CG1' ' HB2' ' A' ' 20' ' ' TYR . 2.4 p -89.37 124.76 63.71 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 120.788 0.328 . . . . 0.0 110.682 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.475 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 50.8 Cg_exo -56.36 138.8 85.1 Favored 'Trans proline' 0 N--CA 1.474 0.367 0 C-N-CA 123.53 2.82 . . . . 0.0 114.467 -178.341 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 89.8 mt-10 -98.5 -72.88 0.64 Allowed 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.55 178.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -118.84 140.8 49.37 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.085 -179.432 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.429 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 5.0 m-85 -108.74 145.68 34.72 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.389 -0.823 . . . . 0.0 108.973 179.295 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.0 p -165.44 151.06 2.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.172 0.511 . . . . 0.0 111.435 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.453 ' O ' HG21 ' A' ' 13' ' ' ILE . . . 101.22 -62.17 0.57 Allowed Glycine 0 CA--C 1.505 -0.553 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.678 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.453 HG21 ' O ' ' A' ' 12' ' ' GLY . 5.1 pt -155.75 41.7 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 114.828 -0.686 . . . . 0.0 109.71 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.51 13.18 82.02 Favored Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.645 -179.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.8 p -89.66 129.89 45.21 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.688 -0.256 . . . . 0.0 110.88 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.475 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 56.2 Cg_endo -74.14 122.51 7.65 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.238 1.959 . . . . 0.0 112.069 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 16.9 mm -113.51 37.19 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 122.182 0.991 . . . . 0.0 109.028 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 25.1 p 179.85 148.25 0.28 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.566 -1.197 . . . . 0.0 109.789 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.584 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 9.1 m-85 -141.04 167.53 21.96 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.413 ' HB2' ' CG1' ' A' ' 6' ' ' VAL . 94.1 m-85 -84.37 -114.54 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.453 0 CA-C-O 117.998 -1.445 . . . . 0.0 111.023 178.857 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.338 0 CA-C-O 120.437 -0.091 . . . . 0.0 113.247 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.66 -137.08 4.15 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.144 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.85 140.12 26.82 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.663 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.53 -128.23 1.51 Allowed Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.344 -179.255 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -115.06 -40.63 3.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.672 0.236 . . . . 0.0 111.493 -178.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.8 t -88.54 115.75 64.27 Favored Pre-proline 0 C--O 1.221 -0.401 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -64.25 140.03 68.87 Favored 'Trans proline' 0 CA--C 1.532 0.388 0 C-N-CA 123.208 2.605 . . . . 0.0 114.133 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -97.36 -74.4 0.57 Allowed 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.689 179.095 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.0 m-85 -105.3 142.6 34.79 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.457 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.48 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 5.8 m-85 -120.45 143.01 48.73 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.402 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.668 HG23 HD11 ' A' ' 17' ' ' ILE . 38.4 t -84.18 153.77 3.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -52.32 -28.02 26.24 Favored Glycine 0 C--O 1.228 -0.252 0 C-N-CA 121.551 -0.357 . . . . 0.0 113.683 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.668 HG13 HG21 ' A' ' 15' ' ' THR . 24.9 pt -82.94 31.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 55.25 52.62 46.15 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 114.926 0.73 . . . . 0.0 114.926 177.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.668 HG21 HG13 ' A' ' 13' ' ' ILE . 9.5 t -150.71 129.24 6.06 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 117.703 0.752 . . . . 0.0 111.198 179.089 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.48 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 85.5 Cg_endo -85.46 130.44 3.86 Favored 'Trans proline' 0 N--CA 1.459 -0.501 0 C-N-CA 122.803 2.336 . . . . 0.0 112.704 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.722 HD13 ' H ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -112.95 33.26 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.457 0.646 . . . . 0.0 110.932 179.839 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.6 p -176.98 150.24 0.75 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.157 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.663 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 15.9 m-85 -141.18 173.0 11.91 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -91.05 -56.67 3.08 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.396 0.617 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.343 0 CA-C-O 117.648 -1.64 . . . . 0.0 110.144 -179.792 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.41 0 N-CA-C 113.347 0.099 . . . . 0.0 113.347 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.59 -143.14 7.57 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.869 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.4 48.4 1.56 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.134 0.492 . . . . 0.0 110.865 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.75 -124.5 0.38 Allowed Glycine 0 CA--C 1.519 0.306 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.41 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 67.8 m80 -121.87 -43.84 2.34 Favored 'General case' 0 C--N 1.328 -0.364 0 O-C-N 122.457 -0.437 . . . . 0.0 111.596 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.4 t -88.94 128.79 50.73 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -57.7 136.43 75.52 Favored 'Trans proline' 0 CA--C 1.529 0.256 0 C-N-CA 123.186 2.591 . . . . 0.0 113.677 -178.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.636 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 94.1 mt-10 -93.4 -73.81 0.55 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.523 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -124.27 142.02 51.6 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.926 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.546 ' O ' HG13 ' A' ' 11' ' ' VAL . 2.5 m-85 -107.24 136.95 46.2 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.306 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.546 HG13 ' O ' ' A' ' 10' ' ' PHE . 3.5 m -153.64 -177.48 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.687 179.824 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.59 -50.38 2.5 Favored Glycine 0 C--O 1.227 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 113.01 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.411 HG13 ' O ' ' A' ' 13' ' ' ILE . 10.9 tp -170.91 37.75 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-O 122.364 1.078 . . . . 0.0 109.419 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.09 13.41 83.38 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.674 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.0 t -96.81 136.6 21.58 Favored Pre-proline 0 C--N 1.325 -0.461 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -71.35 122.88 9.07 Favored 'Trans proline' 0 N--CA 1.462 -0.34 0 C-N-CA 122.289 1.993 . . . . 0.0 112.272 -179.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.404 ' O ' HG22 ' A' ' 17' ' ' ILE . 20.9 mm -114.42 37.85 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 122.298 1.047 . . . . 0.0 108.834 179.343 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 17.1 p -179.65 145.77 0.24 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.446 -1.252 . . . . 0.0 109.702 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -147.01 166.94 25.3 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.328 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.636 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -145.87 170.6 16.26 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.292 178.013 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.141 0 CA-C-O 118.552 -1.138 . . . . 0.0 111.963 -179.466 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.404 0 N-CA-C 113.382 0.113 . . . . 0.0 113.382 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.7 -142.8 7.34 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.845 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.68 48.34 1.53 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.169 0.509 . . . . 0.0 110.755 179.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.69 -124.34 0.37 Allowed Glycine 0 N--CA 1.451 -0.329 0 CA-C-N 115.553 -0.749 . . . . 0.0 112.391 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 67.4 m80 -122.33 -43.58 2.3 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 122.515 -0.403 . . . . 0.0 111.509 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.7 t -89.0 127.95 53.79 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.714 -0.221 . . . . 0.0 110.405 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.456 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 52.7 Cg_exo -56.17 136.03 73.07 Favored 'Trans proline' 0 CA--C 1.53 0.287 0 C-N-CA 123.229 2.619 . . . . 0.0 113.717 -179.065 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.634 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 94.1 mt-10 -93.72 -74.25 0.54 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.626 179.265 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -122.78 141.03 52.26 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.846 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.549 ' O ' HG13 ' A' ' 11' ' ' VAL . 2.2 m-85 -108.06 136.52 47.61 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.431 179.407 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.549 HG13 ' O ' ' A' ' 10' ' ' PHE . 3.6 m -153.83 -178.3 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 O-C-N 123.282 0.364 . . . . 0.0 110.555 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.92 -50.39 2.62 Favored Glycine 0 C--N 1.332 0.306 0 CA-C-N 116.076 -0.511 . . . . 0.0 113.053 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.403 HG12 ' O ' ' A' ' 13' ' ' ILE . 15.3 tt -170.99 38.31 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-O 122.349 1.071 . . . . 0.0 109.353 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.32 14.13 82.85 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.098 -0.955 . . . . 0.0 112.687 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.0 t -97.31 135.82 21.66 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.456 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 50.8 Cg_endo -72.1 123.5 9.3 Favored 'Trans proline' 0 N--CA 1.46 -0.463 0 C-N-CA 122.19 1.926 . . . . 0.0 112.404 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 20.8 mm -113.06 37.35 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 122.276 1.036 . . . . 0.0 108.754 179.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 p -179.89 146.37 0.24 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 114.365 -1.289 . . . . 0.0 109.612 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -146.95 166.45 26.74 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.259 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.634 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -145.04 170.67 15.74 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.421 178.054 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.242 0.625 0 CA-C-O 119.019 -0.879 . . . . 0.0 111.951 -179.574 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.435 0 CA-C-O 120.272 -0.182 . . . . 0.0 113.553 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -122.81 -127.15 3.25 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.865 -179.151 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -134.86 143.33 46.94 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.665 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 176.43 -133.94 2.45 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.34 -179.346 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.455 ' H ' ' C ' ' A' ' 21' ' ' GLY . 23.7 m170 -109.31 -46.92 3.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.664 0.268 . . . . 0.0 111.201 -178.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.446 HG22 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.49 122.54 68.25 Favored Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.187 -179.232 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.18 139.98 69.02 Favored 'Trans proline' 0 N--CA 1.472 0.243 0 C-N-CA 123.427 2.751 . . . . 0.0 114.312 -178.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.401 ' HG3' ' C ' ' A' ' 19' ' ' PHE . 92.6 mt-10 -92.47 -71.3 0.65 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.347 178.603 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 53.1 m-85 -128.43 142.64 51.04 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.598 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.573 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.2 m-85 -98.23 149.91 22.08 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.053 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.559 ' CG1' HG23 ' A' ' 13' ' ' ILE . 6.6 p -87.96 172.62 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.643 179.201 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.94 41.37 0.71 Allowed Glycine 0 C--O 1.229 -0.203 0 N-CA-C 115.056 0.782 . . . . 0.0 115.056 -178.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.57 HG22 HG22 ' A' ' 15' ' ' THR . 10.7 tp -154.21 28.99 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-O 122.169 0.985 . . . . 0.0 110.441 178.291 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 60.04 43.76 97.91 Favored Glycine 0 CA--C 1.521 0.411 0 CA-C-N 114.673 -1.149 . . . . 0.0 115.141 177.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.57 HG22 HG22 ' A' ' 13' ' ' ILE . 15.1 t -151.27 137.03 10.9 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-N 117.726 0.763 . . . . 0.0 110.435 178.571 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.573 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 72.3 Cg_endo -77.71 127.01 8.5 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.725 2.283 . . . . 0.0 112.921 -179.069 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 17.6 mm -114.28 38.03 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 122.016 0.912 . . . . 0.0 108.964 179.246 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.7 p -177.96 147.73 0.48 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.029 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.665 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.8 m-85 -144.34 171.85 13.76 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.446 ' HB2' HG22 ' A' ' 6' ' ' VAL . 90.5 m-85 -96.08 -58.82 1.98 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.303 0.573 . . . . 0.0 110.626 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.455 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.252 1.252 0 CA-C-O 117.459 -1.745 . . . . 0.0 110.003 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.332 0 CA-C-O 120.221 -0.211 . . . . 0.0 113.403 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -139.57 -120.97 1.82 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.717 -179.273 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -126.07 143.81 50.97 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.712 ' HA3' ' O ' ' A' ' 20' ' ' TYR . . . -179.99 -125.45 0.96 Allowed Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.551 -179.438 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -118.99 -57.54 2.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.85 0.325 . . . . 0.0 111.575 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.517 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 47.3 t -88.6 128.84 51.2 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-O 120.888 0.375 . . . . 0.0 110.345 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -61.01 140.91 92.59 Favored 'Trans proline' 0 CA--C 1.53 0.285 0 C-N-CA 123.523 2.815 . . . . 0.0 114.495 -178.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.755 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.2 mt-10 -91.14 -70.83 0.66 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.205 178.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 42.9 m-85 -124.48 144.47 50.08 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.901 -179.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.565 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.0 OUTLIER -107.88 149.48 28.23 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.823 179.645 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.467 HG22 ' O ' ' A' ' 15' ' ' THR . 27.2 m -92.66 175.53 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.2 178.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.35 -21.79 60.32 Favored Glycine 0 C--O 1.228 -0.247 0 CA-C-N 116.09 -0.505 . . . . 0.0 113.436 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.402 ' H ' HG21 ' A' ' 11' ' ' VAL . 4.7 mt -83.02 28.92 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 121.185 0.517 . . . . 0.0 111.328 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 49.28 44.38 34.77 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 115.559 -0.746 . . . . 0.0 114.162 178.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.467 ' O ' HG22 ' A' ' 11' ' ' VAL . 7.8 t -150.67 140.42 13.84 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 117.115 0.457 . . . . 0.0 110.849 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.565 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 51.3 Cg_endo -70.18 140.53 41.32 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.79 2.327 . . . . 0.0 112.194 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.7 tt -123.44 30.29 2.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 122.302 1.048 . . . . 0.0 109.713 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.1 p -179.15 151.48 0.5 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.479 -1.237 . . . . 0.0 110.071 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.477 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 10.3 m-85 -146.26 171.35 15.1 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.165 -0.679 . . . . 0.0 109.165 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.755 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.2 OUTLIER -139.99 -120.91 0.12 Allowed 'General case' 0 C--N 1.325 -0.483 0 O-C-N 123.045 0.216 . . . . 0.0 110.698 178.78 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.422 ' N ' ' HD1' ' A' ' 20' ' ' TYR . . . . . . . . 0 C--O 1.245 0.811 0 CA-C-O 118.516 -1.158 . . . . 0.0 112.569 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.289 0 CA-C-O 120.573 -0.015 . . . . 0.0 113.133 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 178.9 -137.59 3.26 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.063 -0.589 . . . . 0.0 111.776 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.75 137.77 25.36 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.629 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.45 -129.24 1.57 Allowed Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.369 -179.293 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 15.1 m-70 -118.57 -36.53 3.48 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.572 0.186 . . . . 0.0 111.204 -179.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.7 t -88.1 117.04 67.97 Favored Pre-proline 0 C--N 1.33 -0.26 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 -179.281 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -62.68 134.66 48.47 Favored 'Trans proline' 0 N--CA 1.471 0.189 0 C-N-CA 123.2 2.6 . . . . 0.0 113.845 -178.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -90.62 -72.24 0.58 Allowed 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.667 178.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -128.36 144.47 51.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.856 -179.61 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.473 ' O ' HG22 ' A' ' 11' ' ' VAL . 1.7 m-85 -109.56 135.03 51.21 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 179.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.546 ' HB ' HD11 ' A' ' 17' ' ' ILE . 66.9 t -147.76 145.5 18.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.963 0.411 . . . . 0.0 111.159 -179.411 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.73 -60.82 0.74 Allowed Glycine 0 CA--C 1.503 -0.683 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.906 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 8.2 pt -152.31 40.07 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-O 121.15 0.5 . . . . 0.0 110.445 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.06 23.85 74.53 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.262 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.8 t -102.64 133.73 20.3 Favored Pre-proline 0 C--N 1.325 -0.479 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -76.73 116.7 4.32 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.233 1.955 . . . . 0.0 112.751 -178.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.755 HD13 ' H ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -103.2 30.23 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 121.964 0.888 . . . . 0.0 109.72 179.047 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 p -175.88 146.77 0.74 Allowed 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 114.353 -1.294 . . . . 0.0 109.9 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.629 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 22.6 m-85 -136.97 173.24 11.91 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -91.45 -56.72 3.02 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.358 0.599 . . . . 0.0 110.417 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.414 0 CA-C-O 117.564 -1.687 . . . . 0.0 110.092 -179.714 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.235 0 N-CA-C 113.755 0.262 . . . . 0.0 113.755 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 164.7 -137.82 4.93 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.178 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -130.66 141.94 50.43 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 179.142 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.75 -127.62 1.13 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.101 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 35.3 m170 -125.94 -43.66 1.82 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.553 0.216 . . . . 0.0 111.1 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.22 127.45 55.22 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -63.0 137.3 61.4 Favored 'Trans proline' 0 CA--C 1.529 0.246 0 C-N-CA 123.017 2.478 . . . . 0.0 113.807 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.599 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.2 mt-10 -89.67 -73.25 0.52 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.885 179.271 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -121.93 143.66 49.33 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.158 -179.211 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.409 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 3.3 m-85 -110.88 149.01 31.22 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.706 179.442 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.7 m -83.84 -167.56 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.589 179.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.65 -41.36 95.66 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 121.251 -0.499 . . . . 0.0 113.506 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 18.8 pt -87.67 33.27 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.27 32.47 36.78 Favored Glycine 0 CA--C 1.52 0.352 0 CA-C-N 115.71 -0.677 . . . . 0.0 114.224 178.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.1 m -105.5 121.61 45.55 Favored Pre-proline 0 C--N 1.322 -0.622 0 O-C-N 122.476 -0.426 . . . . 0.0 110.361 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.409 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 56.2 Cg_endo -73.05 125.54 10.45 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.338 2.025 . . . . 0.0 112.373 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 pt -113.79 34.29 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.45 0.643 . . . . 0.0 110.444 179.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.0 p -179.71 147.96 0.31 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.749 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -144.29 174.37 10.96 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 -179.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.599 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -159.82 -160.54 0.82 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.083 178.557 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.046 0 CA-C-O 117.706 -1.608 . . . . 0.0 110.981 179.718 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 113.723 0.249 . . . . 0.0 113.723 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.92 -118.54 1.02 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.376 -0.916 . . . . 0.0 112.833 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.4 144.2 46.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.813 0.34 . . . . 0.0 110.559 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.46 -122.9 0.8 Allowed Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.892 -179.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -137.21 -43.19 0.56 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.661 0.267 . . . . 0.0 110.645 179.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.21 127.36 55.57 Favored Pre-proline 0 C--N 1.328 -0.353 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -62.7 135.99 55.55 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.979 2.453 . . . . 0.0 113.988 -178.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.592 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 90.0 mt-10 -91.43 -75.87 0.46 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.246 178.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 27.9 m-85 -110.25 141.66 42.91 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.133 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.527 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 6.5 m-85 -110.34 143.94 39.81 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.684 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 40.7 t -85.78 152.08 3.62 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -54.49 -23.27 26.91 Favored Glycine 0 CA--C 1.52 0.359 0 C-N-CA 121.409 -0.424 . . . . 0.0 113.389 -179.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.416 HG21 HD12 ' A' ' 13' ' ' ILE . 10.0 mm -82.64 32.32 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-O 121.379 0.609 . . . . 0.0 110.942 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.3 46.55 57.27 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 115.613 -0.721 . . . . 0.0 114.334 178.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.407 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 6.2 t -150.52 133.84 8.75 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 117.381 0.591 . . . . 0.0 111.23 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 11.2 Cg_exo -70.57 142.37 44.18 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 123.021 2.48 . . . . 0.0 111.821 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.421 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.4 tp -124.25 29.94 2.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 122.26 1.029 . . . . 0.0 110.178 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.406 ' OG ' ' HB2' ' A' ' 8' ' ' GLU . 9.8 p 179.63 149.9 0.32 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.703 179.619 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -144.97 172.24 13.32 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.731 0.301 . . . . 0.0 110.316 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.592 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -160.1 -161.52 0.89 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.652 -0.703 . . . . 0.0 109.859 178.542 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 117.718 -1.601 . . . . 0.0 111.031 179.664 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.263 0 N-CA-C 113.419 0.128 . . . . 0.0 113.419 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 162.68 -137.35 4.77 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.063 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -140.01 141.22 36.34 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.125 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.566 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 175.79 -120.5 0.76 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.413 -179.14 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -126.3 -41.41 1.9 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 42.6 t -88.33 120.53 70.49 Favored Pre-proline 0 C--O 1.22 -0.474 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.266 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -61.32 132.98 43.8 Favored 'Trans proline' 0 CA--C 1.53 0.312 0 C-N-CA 122.892 2.395 . . . . 0.0 113.901 -178.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.535 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 91.4 mt-10 -92.57 -74.91 0.5 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.185 178.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -117.59 143.55 46.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.103 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -107.23 146.93 30.81 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.241 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.475 HG13 HG21 ' A' ' 13' ' ' ILE . 9.1 p -79.81 165.13 2.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.29 178.811 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.7 41.34 0.54 Allowed Glycine 0 CA--C 1.518 0.254 0 N-CA-C 114.763 0.665 . . . . 0.0 114.763 -178.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.475 HG21 HG13 ' A' ' 11' ' ' VAL . 13.0 tt -157.46 28.27 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-O 122.09 0.947 . . . . 0.0 110.192 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.22 53.4 44.94 Favored Glycine 0 CA--C 1.519 0.312 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.727 178.3 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.428 ' HB ' HG11 ' A' ' 11' ' ' VAL . 27.8 m -148.94 126.53 5.65 Favored Pre-proline 0 C--N 1.323 -0.574 0 O-C-N 122.39 -0.476 . . . . 0.0 110.391 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 11.5 Cg_exo -70.17 126.38 12.98 Favored 'Trans proline' 0 N--CA 1.465 -0.205 0 C-N-CA 122.408 2.072 . . . . 0.0 111.752 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.3 pt -115.58 31.95 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.52 0.676 . . . . 0.0 110.655 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 11.2 p 179.23 148.31 0.23 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.825 -1.079 . . . . 0.0 109.543 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.566 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 3.7 m-85 -147.43 164.19 34.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.688 0.28 . . . . 0.0 110.736 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.55 ' O ' ' HA3' ' A' ' 4' ' ' GLY . 29.4 m-85 -97.25 163.89 12.72 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.429 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.15 0 CA-C-O 117.751 -1.583 . . . . 0.0 110.998 179.105 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . 0.439 ' N ' ' HB2' ' A' ' 18' ' ' SER . . . . . . . . 0 CA--C 1.52 0.388 0 N-CA-C 113.918 0.327 . . . . 0.0 113.918 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -120.38 -134.51 4.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.317 -0.944 . . . . 0.0 113.084 -179.097 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -132.99 52.63 2.07 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.093 0.473 . . . . 0.0 110.776 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -76.08 -121.96 0.16 Allowed Glycine 0 CA--C 1.519 0.317 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.633 179.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 44.9 m170 -122.15 -51.7 1.99 Allowed 'General case' 0 C--N 1.326 -0.448 0 O-C-N 122.465 -0.432 . . . . 0.0 111.296 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.448 HG23 ' CE1' ' A' ' 20' ' ' TYR . 4.4 m -89.63 132.88 35.57 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 110.194 -0.299 . . . . 0.0 110.194 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_endo -58.03 139.34 90.08 Favored 'Trans proline' 0 CA--C 1.53 0.314 0 C-N-CA 123.513 2.809 . . . . 0.0 114.484 -178.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.519 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.7 mt-10 -92.64 -69.97 0.72 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.065 178.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -121.82 144.43 48.83 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.292 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.453 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 4.6 m-85 -111.28 145.95 37.87 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.48 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 42.7 t -76.62 153.69 5.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 177.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -52.28 -26.6 21.93 Favored Glycine 0 C--O 1.227 -0.333 0 C-N-CA 121.485 -0.388 . . . . 0.0 113.763 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.0 mt -84.32 31.19 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 CA-C-O 121.283 0.563 . . . . 0.0 111.19 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 53.53 51.45 47.97 Favored Glycine 0 CA--C 1.521 0.428 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.842 178.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 26.9 m -144.62 123.74 7.0 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 122.332 -0.511 . . . . 0.0 111.048 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 39.9 Cg_endo -67.89 136.71 39.27 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.485 2.123 . . . . 0.0 111.916 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.41 HG12 ' O ' ' A' ' 17' ' ' ILE . 15.3 tt -129.93 34.07 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 122.227 1.013 . . . . 0.0 110.42 -179.528 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.439 ' HB2' ' N ' ' A' ' 1' ' ' GLY . 13.1 p 179.76 149.44 0.31 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.825 -1.08 . . . . 0.0 109.637 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -147.58 165.9 28.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.708 0.29 . . . . 0.0 110.386 -179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.519 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -158.24 -149.08 0.21 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.189 178.818 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.811 0 CA-C-O 118.68 -1.067 . . . . 0.0 110.668 179.883 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 CA-C-O 120.235 -0.203 . . . . 0.0 113.592 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.5 -120.54 1.49 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.81 -179.178 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.44 145.75 44.98 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.692 0.282 . . . . 0.0 110.62 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.21 -124.48 0.86 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.005 -179.651 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 70.5 m80 -133.29 -47.91 0.84 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.447 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 2.5 p -89.47 128.34 51.35 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.863 179.175 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.459 ' HB3' ' HG3' ' A' ' 16' ' ' PRO . 37.8 Cg_exo -58.77 137.89 82.6 Favored 'Trans proline' 0 N--CA 1.473 0.301 0 C-N-CA 123.443 2.762 . . . . 0.0 113.968 -178.37 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.445 ' HG2' ' CD1' ' A' ' 20' ' ' TYR . 91.8 mt-10 -89.73 -73.32 0.52 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.475 178.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -125.35 135.58 52.59 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.672 -179.704 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.551 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.7 m-85 -91.19 156.28 17.97 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.458 178.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.575 HG22 ' H ' ' A' ' 13' ' ' ILE . 35.1 m -120.38 -175.57 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 120.748 0.309 . . . . 0.0 110.854 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.05 -18.58 64.85 Favored Glycine 0 C--O 1.227 -0.305 0 CA-C-N 116.03 -0.532 . . . . 0.0 113.404 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.575 ' H ' HG22 ' A' ' 11' ' ' VAL . 6.0 mt -84.14 19.27 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.542 0.687 . . . . 0.0 111.022 -179.637 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.89 -44.03 0.82 Allowed Glycine 0 CA--C 1.521 0.42 0 CA-C-N 115.396 -0.82 . . . . 0.0 113.852 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.431 ' O ' HG23 ' A' ' 11' ' ' VAL . 10.0 t -88.47 137.58 30.53 Favored Pre-proline 0 C--N 1.32 -0.712 0 CA-C-O 121.097 0.475 . . . . 0.0 111.226 -179.012 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.551 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 59.7 Cg_endo -72.65 140.68 33.02 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.891 2.394 . . . . 0.0 111.971 179.83 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.443 HD13 HG21 ' A' ' 17' ' ' ILE . 13.2 mt -108.24 38.21 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 122.213 1.006 . . . . 0.0 109.173 179.416 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.8 p -167.9 143.82 3.93 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.381 179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -147.15 174.16 11.84 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.453 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.445 ' CD1' ' HG2' ' A' ' 8' ' ' GLU . 20.6 p90 -158.75 -159.84 0.82 Allowed 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.076 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.899 0 CA-C-O 118.637 -1.09 . . . . 0.0 111.035 179.833 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.32 0 CA-C-O 120.488 -0.062 . . . . 0.0 113.117 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.62 -138.33 4.34 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.183 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.446 ' HA ' ' HB2' ' A' ' 19' ' ' PHE . . . -145.94 141.94 28.25 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.591 0.234 . . . . 0.0 110.415 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.422 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.25 -127.52 1.41 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 121.014 -0.612 . . . . 0.0 111.932 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.462 ' H ' ' C ' ' A' ' 21' ' ' GLY . 45.3 m80 -116.88 -37.16 3.66 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.604 0.24 . . . . 0.0 110.762 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.7 t -88.45 120.18 70.32 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.302 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.07 139.14 45.83 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 122.954 2.436 . . . . 0.0 113.236 -179.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -95.34 -75.57 0.52 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.601 179.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.404 ' O ' ' HA ' ' A' ' 16' ' ' PRO . 27.6 m-85 -107.41 140.58 40.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.073 0.463 . . . . 0.0 111.831 -178.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.431 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.5 m-85 -115.8 147.7 40.69 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.239 -0.891 . . . . 0.0 109.053 178.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.629 HG13 HD11 ' A' ' 17' ' ' ILE . 29.9 m -86.64 -167.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 C-N-CA 120.992 -0.283 . . . . 0.0 110.92 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -57.56 -42.18 93.91 Favored Glycine 0 C--O 1.227 -0.329 0 C-N-CA 121.387 -0.435 . . . . 0.0 113.64 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 17.6 pt -86.75 32.65 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 120.932 0.396 . . . . 0.0 111.964 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.59 29.13 31.45 Favored Glycine 0 CA--C 1.519 0.33 0 CA-C-N 115.666 -0.697 . . . . 0.0 114.051 178.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.434 ' O ' HG23 ' A' ' 11' ' ' VAL . 18.9 m -102.57 120.21 53.68 Favored Pre-proline 0 C--N 1.321 -0.671 0 CA-C-N 117.003 0.401 . . . . 0.0 110.497 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 72.8 Cg_endo -80.2 124.64 5.49 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.269 1.98 . . . . 0.0 112.691 -179.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.629 HD11 HG13 ' A' ' 11' ' ' VAL . 13.0 mt -116.15 39.33 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 122.333 1.063 . . . . 0.0 108.894 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 p -175.92 146.48 0.71 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.451 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.446 ' HB2' ' HA ' ' A' ' 3' ' ' ALA . 56.4 m-85 -131.54 -172.7 2.92 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 10.6 t80 -122.71 -62.66 1.34 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.55 0.691 . . . . 0.0 110.197 -179.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.462 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.442 -0.904 0 CA-C-N 114.596 -1.184 . . . . 0.0 110.233 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.286 0 N-CA-C 113.221 0.048 . . . . 0.0 113.221 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.35 -137.03 3.91 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.112 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.9 138.76 25.8 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.333 -0.247 . . . . 0.0 110.333 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.656 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 173.71 -127.54 1.36 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.255 -179.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -118.64 -37.75 3.23 Favored 'General case' 0 C--N 1.328 -0.363 0 O-C-N 122.827 -0.219 . . . . 0.0 111.248 -179.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.5 t -88.14 115.22 62.49 Favored Pre-proline 0 C--O 1.222 -0.345 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 -179.306 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.718 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 34.8 Cg_exo -62.57 137.55 64.96 Favored 'Trans proline' 0 N--CA 1.473 0.28 0 C-N-CA 123.423 2.749 . . . . 0.0 114.165 -178.692 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.0 mt-10 -97.13 -72.11 0.65 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.257 178.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 27.8 m-85 -116.62 142.53 46.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.667 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -110.73 149.04 31.06 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.84 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 26.9 m -82.87 -167.41 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.688 179.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.78 -42.01 96.25 Favored Glycine 0 C--O 1.227 -0.322 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.588 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.42 HG23 HD11 ' A' ' 13' ' ' ILE . 18.2 pt -87.5 33.83 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.638 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.08 31.28 32.92 Favored Glycine 0 CA--C 1.519 0.335 0 CA-C-N 115.71 -0.677 . . . . 0.0 114.174 178.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 18.0 m -104.77 125.76 33.0 Favored Pre-proline 0 C--N 1.322 -0.588 0 O-C-N 122.539 -0.389 . . . . 0.0 110.135 179.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.718 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 31.3 Cg_endo -65.07 125.77 15.24 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.4 2.067 . . . . 0.0 112.226 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.416 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -115.98 29.09 2.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 122.508 1.147 . . . . 0.0 109.581 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.8 p 179.68 150.08 0.33 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 114.249 -1.341 . . . . 0.0 109.725 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.656 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 14.1 m-85 -140.31 171.38 14.23 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -90.78 -56.41 3.19 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.48 0.657 . . . . 0.0 110.349 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.256 1.492 0 CA-C-O 117.56 -1.689 . . . . 0.0 110.001 -179.841 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.38 0 N-CA-C 113.59 0.196 . . . . 0.0 113.59 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -108.27 -134.68 7.34 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.655 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.38 47.89 1.28 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.031 0.443 . . . . 0.0 111.16 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.622 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . -80.41 -126.06 0.64 Allowed Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.931 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 61.6 m80 -111.47 -44.83 3.46 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -178.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.586 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.8 m -89.42 122.92 67.99 Favored Pre-proline 0 C--O 1.221 -0.431 0 CA-C-O 120.744 0.307 . . . . 0.0 110.962 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.614 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 40.1 Cg_exo -58.27 139.55 90.95 Favored 'Trans proline' 0 N--CA 1.474 0.379 0 C-N-CA 123.32 2.68 . . . . 0.0 114.449 -178.312 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.429 ' HG3' ' C ' ' A' ' 19' ' ' PHE . 94.7 mt-10 -95.26 -72.28 0.63 Allowed 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.675 179.078 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -108.17 144.91 34.94 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.541 -179.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.509 ' CZ ' ' HB2' ' A' ' 7' ' ' PRO . 4.7 m-85 -123.72 141.74 51.73 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.205 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 12' ' ' GLY . 43.8 t -78.2 155.12 5.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.493 ' N ' HG12 ' A' ' 11' ' ' VAL . . . -50.99 -30.52 23.08 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.496 -0.383 . . . . 0.0 113.494 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.2 pt -84.41 30.53 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.847 0.356 . . . . 0.0 111.898 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 55.8 50.09 62.82 Favored Glycine 0 CA--C 1.519 0.283 0 CA-C-N 115.926 -0.579 . . . . 0.0 113.64 178.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.417 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 15.2 m -133.85 118.0 14.18 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 117.142 0.471 . . . . 0.0 111.311 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.614 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 4.6 Cg_exo -77.05 130.97 11.62 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.988 2.459 . . . . 0.0 111.719 179.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.568 HD13 ' H ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -123.88 33.61 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.541 0.686 . . . . 0.0 111.055 179.979 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 p 179.83 152.92 0.47 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.463 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.622 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 8.5 m-85 -144.48 166.92 23.76 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.586 ' HB2' HG23 ' A' ' 6' ' ' VAL . 97.2 m-85 -90.06 -115.72 0.07 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.102 0 CA-C-O 118.123 -1.376 . . . . 0.0 110.633 178.245 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.226 0 CA-C-O 120.555 -0.025 . . . . 0.0 113.077 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.49 -139.14 4.57 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.976 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.62 140.35 30.09 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.649 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.64 -128.94 1.51 Allowed Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.077 -179.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 62.7 m80 -114.65 -43.11 3.18 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 111.59 0.219 . . . . 0.0 111.59 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.605 HG22 ' HB2' ' A' ' 20' ' ' TYR . 3.5 m -89.89 117.82 68.42 Favored Pre-proline 0 C--O 1.223 -0.296 0 CA-C-O 120.825 0.345 . . . . 0.0 110.757 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.445 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 26.8 Cg_exo -63.61 139.61 70.71 Favored 'Trans proline' 0 CA--C 1.53 0.296 0 C-N-CA 123.506 2.804 . . . . 0.0 114.236 -178.301 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.421 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 93.2 mt-10 -91.67 -72.41 0.59 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.425 178.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -112.67 139.93 47.87 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.266 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.522 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 4.5 m-85 -111.41 143.82 41.61 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.192 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.485 HG21 HG22 ' A' ' 17' ' ' ILE . 45.9 t -85.43 151.12 3.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 178.373 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.484 ' N ' HG11 ' A' ' 11' ' ' VAL . . . -53.58 -24.53 24.91 Favored Glycine 0 C--O 1.226 -0.404 0 C-N-CA 121.499 -0.381 . . . . 0.0 113.539 -179.493 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.3 mt -82.22 32.61 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-O 121.182 0.515 . . . . 0.0 111.092 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.0 47.55 54.06 Favored Glycine 0 CA--C 1.52 0.368 0 CA-C-N 115.699 -0.682 . . . . 0.0 114.237 178.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.2 t -150.62 129.58 6.27 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 117.359 0.58 . . . . 0.0 111.43 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 85.5 Cg_endo -85.64 131.63 4.0 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.918 2.412 . . . . 0.0 112.493 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.485 HG22 HG21 ' A' ' 11' ' ' VAL . 34.8 pt -115.47 35.92 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.355 0.598 . . . . 0.0 110.959 179.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.5 p -176.2 148.66 0.8 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.189 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.649 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 11.9 m-85 -141.34 172.13 13.11 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.605 ' HB2' HG22 ' A' ' 6' ' ' VAL . 93.7 m-85 -95.02 -56.79 2.63 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.554 0.692 . . . . 0.0 110.008 179.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -1.006 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.869 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.261 0 CA-C-O 120.313 -0.159 . . . . 0.0 113.305 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.15 -118.0 1.04 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.446 -179.303 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.52 145.09 45.58 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.632 0.253 . . . . 0.0 110.528 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.27 -131.82 1.67 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 121.033 -0.603 . . . . 0.0 111.632 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -123.18 -48.5 1.98 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.069 0.435 . . . . 0.0 110.457 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.473 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 41.8 t -89.96 130.04 44.01 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.253 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.47 ' HD2' HG11 ' A' ' 6' ' ' VAL . 19.6 Cg_endo -60.74 137.98 76.54 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 123.154 2.569 . . . . 0.0 113.798 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.744 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 90.9 mt-10 -89.09 -73.95 0.49 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.622 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -124.43 143.29 50.71 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.022 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.562 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.0 OUTLIER -104.9 148.39 26.73 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.552 179.167 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.448 HG21 ' O ' ' A' ' 15' ' ' THR . 35.9 m -92.46 178.87 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 116.561 -0.29 . . . . 0.0 110.543 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -60.28 -26.2 63.6 Favored Glycine 0 N--CA 1.453 -0.218 0 CA-C-N 116.087 -0.506 . . . . 0.0 113.54 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 9.6 mm -84.06 31.48 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.064 0.459 . . . . 0.0 110.958 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 46.0 43.39 12.84 Favored Glycine 0 N--CA 1.46 0.297 0 CA-C-N 115.575 -0.739 . . . . 0.0 113.782 179.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.448 ' O ' HG21 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -143.23 135.39 13.23 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-O 120.795 0.331 . . . . 0.0 111.287 -179.261 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.562 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 71.7 Cg_endo -84.49 127.35 3.79 Favored 'Trans proline' 0 N--CA 1.454 -0.818 0 C-N-CA 122.562 2.174 . . . . 0.0 112.322 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.6 mt -115.77 39.97 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 122.216 1.007 . . . . 0.0 108.857 179.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.9 p -171.58 144.58 1.91 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.841 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -147.32 173.42 12.61 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.744 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -153.61 169.64 22.76 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.216 0.532 . . . . 0.0 111.398 178.741 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.949 0 CA-C-N 114.648 -1.16 . . . . 0.0 112.529 -179.963 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.244 0 CA-C-O 120.541 -0.033 . . . . 0.0 113.074 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.9 -138.33 4.46 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.988 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.34 140.78 32.22 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.68 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.11 -132.86 2.37 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.459 -179.152 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.468 ' H ' ' C ' ' A' ' 21' ' ' GLY . 23.8 m170 -109.23 -47.34 3.43 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.571 0.224 . . . . 0.0 111.352 -178.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.539 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.45 120.72 69.66 Favored Pre-proline 0 C--O 1.225 -0.233 0 CA-C-O 120.804 0.335 . . . . 0.0 111.206 -179.218 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.556 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 24.7 Cg_exo -64.17 138.98 64.24 Favored 'Trans proline' 0 CA--C 1.529 0.247 0 C-N-CA 123.601 2.868 . . . . 0.0 114.288 -178.584 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.433 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 94.4 mt-10 -91.63 -68.93 0.76 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.568 178.054 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -128.54 142.74 50.97 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.998 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.529 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.5 m-85 -98.07 150.13 21.74 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.369 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 9.1 p -88.89 165.41 2.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.206 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -55.85 -24.21 40.65 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 121.568 -0.348 . . . . 0.0 113.854 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.0 mt -82.41 33.32 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 120.938 0.399 . . . . 0.0 111.333 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 47.5 43.11 20.38 Favored Glycine 0 CA--C 1.521 0.426 0 CA-C-N 115.827 -0.624 . . . . 0.0 114.027 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.92 140.73 15.28 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.902 0.351 . . . . 0.0 111.045 -179.472 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.556 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 35.6 Cg_endo -66.28 126.38 15.57 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.29 1.993 . . . . 0.0 111.824 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.43 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -114.53 31.07 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 122.243 1.021 . . . . 0.0 110.027 -179.606 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 25.2 p 179.63 149.13 0.29 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.12 179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.68 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 11.3 m-85 -142.72 172.0 13.28 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.539 ' HB2' HG23 ' A' ' 6' ' ' VAL . 93.6 m-85 -95.6 -58.35 2.14 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.363 0.601 . . . . 0.0 110.42 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.468 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.253 1.316 0 CA-C-O 117.414 -1.77 . . . . 0.0 110.064 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.301 0 N-CA-C 113.214 0.045 . . . . 0.0 113.214 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.28 -139.29 4.49 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.005 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.91 140.01 29.49 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.651 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.43 -129.24 1.57 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.054 -179.245 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 62.8 m80 -114.6 -43.03 3.2 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.481 0.178 . . . . 0.0 111.481 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.616 HG21 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.71 117.31 68.02 Favored Pre-proline 0 C--N 1.33 -0.274 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.826 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.451 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 24.6 Cg_exo -64.09 140.44 71.93 Favored 'Trans proline' 0 CA--C 1.529 0.271 0 C-N-CA 123.518 2.812 . . . . 0.0 114.258 -178.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.427 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 94.2 mt-10 -91.91 -70.93 0.67 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.447 178.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -116.19 142.4 46.87 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.551 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.52 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 3.7 m-85 -114.06 145.41 41.63 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.405 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.458 ' HB ' HG21 ' A' ' 15' ' ' THR . 42.3 t -82.94 152.92 3.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -54.41 -23.65 27.66 Favored Glycine 0 C--O 1.226 -0.347 0 C-N-CA 121.383 -0.437 . . . . 0.0 113.245 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.2 mt -83.11 32.26 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 CA-C-O 121.209 0.528 . . . . 0.0 111.091 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 51.93 50.14 45.74 Favored Glycine 0 CA--C 1.52 0.348 0 CA-C-N 115.632 -0.713 . . . . 0.0 114.323 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.458 HG21 ' HB ' ' A' ' 11' ' ' VAL . 8.2 t -150.54 129.44 6.23 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 117.437 0.619 . . . . 0.0 111.345 179.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.52 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 71.7 Cg_endo -80.26 134.8 10.45 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.807 2.338 . . . . 0.0 112.629 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.0 pp -119.14 33.19 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.254 0.549 . . . . 0.0 111.547 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 p -179.22 150.76 0.46 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.094 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.651 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.3 m-85 -140.78 172.17 13.08 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.476 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.616 ' HB2' HG21 ' A' ' 6' ' ' VAL . 95.2 m-85 -95.61 -56.68 2.61 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.509 0.671 . . . . 0.0 110.086 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.978 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.87 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.257 0 CA-C-O 120.475 -0.07 . . . . 0.0 113.108 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.95 -136.15 3.71 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.965 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -144.6 140.75 28.94 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 179.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.685 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.33 -132.67 2.45 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.668 -179.156 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.482 ' H ' ' C ' ' A' ' 21' ' ' GLY . 20.4 m170 -110.03 -43.74 3.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.534 0.207 . . . . 0.0 111.352 -178.703 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 40.7 t -88.2 118.96 70.15 Favored Pre-proline 0 C--O 1.223 -0.334 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.728 -178.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.495 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 31.8 Cg_endo -64.41 138.23 59.29 Favored 'Trans proline' 0 CA--C 1.528 0.225 0 C-N-CA 123.208 2.606 . . . . 0.0 114.234 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.4 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 92.2 mt-10 -95.67 -71.66 0.66 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.516 -0.766 . . . . 0.0 110.372 178.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -117.9 142.35 47.43 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.687 -179.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.455 ' C ' HG21 ' A' ' 11' ' ' VAL . 2.8 m-85 -111.95 136.94 50.61 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.455 HG21 ' C ' ' A' ' 10' ' ' PHE . 43.4 t -145.33 137.69 20.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 120.966 0.412 . . . . 0.0 110.932 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.475 ' O ' HG21 ' A' ' 13' ' ' ILE . . . 111.69 -68.4 0.23 Allowed Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.133 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.475 HG21 ' O ' ' A' ' 12' ' ' GLY . 5.3 pt -156.16 46.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 114.78 -0.71 . . . . 0.0 109.736 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.38 18.23 79.98 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -178.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.431 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 0.7 OUTLIER -89.41 125.81 60.41 Favored Pre-proline 0 N--CA 1.447 -0.595 0 CA-C-N 115.113 -0.544 . . . . 0.0 110.623 179.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.495 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 17.9 Cg_exo -66.66 125.64 14.14 Favored 'Trans proline' 0 N--CA 1.463 -0.28 0 C-N-CA 122.778 2.319 . . . . 0.0 112.33 -179.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.411 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -118.34 27.88 3.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 122.714 1.245 . . . . 0.0 109.376 179.343 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.4 p 179.57 150.28 0.33 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 113.899 -1.5 . . . . 0.0 109.475 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.685 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.5 m-85 -142.18 172.22 12.99 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.4 ' CZ ' ' HG2' ' A' ' 8' ' ' GLU . 93.6 m-85 -92.82 -59.46 2.05 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.461 0.648 . . . . 0.0 110.444 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.482 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.253 1.328 0 CA-C-O 117.244 -1.864 . . . . 0.0 109.987 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.281 0 N-CA-C 112.969 -0.052 . . . . 0.0 112.969 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.93 -141.95 5.62 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.93 -0.652 . . . . 0.0 111.714 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.73 46.24 1.02 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.133 0.492 . . . . 0.0 111.095 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.584 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . -81.83 -127.33 0.94 Allowed Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.668 -0.696 . . . . 0.0 112.815 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.1 m-70 -114.31 -43.37 3.21 Favored 'General case' 0 C--N 1.327 -0.402 0 O-C-N 122.444 -0.445 . . . . 0.0 111.89 -178.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.413 ' CG1' ' HB2' ' A' ' 20' ' ' TYR . 2.4 p -89.37 124.76 63.71 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 120.788 0.328 . . . . 0.0 110.682 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.475 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 50.8 Cg_exo -56.36 138.8 85.1 Favored 'Trans proline' 0 N--CA 1.474 0.367 0 C-N-CA 123.53 2.82 . . . . 0.0 114.467 -178.341 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 89.8 mt-10 -98.5 -72.88 0.64 Allowed 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.55 178.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -118.84 140.8 49.37 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.085 -179.432 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.429 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 5.0 m-85 -108.74 145.68 34.72 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.389 -0.823 . . . . 0.0 108.973 179.295 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.0 p -165.44 151.06 2.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.172 0.511 . . . . 0.0 111.435 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.453 ' O ' HG21 ' A' ' 13' ' ' ILE . . . 101.22 -62.17 0.57 Allowed Glycine 0 CA--C 1.505 -0.553 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.678 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.453 HG21 ' O ' ' A' ' 12' ' ' GLY . 5.1 pt -155.75 41.7 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 114.828 -0.686 . . . . 0.0 109.71 179.392 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.51 13.18 82.02 Favored Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.645 -179.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.8 p -89.66 129.89 45.21 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.688 -0.256 . . . . 0.0 110.88 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.475 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 56.2 Cg_endo -74.14 122.51 7.65 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.238 1.959 . . . . 0.0 112.069 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 16.9 mm -113.51 37.19 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 122.182 0.991 . . . . 0.0 109.028 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 25.1 p 179.85 148.25 0.28 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.566 -1.197 . . . . 0.0 109.789 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.584 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 9.1 m-85 -141.04 167.53 21.96 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.413 ' HB2' ' CG1' ' A' ' 6' ' ' VAL . 94.1 m-85 -84.37 -114.54 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.453 0 CA-C-O 117.998 -1.445 . . . . 0.0 111.023 178.857 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.338 0 CA-C-O 120.437 -0.091 . . . . 0.0 113.247 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.66 -137.08 4.15 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.144 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.85 140.12 26.82 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.663 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.53 -128.23 1.51 Allowed Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.344 -179.255 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -115.06 -40.63 3.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.672 0.236 . . . . 0.0 111.493 -178.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.8 t -88.54 115.75 64.27 Favored Pre-proline 0 C--O 1.221 -0.401 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -64.25 140.03 68.87 Favored 'Trans proline' 0 CA--C 1.532 0.388 0 C-N-CA 123.208 2.605 . . . . 0.0 114.133 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -97.36 -74.4 0.57 Allowed 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.689 179.095 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.0 m-85 -105.3 142.6 34.79 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.457 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.48 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 5.8 m-85 -120.45 143.01 48.73 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.402 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.668 HG23 HD11 ' A' ' 17' ' ' ILE . 38.4 t -84.18 153.77 3.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -52.32 -28.02 26.24 Favored Glycine 0 C--O 1.228 -0.252 0 C-N-CA 121.551 -0.357 . . . . 0.0 113.683 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.668 HG13 HG21 ' A' ' 15' ' ' THR . 24.9 pt -82.94 31.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 55.25 52.62 46.15 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 114.926 0.73 . . . . 0.0 114.926 177.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.668 HG21 HG13 ' A' ' 13' ' ' ILE . 9.5 t -150.71 129.24 6.06 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 117.703 0.752 . . . . 0.0 111.198 179.089 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.48 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 85.5 Cg_endo -85.46 130.44 3.86 Favored 'Trans proline' 0 N--CA 1.459 -0.501 0 C-N-CA 122.803 2.336 . . . . 0.0 112.704 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.722 HD13 ' H ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -112.95 33.26 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.457 0.646 . . . . 0.0 110.932 179.839 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.6 p -176.98 150.24 0.75 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.157 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.663 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 15.9 m-85 -141.18 173.0 11.91 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -91.05 -56.67 3.08 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.396 0.617 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.343 0 CA-C-O 117.648 -1.64 . . . . 0.0 110.144 -179.792 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.41 0 N-CA-C 113.347 0.099 . . . . 0.0 113.347 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.59 -143.14 7.57 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.869 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.4 48.4 1.56 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.134 0.492 . . . . 0.0 110.865 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.75 -124.5 0.38 Allowed Glycine 0 CA--C 1.519 0.306 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.41 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 67.8 m80 -121.87 -43.84 2.34 Favored 'General case' 0 C--N 1.328 -0.364 0 O-C-N 122.457 -0.437 . . . . 0.0 111.596 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.4 t -88.94 128.79 50.73 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -57.7 136.43 75.52 Favored 'Trans proline' 0 CA--C 1.529 0.256 0 C-N-CA 123.186 2.591 . . . . 0.0 113.677 -178.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.636 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 94.1 mt-10 -93.4 -73.81 0.55 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.523 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -124.27 142.02 51.6 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.926 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.546 ' O ' HG13 ' A' ' 11' ' ' VAL . 2.5 m-85 -107.24 136.95 46.2 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.306 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.546 HG13 ' O ' ' A' ' 10' ' ' PHE . 3.5 m -153.64 -177.48 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.687 179.824 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.59 -50.38 2.5 Favored Glycine 0 C--O 1.227 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 113.01 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.411 HG13 ' O ' ' A' ' 13' ' ' ILE . 10.9 tp -170.91 37.75 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-O 122.364 1.078 . . . . 0.0 109.419 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.09 13.41 83.38 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.674 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.0 t -96.81 136.6 21.58 Favored Pre-proline 0 C--N 1.325 -0.461 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -71.35 122.88 9.07 Favored 'Trans proline' 0 N--CA 1.462 -0.34 0 C-N-CA 122.289 1.993 . . . . 0.0 112.272 -179.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.404 ' O ' HG22 ' A' ' 17' ' ' ILE . 20.9 mm -114.42 37.85 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 122.298 1.047 . . . . 0.0 108.834 179.343 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 17.1 p -179.65 145.77 0.24 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.446 -1.252 . . . . 0.0 109.702 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -147.01 166.94 25.3 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.328 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.636 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -145.87 170.6 16.26 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.292 178.013 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.141 0 CA-C-O 118.552 -1.138 . . . . 0.0 111.963 -179.466 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.404 0 N-CA-C 113.382 0.113 . . . . 0.0 113.382 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.7 -142.8 7.34 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.845 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.68 48.34 1.53 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.169 0.509 . . . . 0.0 110.755 179.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.69 -124.34 0.37 Allowed Glycine 0 N--CA 1.451 -0.329 0 CA-C-N 115.553 -0.749 . . . . 0.0 112.391 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 67.4 m80 -122.33 -43.58 2.3 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 122.515 -0.403 . . . . 0.0 111.509 -179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 25.7 t -89.0 127.95 53.79 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.714 -0.221 . . . . 0.0 110.405 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.456 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 52.7 Cg_exo -56.17 136.03 73.07 Favored 'Trans proline' 0 CA--C 1.53 0.287 0 C-N-CA 123.229 2.619 . . . . 0.0 113.717 -179.065 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.634 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 94.1 mt-10 -93.72 -74.25 0.54 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.626 179.265 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -122.78 141.03 52.26 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.846 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.549 ' O ' HG13 ' A' ' 11' ' ' VAL . 2.2 m-85 -108.06 136.52 47.61 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.431 179.407 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.549 HG13 ' O ' ' A' ' 10' ' ' PHE . 3.6 m -153.83 -178.3 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 O-C-N 123.282 0.364 . . . . 0.0 110.555 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.92 -50.39 2.62 Favored Glycine 0 C--N 1.332 0.306 0 CA-C-N 116.076 -0.511 . . . . 0.0 113.053 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.403 HG12 ' O ' ' A' ' 13' ' ' ILE . 15.3 tt -170.99 38.31 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-O 122.349 1.071 . . . . 0.0 109.353 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.32 14.13 82.85 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.098 -0.955 . . . . 0.0 112.687 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.0 t -97.31 135.82 21.66 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.456 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 50.8 Cg_endo -72.1 123.5 9.3 Favored 'Trans proline' 0 N--CA 1.46 -0.463 0 C-N-CA 122.19 1.926 . . . . 0.0 112.404 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 20.8 mm -113.06 37.35 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 122.276 1.036 . . . . 0.0 108.754 179.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 p -179.89 146.37 0.24 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 114.365 -1.289 . . . . 0.0 109.612 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -146.95 166.45 26.74 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.259 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.634 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -145.04 170.67 15.74 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.421 178.054 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.242 0.625 0 CA-C-O 119.019 -0.879 . . . . 0.0 111.951 -179.574 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.435 0 CA-C-O 120.272 -0.182 . . . . 0.0 113.553 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -122.81 -127.15 3.25 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.865 -179.151 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -134.86 143.33 46.94 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.665 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 176.43 -133.94 2.45 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.34 -179.346 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.455 ' H ' ' C ' ' A' ' 21' ' ' GLY . 23.7 m170 -109.31 -46.92 3.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.664 0.268 . . . . 0.0 111.201 -178.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.446 HG22 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.49 122.54 68.25 Favored Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.187 -179.232 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.18 139.98 69.02 Favored 'Trans proline' 0 N--CA 1.472 0.243 0 C-N-CA 123.427 2.751 . . . . 0.0 114.312 -178.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.401 ' HG3' ' C ' ' A' ' 19' ' ' PHE . 92.6 mt-10 -92.47 -71.3 0.65 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.347 178.603 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 53.1 m-85 -128.43 142.64 51.04 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.598 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.573 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.2 m-85 -98.23 149.91 22.08 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.053 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.559 ' CG1' HG23 ' A' ' 13' ' ' ILE . 6.6 p -87.96 172.62 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.643 179.201 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.94 41.37 0.71 Allowed Glycine 0 C--O 1.229 -0.203 0 N-CA-C 115.056 0.782 . . . . 0.0 115.056 -178.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.57 HG22 HG22 ' A' ' 15' ' ' THR . 10.7 tp -154.21 28.99 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-O 122.169 0.985 . . . . 0.0 110.441 178.291 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 60.04 43.76 97.91 Favored Glycine 0 CA--C 1.521 0.411 0 CA-C-N 114.673 -1.149 . . . . 0.0 115.141 177.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.57 HG22 HG22 ' A' ' 13' ' ' ILE . 15.1 t -151.27 137.03 10.9 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-N 117.726 0.763 . . . . 0.0 110.435 178.571 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.573 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 72.3 Cg_endo -77.71 127.01 8.5 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.725 2.283 . . . . 0.0 112.921 -179.069 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 17.6 mm -114.28 38.03 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 122.016 0.912 . . . . 0.0 108.964 179.246 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.7 p -177.96 147.73 0.48 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.029 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.665 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.8 m-85 -144.34 171.85 13.76 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.446 ' HB2' HG22 ' A' ' 6' ' ' VAL . 90.5 m-85 -96.08 -58.82 1.98 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.303 0.573 . . . . 0.0 110.626 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.455 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.252 1.252 0 CA-C-O 117.459 -1.745 . . . . 0.0 110.003 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.332 0 CA-C-O 120.221 -0.211 . . . . 0.0 113.403 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -139.57 -120.97 1.82 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.717 -179.273 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -126.07 143.81 50.97 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.712 ' HA3' ' O ' ' A' ' 20' ' ' TYR . . . -179.99 -125.45 0.96 Allowed Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.551 -179.438 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -118.99 -57.54 2.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.85 0.325 . . . . 0.0 111.575 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.517 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 47.3 t -88.6 128.84 51.2 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-O 120.888 0.375 . . . . 0.0 110.345 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -61.01 140.91 92.59 Favored 'Trans proline' 0 CA--C 1.53 0.285 0 C-N-CA 123.523 2.815 . . . . 0.0 114.495 -178.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.755 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.2 mt-10 -91.14 -70.83 0.66 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.205 178.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 42.9 m-85 -124.48 144.47 50.08 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.901 -179.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.565 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.0 OUTLIER -107.88 149.48 28.23 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.823 179.645 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.467 HG22 ' O ' ' A' ' 15' ' ' THR . 27.2 m -92.66 175.53 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.2 178.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.35 -21.79 60.32 Favored Glycine 0 C--O 1.228 -0.247 0 CA-C-N 116.09 -0.505 . . . . 0.0 113.436 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.402 ' H ' HG21 ' A' ' 11' ' ' VAL . 4.7 mt -83.02 28.92 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 121.185 0.517 . . . . 0.0 111.328 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 49.28 44.38 34.77 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 115.559 -0.746 . . . . 0.0 114.162 178.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.467 ' O ' HG22 ' A' ' 11' ' ' VAL . 7.8 t -150.67 140.42 13.84 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 117.115 0.457 . . . . 0.0 110.849 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.565 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 51.3 Cg_endo -70.18 140.53 41.32 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.79 2.327 . . . . 0.0 112.194 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.7 tt -123.44 30.29 2.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 122.302 1.048 . . . . 0.0 109.713 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.1 p -179.15 151.48 0.5 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.479 -1.237 . . . . 0.0 110.071 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.477 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 10.3 m-85 -146.26 171.35 15.1 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.165 -0.679 . . . . 0.0 109.165 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.755 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.2 OUTLIER -139.99 -120.91 0.12 Allowed 'General case' 0 C--N 1.325 -0.483 0 O-C-N 123.045 0.216 . . . . 0.0 110.698 178.78 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.422 ' N ' ' HD1' ' A' ' 20' ' ' TYR . . . . . . . . 0 C--O 1.245 0.811 0 CA-C-O 118.516 -1.158 . . . . 0.0 112.569 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.289 0 CA-C-O 120.573 -0.015 . . . . 0.0 113.133 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 178.9 -137.59 3.26 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.063 -0.589 . . . . 0.0 111.776 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.75 137.77 25.36 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.629 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.45 -129.24 1.57 Allowed Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.369 -179.293 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 15.1 m-70 -118.57 -36.53 3.48 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.572 0.186 . . . . 0.0 111.204 -179.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.7 t -88.1 117.04 67.97 Favored Pre-proline 0 C--N 1.33 -0.26 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 -179.281 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -62.68 134.66 48.47 Favored 'Trans proline' 0 N--CA 1.471 0.189 0 C-N-CA 123.2 2.6 . . . . 0.0 113.845 -178.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -90.62 -72.24 0.58 Allowed 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.667 178.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -128.36 144.47 51.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.856 -179.61 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.473 ' O ' HG22 ' A' ' 11' ' ' VAL . 1.7 m-85 -109.56 135.03 51.21 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 179.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.546 ' HB ' HD11 ' A' ' 17' ' ' ILE . 66.9 t -147.76 145.5 18.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.963 0.411 . . . . 0.0 111.159 -179.411 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.73 -60.82 0.74 Allowed Glycine 0 CA--C 1.503 -0.683 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.906 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 8.2 pt -152.31 40.07 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-O 121.15 0.5 . . . . 0.0 110.445 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.06 23.85 74.53 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.262 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.8 t -102.64 133.73 20.3 Favored Pre-proline 0 C--N 1.325 -0.479 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -76.73 116.7 4.32 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.233 1.955 . . . . 0.0 112.751 -178.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.755 HD13 ' H ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -103.2 30.23 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 121.964 0.888 . . . . 0.0 109.72 179.047 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 p -175.88 146.77 0.74 Allowed 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 114.353 -1.294 . . . . 0.0 109.9 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.629 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 22.6 m-85 -136.97 173.24 11.91 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -91.45 -56.72 3.02 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.358 0.599 . . . . 0.0 110.417 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.414 0 CA-C-O 117.564 -1.687 . . . . 0.0 110.092 -179.714 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.235 0 N-CA-C 113.755 0.262 . . . . 0.0 113.755 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 164.7 -137.82 4.93 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.178 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -130.66 141.94 50.43 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 179.142 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.75 -127.62 1.13 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.101 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 35.3 m170 -125.94 -43.66 1.82 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.553 0.216 . . . . 0.0 111.1 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.22 127.45 55.22 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -63.0 137.3 61.4 Favored 'Trans proline' 0 CA--C 1.529 0.246 0 C-N-CA 123.017 2.478 . . . . 0.0 113.807 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.599 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.2 mt-10 -89.67 -73.25 0.52 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.885 179.271 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -121.93 143.66 49.33 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.158 -179.211 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.409 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 3.3 m-85 -110.88 149.01 31.22 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.706 179.442 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.7 m -83.84 -167.56 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.589 179.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.65 -41.36 95.66 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 121.251 -0.499 . . . . 0.0 113.506 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 18.8 pt -87.67 33.27 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.27 32.47 36.78 Favored Glycine 0 CA--C 1.52 0.352 0 CA-C-N 115.71 -0.677 . . . . 0.0 114.224 178.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.1 m -105.5 121.61 45.55 Favored Pre-proline 0 C--N 1.322 -0.622 0 O-C-N 122.476 -0.426 . . . . 0.0 110.361 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.409 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 56.2 Cg_endo -73.05 125.54 10.45 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.338 2.025 . . . . 0.0 112.373 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 pt -113.79 34.29 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.45 0.643 . . . . 0.0 110.444 179.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.0 p -179.71 147.96 0.31 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.749 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -144.29 174.37 10.96 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 -179.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.599 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -159.82 -160.54 0.82 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.083 178.557 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.046 0 CA-C-O 117.706 -1.608 . . . . 0.0 110.981 179.718 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 113.723 0.249 . . . . 0.0 113.723 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.92 -118.54 1.02 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.376 -0.916 . . . . 0.0 112.833 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.4 144.2 46.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.813 0.34 . . . . 0.0 110.559 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.46 -122.9 0.8 Allowed Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.892 -179.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -137.21 -43.19 0.56 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.661 0.267 . . . . 0.0 110.645 179.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.21 127.36 55.57 Favored Pre-proline 0 C--N 1.328 -0.353 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -62.7 135.99 55.55 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.979 2.453 . . . . 0.0 113.988 -178.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.592 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 90.0 mt-10 -91.43 -75.87 0.46 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.246 178.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 27.9 m-85 -110.25 141.66 42.91 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.133 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.527 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 6.5 m-85 -110.34 143.94 39.81 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.684 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 40.7 t -85.78 152.08 3.62 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -54.49 -23.27 26.91 Favored Glycine 0 CA--C 1.52 0.359 0 C-N-CA 121.409 -0.424 . . . . 0.0 113.389 -179.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.416 HG21 HD12 ' A' ' 13' ' ' ILE . 10.0 mm -82.64 32.32 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-O 121.379 0.609 . . . . 0.0 110.942 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.3 46.55 57.27 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 115.613 -0.721 . . . . 0.0 114.334 178.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.407 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 6.2 t -150.52 133.84 8.75 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 117.381 0.591 . . . . 0.0 111.23 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 11.2 Cg_exo -70.57 142.37 44.18 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 123.021 2.48 . . . . 0.0 111.821 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.421 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.4 tp -124.25 29.94 2.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 122.26 1.029 . . . . 0.0 110.178 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.406 ' OG ' ' HB2' ' A' ' 8' ' ' GLU . 9.8 p 179.63 149.9 0.32 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.703 179.619 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -144.97 172.24 13.32 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.731 0.301 . . . . 0.0 110.316 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.592 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -160.1 -161.52 0.89 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.652 -0.703 . . . . 0.0 109.859 178.542 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 117.718 -1.601 . . . . 0.0 111.031 179.664 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.263 0 N-CA-C 113.419 0.128 . . . . 0.0 113.419 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 162.68 -137.35 4.77 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.063 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -140.01 141.22 36.34 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.125 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.566 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 175.79 -120.5 0.76 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.413 -179.14 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -126.3 -41.41 1.9 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 42.6 t -88.33 120.53 70.49 Favored Pre-proline 0 C--O 1.22 -0.474 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.266 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -61.32 132.98 43.8 Favored 'Trans proline' 0 CA--C 1.53 0.312 0 C-N-CA 122.892 2.395 . . . . 0.0 113.901 -178.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.535 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 91.4 mt-10 -92.57 -74.91 0.5 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.185 178.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -117.59 143.55 46.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.103 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -107.23 146.93 30.81 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.241 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.475 HG13 HG21 ' A' ' 13' ' ' ILE . 9.1 p -79.81 165.13 2.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.29 178.811 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.7 41.34 0.54 Allowed Glycine 0 CA--C 1.518 0.254 0 N-CA-C 114.763 0.665 . . . . 0.0 114.763 -178.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.475 HG21 HG13 ' A' ' 11' ' ' VAL . 13.0 tt -157.46 28.27 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-O 122.09 0.947 . . . . 0.0 110.192 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.22 53.4 44.94 Favored Glycine 0 CA--C 1.519 0.312 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.727 178.3 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.428 ' HB ' HG11 ' A' ' 11' ' ' VAL . 27.8 m -148.94 126.53 5.65 Favored Pre-proline 0 C--N 1.323 -0.574 0 O-C-N 122.39 -0.476 . . . . 0.0 110.391 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 11.5 Cg_exo -70.17 126.38 12.98 Favored 'Trans proline' 0 N--CA 1.465 -0.205 0 C-N-CA 122.408 2.072 . . . . 0.0 111.752 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.3 pt -115.58 31.95 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.52 0.676 . . . . 0.0 110.655 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 11.2 p 179.23 148.31 0.23 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.825 -1.079 . . . . 0.0 109.543 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.566 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 3.7 m-85 -147.43 164.19 34.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.688 0.28 . . . . 0.0 110.736 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.55 ' O ' ' HA3' ' A' ' 4' ' ' GLY . 29.4 m-85 -97.25 163.89 12.72 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.429 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.15 0 CA-C-O 117.751 -1.583 . . . . 0.0 110.998 179.105 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.439 ' N ' ' HB2' ' A' ' 18' ' ' SER . . . . . . . . 0 CA--C 1.52 0.388 0 N-CA-C 113.918 0.327 . . . . 0.0 113.918 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -120.38 -134.51 4.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.317 -0.944 . . . . 0.0 113.084 -179.097 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -132.99 52.63 2.07 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.093 0.473 . . . . 0.0 110.776 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -76.08 -121.96 0.16 Allowed Glycine 0 CA--C 1.519 0.317 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.633 179.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 44.9 m170 -122.15 -51.7 1.99 Allowed 'General case' 0 C--N 1.326 -0.448 0 O-C-N 122.465 -0.432 . . . . 0.0 111.296 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.448 HG23 ' CE1' ' A' ' 20' ' ' TYR . 4.4 m -89.63 132.88 35.57 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 110.194 -0.299 . . . . 0.0 110.194 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_endo -58.03 139.34 90.08 Favored 'Trans proline' 0 CA--C 1.53 0.314 0 C-N-CA 123.513 2.809 . . . . 0.0 114.484 -178.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.519 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.7 mt-10 -92.64 -69.97 0.72 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.065 178.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -121.82 144.43 48.83 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.292 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.453 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 4.6 m-85 -111.28 145.95 37.87 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.48 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 42.7 t -76.62 153.69 5.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 177.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -52.28 -26.6 21.93 Favored Glycine 0 C--O 1.227 -0.333 0 C-N-CA 121.485 -0.388 . . . . 0.0 113.763 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.0 mt -84.32 31.19 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 CA-C-O 121.283 0.563 . . . . 0.0 111.19 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 53.53 51.45 47.97 Favored Glycine 0 CA--C 1.521 0.428 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.842 178.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 26.9 m -144.62 123.74 7.0 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 122.332 -0.511 . . . . 0.0 111.048 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 39.9 Cg_endo -67.89 136.71 39.27 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.485 2.123 . . . . 0.0 111.916 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.41 HG12 ' O ' ' A' ' 17' ' ' ILE . 15.3 tt -129.93 34.07 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 122.227 1.013 . . . . 0.0 110.42 -179.528 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.439 ' HB2' ' N ' ' A' ' 1' ' ' GLY . 13.1 p 179.76 149.44 0.31 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.825 -1.08 . . . . 0.0 109.637 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -147.58 165.9 28.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.708 0.29 . . . . 0.0 110.386 -179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.519 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -158.24 -149.08 0.21 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.189 178.818 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.811 0 CA-C-O 118.68 -1.067 . . . . 0.0 110.668 179.883 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 CA-C-O 120.235 -0.203 . . . . 0.0 113.592 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.5 -120.54 1.49 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.81 -179.178 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.44 145.75 44.98 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.692 0.282 . . . . 0.0 110.62 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.21 -124.48 0.86 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.005 -179.651 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 70.5 m80 -133.29 -47.91 0.84 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.447 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 2.5 p -89.47 128.34 51.35 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.863 179.175 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.459 ' HB3' ' HG3' ' A' ' 16' ' ' PRO . 37.8 Cg_exo -58.77 137.89 82.6 Favored 'Trans proline' 0 N--CA 1.473 0.301 0 C-N-CA 123.443 2.762 . . . . 0.0 113.968 -178.37 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.445 ' HG2' ' CD1' ' A' ' 20' ' ' TYR . 91.8 mt-10 -89.73 -73.32 0.52 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.475 178.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -125.35 135.58 52.59 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.672 -179.704 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.551 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.7 m-85 -91.19 156.28 17.97 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.458 178.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.575 HG22 ' H ' ' A' ' 13' ' ' ILE . 35.1 m -120.38 -175.57 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 120.748 0.309 . . . . 0.0 110.854 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.05 -18.58 64.85 Favored Glycine 0 C--O 1.227 -0.305 0 CA-C-N 116.03 -0.532 . . . . 0.0 113.404 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.575 ' H ' HG22 ' A' ' 11' ' ' VAL . 6.0 mt -84.14 19.27 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.542 0.687 . . . . 0.0 111.022 -179.637 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.89 -44.03 0.82 Allowed Glycine 0 CA--C 1.521 0.42 0 CA-C-N 115.396 -0.82 . . . . 0.0 113.852 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.431 ' O ' HG23 ' A' ' 11' ' ' VAL . 10.0 t -88.47 137.58 30.53 Favored Pre-proline 0 C--N 1.32 -0.712 0 CA-C-O 121.097 0.475 . . . . 0.0 111.226 -179.012 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.551 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 59.7 Cg_endo -72.65 140.68 33.02 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.891 2.394 . . . . 0.0 111.971 179.83 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.443 HD13 HG21 ' A' ' 17' ' ' ILE . 13.2 mt -108.24 38.21 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 122.213 1.006 . . . . 0.0 109.173 179.416 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.8 p -167.9 143.82 3.93 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.381 179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -147.15 174.16 11.84 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.453 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.445 ' CD1' ' HG2' ' A' ' 8' ' ' GLU . 20.6 p90 -158.75 -159.84 0.82 Allowed 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.076 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.899 0 CA-C-O 118.637 -1.09 . . . . 0.0 111.035 179.833 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.32 0 CA-C-O 120.488 -0.062 . . . . 0.0 113.117 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.62 -138.33 4.34 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.183 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.459 ' HA ' ' HB2' ' A' ' 19' ' ' PHE . . . -145.94 141.94 28.25 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.591 0.234 . . . . 0.0 110.415 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.445 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.25 -127.52 1.41 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 121.014 -0.612 . . . . 0.0 111.932 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.482 ' H ' ' C ' ' A' ' 21' ' ' GLY . 45.3 m80 -116.88 -37.16 3.66 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.604 0.24 . . . . 0.0 110.762 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.7 t -88.45 120.18 70.32 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.302 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.07 139.14 45.83 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 122.954 2.436 . . . . 0.0 113.236 -179.329 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -95.34 -75.57 0.52 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.601 179.679 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.404 ' O ' ' HA ' ' A' ' 16' ' ' PRO . 27.6 m-85 -107.41 140.58 40.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.073 0.463 . . . . 0.0 111.831 -178.731 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.447 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.5 m-85 -115.8 147.7 40.69 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.239 -0.891 . . . . 0.0 109.053 178.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 15' ' ' THR . 29.9 m -86.64 -167.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 C-N-CA 120.992 -0.283 . . . . 0.0 110.92 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -57.56 -42.18 93.91 Favored Glycine 0 C--O 1.227 -0.329 0 C-N-CA 121.387 -0.435 . . . . 0.0 113.64 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 17.6 pt -86.75 32.65 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 120.932 0.396 . . . . 0.0 111.964 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.59 29.13 31.45 Favored Glycine 0 CA--C 1.519 0.33 0 CA-C-N 115.666 -0.697 . . . . 0.0 114.051 178.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.451 ' O ' HG22 ' A' ' 11' ' ' VAL . 18.9 m -102.57 120.21 53.68 Favored Pre-proline 0 C--N 1.321 -0.671 0 CA-C-N 117.003 0.401 . . . . 0.0 110.497 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 72.8 Cg_endo -80.2 124.64 5.49 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.269 1.98 . . . . 0.0 112.691 -179.549 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.0 mt -116.15 39.33 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 122.333 1.063 . . . . 0.0 108.894 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 p -175.92 146.48 0.71 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.451 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.459 ' HB2' ' HA ' ' A' ' 3' ' ' ALA . 56.4 m-85 -131.54 -172.7 2.92 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 10.6 t80 -122.71 -62.66 1.34 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.55 0.691 . . . . 0.0 110.197 -179.373 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.482 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.442 -0.904 0 CA-C-N 114.596 -1.184 . . . . 0.0 110.233 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.286 0 N-CA-C 113.221 0.048 . . . . 0.0 113.221 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.35 -137.03 3.91 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.112 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.9 138.76 25.8 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.333 -0.247 . . . . 0.0 110.333 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.669 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 173.71 -127.54 1.36 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.255 -179.227 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -118.64 -37.75 3.23 Favored 'General case' 0 C--N 1.328 -0.363 0 O-C-N 122.827 -0.219 . . . . 0.0 111.248 -179.136 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.5 t -88.14 115.22 62.49 Favored Pre-proline 0 C--O 1.222 -0.345 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 -179.306 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.76 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 34.8 Cg_exo -62.57 137.55 64.96 Favored 'Trans proline' 0 N--CA 1.473 0.28 0 C-N-CA 123.423 2.749 . . . . 0.0 114.165 -178.692 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.0 mt-10 -97.13 -72.11 0.65 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.257 178.439 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 27.8 m-85 -116.62 142.53 46.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.667 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -110.73 149.04 31.06 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.84 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 26.9 m -82.87 -167.41 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.688 179.35 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.78 -42.01 96.25 Favored Glycine 0 C--O 1.227 -0.322 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.588 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 18.2 pt -87.5 33.83 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.08 31.28 32.92 Favored Glycine 0 CA--C 1.519 0.335 0 CA-C-N 115.71 -0.677 . . . . 0.0 114.174 178.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 18.0 m -104.77 125.76 33.0 Favored Pre-proline 0 C--N 1.322 -0.588 0 O-C-N 122.539 -0.389 . . . . 0.0 110.135 179.751 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.76 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 31.3 Cg_endo -65.07 125.77 15.24 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.4 2.067 . . . . 0.0 112.226 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.416 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -115.98 29.09 2.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 122.508 1.147 . . . . 0.0 109.581 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.8 p 179.68 150.08 0.33 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 114.249 -1.341 . . . . 0.0 109.725 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.669 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 14.1 m-85 -140.31 171.38 14.23 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -90.78 -56.41 3.19 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.48 0.657 . . . . 0.0 110.349 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.256 1.492 0 CA-C-O 117.56 -1.689 . . . . 0.0 110.001 -179.841 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.38 0 N-CA-C 113.59 0.196 . . . . 0.0 113.59 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -108.27 -134.68 7.34 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.655 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.417 ' HA ' ' HD1' ' A' ' 19' ' ' PHE . . . -145.38 47.89 1.28 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.031 0.443 . . . . 0.0 111.16 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.639 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . -80.41 -126.06 0.64 Allowed Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.931 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 61.6 m80 -111.47 -44.83 3.46 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -178.689 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.574 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.8 m -89.42 122.92 67.99 Favored Pre-proline 0 C--O 1.221 -0.431 0 CA-C-O 120.744 0.307 . . . . 0.0 110.962 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.662 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 40.1 Cg_exo -58.27 139.55 90.95 Favored 'Trans proline' 0 N--CA 1.474 0.379 0 C-N-CA 123.32 2.68 . . . . 0.0 114.449 -178.312 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.436 ' HG3' ' C ' ' A' ' 19' ' ' PHE . 94.7 mt-10 -95.26 -72.28 0.63 Allowed 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.675 179.078 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -108.17 144.91 34.94 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.541 -179.619 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.532 ' CZ ' ' HB2' ' A' ' 7' ' ' PRO . 4.7 m-85 -123.72 141.74 51.73 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.205 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.487 HG23 HD12 ' A' ' 17' ' ' ILE . 43.8 t -78.2 155.12 5.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -50.99 -30.52 23.08 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.496 -0.383 . . . . 0.0 113.494 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.2 pt -84.41 30.53 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.847 0.356 . . . . 0.0 111.898 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 55.8 50.09 62.82 Favored Glycine 0 CA--C 1.519 0.283 0 CA-C-N 115.926 -0.579 . . . . 0.0 113.64 178.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 15.2 m -133.85 118.0 14.18 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 117.142 0.471 . . . . 0.0 111.311 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.662 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 4.6 Cg_exo -77.05 130.97 11.62 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.988 2.459 . . . . 0.0 111.719 179.572 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.631 HD13 ' H ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -123.88 33.61 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.541 0.686 . . . . 0.0 111.055 179.979 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 p 179.83 152.92 0.47 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.463 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.639 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 8.5 m-85 -144.48 166.92 23.76 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.574 ' HB2' HG23 ' A' ' 6' ' ' VAL . 97.2 m-85 -90.06 -115.72 0.07 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.615 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.102 0 CA-C-O 118.123 -1.376 . . . . 0.0 110.633 178.245 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.226 0 CA-C-O 120.555 -0.025 . . . . 0.0 113.077 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.49 -139.14 4.57 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.976 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.62 140.35 30.09 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.659 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.64 -128.94 1.51 Allowed Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.077 -179.246 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.411 ' H ' ' C ' ' A' ' 21' ' ' GLY . 62.7 m80 -114.65 -43.11 3.18 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 111.59 0.219 . . . . 0.0 111.59 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.607 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.5 m -89.89 117.82 68.42 Favored Pre-proline 0 C--O 1.223 -0.296 0 CA-C-O 120.825 0.345 . . . . 0.0 110.757 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.468 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 26.8 Cg_exo -63.61 139.61 70.71 Favored 'Trans proline' 0 CA--C 1.53 0.296 0 C-N-CA 123.506 2.804 . . . . 0.0 114.236 -178.301 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.433 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 93.2 mt-10 -91.67 -72.41 0.59 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.425 178.584 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -112.67 139.93 47.87 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.266 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.528 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 4.5 m-85 -111.41 143.82 41.61 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.192 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.9 t -85.43 151.12 3.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 178.373 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -53.58 -24.53 24.91 Favored Glycine 0 C--O 1.226 -0.404 0 C-N-CA 121.499 -0.381 . . . . 0.0 113.539 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.3 mt -82.22 32.61 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-O 121.182 0.515 . . . . 0.0 111.092 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.0 47.55 54.06 Favored Glycine 0 CA--C 1.52 0.368 0 CA-C-N 115.699 -0.682 . . . . 0.0 114.237 178.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.2 t -150.62 129.58 6.27 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 117.359 0.58 . . . . 0.0 111.43 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 85.5 Cg_endo -85.64 131.63 4.0 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.918 2.412 . . . . 0.0 112.493 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -115.47 35.92 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.355 0.598 . . . . 0.0 110.959 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.5 p -176.2 148.66 0.8 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.189 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.659 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 11.9 m-85 -141.34 172.13 13.11 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.607 ' HB2' HG23 ' A' ' 6' ' ' VAL . 93.7 m-85 -95.02 -56.79 2.63 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.554 0.692 . . . . 0.0 110.008 179.753 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.411 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.441 -1.006 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.261 0 CA-C-O 120.313 -0.159 . . . . 0.0 113.305 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.15 -118.0 1.04 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.446 -179.303 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.52 145.09 45.58 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.632 0.253 . . . . 0.0 110.528 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.27 -131.82 1.67 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 121.033 -0.603 . . . . 0.0 111.632 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -123.18 -48.5 1.98 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.069 0.435 . . . . 0.0 110.457 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.487 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 41.8 t -89.96 130.04 44.01 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.253 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -60.74 137.98 76.54 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 123.154 2.569 . . . . 0.0 113.798 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.752 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 90.9 mt-10 -89.09 -73.95 0.49 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.622 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -124.43 143.29 50.71 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.022 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.552 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.0 OUTLIER -104.9 148.39 26.73 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.552 179.167 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 15' ' ' THR . 35.9 m -92.46 178.87 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 116.561 -0.29 . . . . 0.0 110.543 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -60.28 -26.2 63.6 Favored Glycine 0 N--CA 1.453 -0.218 0 CA-C-N 116.087 -0.506 . . . . 0.0 113.54 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.416 ' H ' HG23 ' A' ' 11' ' ' VAL . 9.6 mm -84.06 31.48 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.064 0.459 . . . . 0.0 110.958 -179.765 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 46.0 43.39 12.84 Favored Glycine 0 N--CA 1.46 0.297 0 CA-C-N 115.575 -0.739 . . . . 0.0 113.782 179.156 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.539 ' O ' HG22 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -143.23 135.39 13.23 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-O 120.795 0.331 . . . . 0.0 111.287 -179.261 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 71.7 Cg_endo -84.49 127.35 3.79 Favored 'Trans proline' 0 N--CA 1.454 -0.818 0 C-N-CA 122.562 2.174 . . . . 0.0 112.322 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.6 mt -115.77 39.97 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 122.216 1.007 . . . . 0.0 108.857 179.129 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.9 p -171.58 144.58 1.91 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.841 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -147.32 173.42 12.61 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.752 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -153.61 169.64 22.76 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.216 0.532 . . . . 0.0 111.398 178.741 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.949 0 CA-C-N 114.648 -1.16 . . . . 0.0 112.529 -179.963 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.244 0 CA-C-O 120.541 -0.033 . . . . 0.0 113.074 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.9 -138.33 4.46 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.988 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.34 140.78 32.22 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.328 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.693 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.11 -132.86 2.37 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.459 -179.152 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.461 ' H ' ' C ' ' A' ' 21' ' ' GLY . 23.8 m170 -109.23 -47.34 3.43 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.571 0.224 . . . . 0.0 111.352 -178.827 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.544 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.45 120.72 69.66 Favored Pre-proline 0 C--O 1.225 -0.233 0 CA-C-O 120.804 0.335 . . . . 0.0 111.206 -179.218 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.607 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 24.7 Cg_exo -64.17 138.98 64.24 Favored 'Trans proline' 0 CA--C 1.529 0.247 0 C-N-CA 123.601 2.868 . . . . 0.0 114.288 -178.584 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.446 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 94.4 mt-10 -91.63 -68.93 0.76 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.568 178.054 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -128.54 142.74 50.97 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.998 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.579 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.5 m-85 -98.07 150.13 21.74 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.369 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.587 HG13 ' H ' ' A' ' 13' ' ' ILE . 9.1 p -88.89 165.41 2.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.206 178.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -55.85 -24.21 40.65 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 121.568 -0.348 . . . . 0.0 113.854 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.587 ' H ' HG13 ' A' ' 11' ' ' VAL . 5.0 mt -82.41 33.32 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 120.938 0.399 . . . . 0.0 111.333 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 47.5 43.11 20.38 Favored Glycine 0 CA--C 1.521 0.426 0 CA-C-N 115.827 -0.624 . . . . 0.0 114.027 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.476 ' O ' HG12 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -146.92 140.73 15.28 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.902 0.351 . . . . 0.0 111.045 -179.472 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.607 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 35.6 Cg_endo -66.28 126.38 15.57 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.29 1.993 . . . . 0.0 111.824 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.43 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -114.53 31.07 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 122.243 1.021 . . . . 0.0 110.027 -179.606 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 25.2 p 179.63 149.13 0.29 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.12 179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.693 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 11.3 m-85 -142.72 172.0 13.28 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.544 ' HB2' HG23 ' A' ' 6' ' ' VAL . 93.6 m-85 -95.6 -58.35 2.14 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.363 0.601 . . . . 0.0 110.42 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.461 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.253 1.316 0 CA-C-O 117.414 -1.77 . . . . 0.0 110.064 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.301 0 N-CA-C 113.214 0.045 . . . . 0.0 113.214 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.28 -139.29 4.49 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.005 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.91 140.01 29.49 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.662 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.43 -129.24 1.57 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.054 -179.245 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.41 ' H ' ' C ' ' A' ' 21' ' ' GLY . 62.8 m80 -114.6 -43.03 3.2 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.481 0.178 . . . . 0.0 111.481 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.608 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.71 117.31 68.02 Favored Pre-proline 0 C--N 1.33 -0.274 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.826 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.478 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 24.6 Cg_exo -64.09 140.44 71.93 Favored 'Trans proline' 0 CA--C 1.529 0.271 0 C-N-CA 123.518 2.812 . . . . 0.0 114.258 -178.391 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.438 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 94.2 mt-10 -91.91 -70.93 0.67 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.447 178.733 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -116.19 142.4 46.87 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.551 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.55 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 3.7 m-85 -114.06 145.41 41.63 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.405 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 42.3 t -82.94 152.92 3.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -54.41 -23.65 27.66 Favored Glycine 0 C--O 1.226 -0.347 0 C-N-CA 121.383 -0.437 . . . . 0.0 113.245 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.2 mt -83.11 32.26 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 CA-C-O 121.209 0.528 . . . . 0.0 111.091 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 51.93 50.14 45.74 Favored Glycine 0 CA--C 1.52 0.348 0 CA-C-N 115.632 -0.713 . . . . 0.0 114.323 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.2 t -150.54 129.44 6.23 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 117.437 0.619 . . . . 0.0 111.345 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 71.7 Cg_endo -80.26 134.8 10.45 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.807 2.338 . . . . 0.0 112.629 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.0 pp -119.14 33.19 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.254 0.549 . . . . 0.0 111.547 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 p -179.22 150.76 0.46 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.094 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.662 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.3 m-85 -140.78 172.17 13.08 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.476 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.608 ' HB2' HG23 ' A' ' 6' ' ' VAL . 95.2 m-85 -95.61 -56.68 2.61 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.509 0.671 . . . . 0.0 110.086 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.41 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.441 -0.978 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.257 0 CA-C-O 120.475 -0.07 . . . . 0.0 113.108 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.95 -136.15 3.71 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.965 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -144.6 140.75 28.94 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 179.286 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.7 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.33 -132.67 2.45 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.668 -179.156 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.48 ' H ' ' C ' ' A' ' 21' ' ' GLY . 20.4 m170 -110.03 -43.74 3.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.534 0.207 . . . . 0.0 111.352 -178.703 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 40.7 t -88.2 118.96 70.15 Favored Pre-proline 0 C--O 1.223 -0.334 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.728 -178.774 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.545 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 31.8 Cg_endo -64.41 138.23 59.29 Favored 'Trans proline' 0 CA--C 1.528 0.225 0 C-N-CA 123.208 2.606 . . . . 0.0 114.234 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.412 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 92.2 mt-10 -95.67 -71.66 0.66 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.516 -0.766 . . . . 0.0 110.372 178.729 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -117.9 142.35 47.43 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.687 -179.611 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -111.95 136.94 50.61 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 43.4 t -145.33 137.69 20.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 120.966 0.412 . . . . 0.0 110.932 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.69 -68.4 0.23 Allowed Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.133 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.3 pt -156.16 46.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 114.78 -0.71 . . . . 0.0 109.736 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.38 18.23 79.98 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -178.59 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.456 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 0.7 OUTLIER -89.41 125.81 60.41 Favored Pre-proline 0 N--CA 1.447 -0.595 0 CA-C-N 115.113 -0.544 . . . . 0.0 110.623 179.975 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.545 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 17.9 Cg_exo -66.66 125.64 14.14 Favored 'Trans proline' 0 N--CA 1.463 -0.28 0 C-N-CA 122.778 2.319 . . . . 0.0 112.33 -179.422 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.411 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -118.34 27.88 3.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 122.714 1.245 . . . . 0.0 109.376 179.343 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.4 p 179.57 150.28 0.33 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 113.899 -1.5 . . . . 0.0 109.475 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.7 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.5 m-85 -142.18 172.22 12.99 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.412 ' CZ ' ' HG2' ' A' ' 8' ' ' GLU . 93.6 m-85 -92.82 -59.46 2.05 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.461 0.648 . . . . 0.0 110.444 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.48 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.253 1.328 0 CA-C-O 117.244 -1.864 . . . . 0.0 109.987 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.281 0 N-CA-C 112.969 -0.052 . . . . 0.0 112.969 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.93 -141.95 5.62 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.93 -0.652 . . . . 0.0 111.714 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.73 46.24 1.02 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.133 0.492 . . . . 0.0 111.095 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.599 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . -81.83 -127.33 0.94 Allowed Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.668 -0.696 . . . . 0.0 112.815 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.1 m-70 -114.31 -43.37 3.21 Favored 'General case' 0 C--N 1.327 -0.402 0 O-C-N 122.444 -0.445 . . . . 0.0 111.89 -178.676 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.543 HG13 ' HB2' ' A' ' 20' ' ' TYR . 2.4 p -89.37 124.76 63.71 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 120.788 0.328 . . . . 0.0 110.682 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.53 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 50.8 Cg_exo -56.36 138.8 85.1 Favored 'Trans proline' 0 N--CA 1.474 0.367 0 C-N-CA 123.53 2.82 . . . . 0.0 114.467 -178.341 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.419 ' HG2' ' CE1' ' A' ' 20' ' ' TYR . 89.8 mt-10 -98.5 -72.88 0.64 Allowed 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.55 178.714 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -118.84 140.8 49.37 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.085 -179.432 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.47 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 5.0 m-85 -108.74 145.68 34.72 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.389 -0.823 . . . . 0.0 108.973 179.295 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.0 p -165.44 151.06 2.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.172 0.511 . . . . 0.0 111.435 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.22 -62.17 0.57 Allowed Glycine 0 CA--C 1.505 -0.553 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.678 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.1 pt -155.75 41.7 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 114.828 -0.686 . . . . 0.0 109.71 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.51 13.18 82.02 Favored Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.645 -179.187 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.8 p -89.66 129.89 45.21 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.688 -0.256 . . . . 0.0 110.88 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.53 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 56.2 Cg_endo -74.14 122.51 7.65 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.238 1.959 . . . . 0.0 112.069 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 16.9 mm -113.51 37.19 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 122.182 0.991 . . . . 0.0 109.028 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 25.1 p 179.85 148.25 0.28 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.566 -1.197 . . . . 0.0 109.789 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.599 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 9.1 m-85 -141.04 167.53 21.96 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.535 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.543 ' HB2' HG13 ' A' ' 6' ' ' VAL . 94.1 m-85 -84.37 -114.54 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.453 0 CA-C-O 117.998 -1.445 . . . . 0.0 111.023 178.857 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.338 0 CA-C-O 120.437 -0.091 . . . . 0.0 113.247 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.66 -137.08 4.15 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.144 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.85 140.12 26.82 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.675 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.53 -128.23 1.51 Allowed Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.344 -179.255 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -115.06 -40.63 3.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.672 0.236 . . . . 0.0 111.493 -178.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.8 t -88.54 115.75 64.27 Favored Pre-proline 0 C--O 1.221 -0.401 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.302 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -64.25 140.03 68.87 Favored 'Trans proline' 0 CA--C 1.532 0.388 0 C-N-CA 123.208 2.605 . . . . 0.0 114.133 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -97.36 -74.4 0.57 Allowed 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.689 179.095 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.0 m-85 -105.3 142.6 34.79 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.457 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.499 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 5.8 m-85 -120.45 143.01 48.73 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.402 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.447 ' CG2' HD12 ' A' ' 17' ' ' ILE . 38.4 t -84.18 153.77 3.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -52.32 -28.02 26.24 Favored Glycine 0 C--O 1.228 -0.252 0 C-N-CA 121.551 -0.357 . . . . 0.0 113.683 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.646 HG13 HG22 ' A' ' 15' ' ' THR . 24.9 pt -82.94 31.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 55.25 52.62 46.15 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 114.926 0.73 . . . . 0.0 114.926 177.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.646 HG22 HG13 ' A' ' 13' ' ' ILE . 9.5 t -150.71 129.24 6.06 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 117.703 0.752 . . . . 0.0 111.198 179.089 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.499 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 85.5 Cg_endo -85.46 130.44 3.86 Favored 'Trans proline' 0 N--CA 1.459 -0.501 0 C-N-CA 122.803 2.336 . . . . 0.0 112.704 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.759 HD13 ' H ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -112.95 33.26 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.457 0.646 . . . . 0.0 110.932 179.839 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.6 p -176.98 150.24 0.75 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.157 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.675 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 15.9 m-85 -141.18 173.0 11.91 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -91.05 -56.67 3.08 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.396 0.617 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.343 0 CA-C-O 117.648 -1.64 . . . . 0.0 110.144 -179.792 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.41 0 N-CA-C 113.347 0.099 . . . . 0.0 113.347 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.59 -143.14 7.57 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.869 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.4 48.4 1.56 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.134 0.492 . . . . 0.0 110.865 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.75 -124.5 0.38 Allowed Glycine 0 CA--C 1.519 0.306 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.41 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.411 ' HD1' ' C ' ' A' ' 21' ' ' GLY . 67.8 m80 -121.87 -43.84 2.34 Favored 'General case' 0 C--N 1.328 -0.364 0 O-C-N 122.457 -0.437 . . . . 0.0 111.596 -179.55 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.408 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 25.4 t -88.94 128.79 50.73 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -57.7 136.43 75.52 Favored 'Trans proline' 0 CA--C 1.529 0.256 0 C-N-CA 123.186 2.591 . . . . 0.0 113.677 -178.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.649 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 94.1 mt-10 -93.4 -73.81 0.55 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.523 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -124.27 142.02 51.6 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.926 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.433 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.5 m-85 -107.24 136.95 46.2 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.306 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.5 m -153.64 -177.48 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.687 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.59 -50.38 2.5 Favored Glycine 0 C--O 1.227 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 113.01 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.408 HG13 ' O ' ' A' ' 13' ' ' ILE . 10.9 tp -170.91 37.75 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-O 122.364 1.078 . . . . 0.0 109.419 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.09 13.41 83.38 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.674 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.409 HG23 HD11 ' A' ' 17' ' ' ILE . 9.0 t -96.81 136.6 21.58 Favored Pre-proline 0 C--N 1.325 -0.461 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 45.5 Cg_endo -71.35 122.88 9.07 Favored 'Trans proline' 0 N--CA 1.462 -0.34 0 C-N-CA 122.289 1.993 . . . . 0.0 112.272 -179.244 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.409 HD11 HG23 ' A' ' 15' ' ' THR . 20.9 mm -114.42 37.85 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 122.298 1.047 . . . . 0.0 108.834 179.343 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 17.1 p -179.65 145.77 0.24 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.446 -1.252 . . . . 0.0 109.702 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -147.01 166.94 25.3 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.328 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.649 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -145.87 170.6 16.26 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.292 178.013 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.411 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.25 1.141 0 CA-C-O 118.552 -1.138 . . . . 0.0 111.963 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.404 0 N-CA-C 113.382 0.113 . . . . 0.0 113.382 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.7 -142.8 7.34 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.845 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.68 48.34 1.53 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.169 0.509 . . . . 0.0 110.755 179.618 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.69 -124.34 0.37 Allowed Glycine 0 N--CA 1.451 -0.329 0 CA-C-N 115.553 -0.749 . . . . 0.0 112.391 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.417 ' HD1' ' C ' ' A' ' 21' ' ' GLY . 67.4 m80 -122.33 -43.58 2.3 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 122.515 -0.403 . . . . 0.0 111.509 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.403 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 25.7 t -89.0 127.95 53.79 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.714 -0.221 . . . . 0.0 110.405 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.516 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 52.7 Cg_exo -56.17 136.03 73.07 Favored 'Trans proline' 0 CA--C 1.53 0.287 0 C-N-CA 123.229 2.619 . . . . 0.0 113.717 -179.065 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.648 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 94.1 mt-10 -93.72 -74.25 0.54 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.626 179.265 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -122.78 141.03 52.26 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.846 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.428 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.2 m-85 -108.06 136.52 47.61 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.431 179.407 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -153.83 -178.3 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 O-C-N 123.282 0.364 . . . . 0.0 110.555 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.92 -50.39 2.62 Favored Glycine 0 C--N 1.332 0.306 0 CA-C-N 116.076 -0.511 . . . . 0.0 113.053 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 13' ' ' ILE . 15.3 tt -170.99 38.31 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-O 122.349 1.071 . . . . 0.0 109.353 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.32 14.13 82.85 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.098 -0.955 . . . . 0.0 112.687 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.0 t -97.31 135.82 21.66 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.516 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 50.8 Cg_endo -72.1 123.5 9.3 Favored 'Trans proline' 0 N--CA 1.46 -0.463 0 C-N-CA 122.19 1.926 . . . . 0.0 112.404 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 20.8 mm -113.06 37.35 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 122.276 1.036 . . . . 0.0 108.754 179.329 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 p -179.89 146.37 0.24 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 114.365 -1.289 . . . . 0.0 109.612 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -146.95 166.45 26.74 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.259 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.648 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -145.04 170.67 15.74 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.421 178.054 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.417 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.242 0.625 0 CA-C-O 119.019 -0.879 . . . . 0.0 111.951 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.435 0 CA-C-O 120.272 -0.182 . . . . 0.0 113.553 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -122.81 -127.15 3.25 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.865 -179.151 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -134.86 143.33 46.94 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.68 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 176.43 -133.94 2.45 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.34 -179.346 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.453 ' H ' ' C ' ' A' ' 21' ' ' GLY . 23.7 m170 -109.31 -46.92 3.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.664 0.268 . . . . 0.0 111.201 -178.835 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.536 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.49 122.54 68.25 Favored Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.187 -179.232 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.18 139.98 69.02 Favored 'Trans proline' 0 N--CA 1.472 0.243 0 C-N-CA 123.427 2.751 . . . . 0.0 114.312 -178.629 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.409 ' HG3' ' C ' ' A' ' 19' ' ' PHE . 92.6 mt-10 -92.47 -71.3 0.65 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.347 178.603 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 53.1 m-85 -128.43 142.64 51.04 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.598 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.595 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.2 m-85 -98.23 149.91 22.08 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.053 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.705 HG13 HG22 ' A' ' 13' ' ' ILE . 6.6 p -87.96 172.62 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.643 179.201 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.563 ' H ' HG22 ' A' ' 11' ' ' VAL . . . -71.94 41.37 0.71 Allowed Glycine 0 C--O 1.229 -0.203 0 N-CA-C 115.056 0.782 . . . . 0.0 115.056 -178.494 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.705 HG22 HG13 ' A' ' 11' ' ' VAL . 10.7 tp -154.21 28.99 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-O 122.169 0.985 . . . . 0.0 110.441 178.291 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 60.04 43.76 97.91 Favored Glycine 0 CA--C 1.521 0.411 0 CA-C-N 114.673 -1.149 . . . . 0.0 115.141 177.505 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.1 t -151.27 137.03 10.9 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-N 117.726 0.763 . . . . 0.0 110.435 178.571 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.595 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 72.3 Cg_endo -77.71 127.01 8.5 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.725 2.283 . . . . 0.0 112.921 -179.069 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 17.6 mm -114.28 38.03 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 122.016 0.912 . . . . 0.0 108.964 179.246 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.7 p -177.96 147.73 0.48 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.029 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.68 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.8 m-85 -144.34 171.85 13.76 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.536 ' HB2' HG23 ' A' ' 6' ' ' VAL . 90.5 m-85 -96.08 -58.82 1.98 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.303 0.573 . . . . 0.0 110.626 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.453 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.252 1.252 0 CA-C-O 117.459 -1.745 . . . . 0.0 110.003 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.332 0 CA-C-O 120.221 -0.211 . . . . 0.0 113.403 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -139.57 -120.97 1.82 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.717 -179.273 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -126.07 143.81 50.97 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.723 ' HA3' ' O ' ' A' ' 20' ' ' TYR . . . -179.99 -125.45 0.96 Allowed Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.551 -179.438 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 30.4 m80 -118.99 -57.54 2.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.85 0.325 . . . . 0.0 111.575 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.528 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 47.3 t -88.6 128.84 51.2 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-O 120.888 0.375 . . . . 0.0 110.345 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -61.01 140.91 92.59 Favored 'Trans proline' 0 CA--C 1.53 0.285 0 C-N-CA 123.523 2.815 . . . . 0.0 114.495 -178.446 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.772 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.2 mt-10 -91.14 -70.83 0.66 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.205 178.919 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 42.9 m-85 -124.48 144.47 50.08 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.901 -179.611 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.622 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.0 OUTLIER -107.88 149.48 28.23 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.823 179.645 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 15' ' ' THR . 27.2 m -92.66 175.53 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.2 178.615 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.35 -21.79 60.32 Favored Glycine 0 C--O 1.228 -0.247 0 CA-C-N 116.09 -0.505 . . . . 0.0 113.436 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.417 ' H ' HG23 ' A' ' 11' ' ' VAL . 4.7 mt -83.02 28.92 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 121.185 0.517 . . . . 0.0 111.328 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 49.28 44.38 34.77 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 115.559 -0.746 . . . . 0.0 114.162 178.733 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.435 ' O ' HG22 ' A' ' 11' ' ' VAL . 7.8 t -150.67 140.42 13.84 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 117.115 0.457 . . . . 0.0 110.849 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.622 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 51.3 Cg_endo -70.18 140.53 41.32 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.79 2.327 . . . . 0.0 112.194 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.407 ' O ' HG12 ' A' ' 17' ' ' ILE . 14.7 tt -123.44 30.29 2.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 122.302 1.048 . . . . 0.0 109.713 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.1 p -179.15 151.48 0.5 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.479 -1.237 . . . . 0.0 110.071 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.494 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 10.3 m-85 -146.26 171.35 15.1 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.165 -0.679 . . . . 0.0 109.165 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.772 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.2 OUTLIER -139.99 -120.91 0.12 Allowed 'General case' 0 C--N 1.325 -0.483 0 O-C-N 123.045 0.216 . . . . 0.0 110.698 178.78 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.419 ' N ' ' HD1' ' A' ' 20' ' ' TYR . . . . . . . . 0 C--O 1.245 0.811 0 CA-C-O 118.516 -1.158 . . . . 0.0 112.569 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.289 0 CA-C-O 120.573 -0.015 . . . . 0.0 113.133 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 178.9 -137.59 3.26 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.063 -0.589 . . . . 0.0 111.776 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.75 137.77 25.36 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.35 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.642 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.45 -129.24 1.57 Allowed Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.369 -179.293 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 15.1 m-70 -118.57 -36.53 3.48 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.572 0.186 . . . . 0.0 111.204 -179.175 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.7 t -88.1 117.04 67.97 Favored Pre-proline 0 C--N 1.33 -0.26 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 -179.281 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -62.68 134.66 48.47 Favored 'Trans proline' 0 N--CA 1.471 0.189 0 C-N-CA 123.2 2.6 . . . . 0.0 113.845 -178.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -90.62 -72.24 0.58 Allowed 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.667 178.882 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -128.36 144.47 51.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.856 -179.61 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -109.56 135.03 51.21 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 66.9 t -147.76 145.5 18.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.963 0.411 . . . . 0.0 111.159 -179.411 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.73 -60.82 0.74 Allowed Glycine 0 CA--C 1.503 -0.683 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.906 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 8.2 pt -152.31 40.07 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-O 121.15 0.5 . . . . 0.0 110.445 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.06 23.85 74.53 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.262 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.8 t -102.64 133.73 20.3 Favored Pre-proline 0 C--N 1.325 -0.479 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -76.73 116.7 4.32 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.233 1.955 . . . . 0.0 112.751 -178.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.82 HD13 ' H ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -103.2 30.23 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 121.964 0.888 . . . . 0.0 109.72 179.047 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 p -175.88 146.77 0.74 Allowed 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 114.353 -1.294 . . . . 0.0 109.9 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.642 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 22.6 m-85 -136.97 173.24 11.91 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -91.45 -56.72 3.02 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.358 0.599 . . . . 0.0 110.417 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.414 0 CA-C-O 117.564 -1.687 . . . . 0.0 110.092 -179.714 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.235 0 N-CA-C 113.755 0.262 . . . . 0.0 113.755 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 164.7 -137.82 4.93 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.178 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -130.66 141.94 50.43 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 179.142 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.4 ' H ' ' HB2' ' A' ' 19' ' ' PHE . . . -179.75 -127.62 1.13 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.101 -179.451 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 35.3 m170 -125.94 -43.66 1.82 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.553 0.216 . . . . 0.0 111.1 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.22 127.45 55.22 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -63.0 137.3 61.4 Favored 'Trans proline' 0 CA--C 1.529 0.246 0 C-N-CA 123.017 2.478 . . . . 0.0 113.807 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.611 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.2 mt-10 -89.67 -73.25 0.52 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.885 179.271 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -121.93 143.66 49.33 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.158 -179.211 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.431 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 3.3 m-85 -110.88 149.01 31.22 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.706 179.442 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.7 m -83.84 -167.56 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.589 179.095 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.65 -41.36 95.66 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 121.251 -0.499 . . . . 0.0 113.506 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 18.8 pt -87.67 33.27 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.766 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.27 32.47 36.78 Favored Glycine 0 CA--C 1.52 0.352 0 CA-C-N 115.71 -0.677 . . . . 0.0 114.224 178.781 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.1 m -105.5 121.61 45.55 Favored Pre-proline 0 C--N 1.322 -0.622 0 O-C-N 122.476 -0.426 . . . . 0.0 110.361 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 56.2 Cg_endo -73.05 125.54 10.45 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.338 2.025 . . . . 0.0 112.373 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 pt -113.79 34.29 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.45 0.643 . . . . 0.0 110.444 179.725 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.0 p -179.71 147.96 0.31 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.749 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.4 ' HB2' ' H ' ' A' ' 4' ' ' GLY . 26.0 m-85 -144.29 174.37 10.96 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 -179.714 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.611 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -159.82 -160.54 0.82 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.083 178.557 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.046 0 CA-C-O 117.706 -1.608 . . . . 0.0 110.981 179.718 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 113.723 0.249 . . . . 0.0 113.723 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.92 -118.54 1.02 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.376 -0.916 . . . . 0.0 112.833 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.4 144.2 46.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.813 0.34 . . . . 0.0 110.559 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.46 -122.9 0.8 Allowed Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.892 -179.634 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -137.21 -43.19 0.56 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.661 0.267 . . . . 0.0 110.645 179.8 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.21 127.36 55.57 Favored Pre-proline 0 C--N 1.328 -0.353 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -62.7 135.99 55.55 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.979 2.453 . . . . 0.0 113.988 -178.487 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.601 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 90.0 mt-10 -91.43 -75.87 0.46 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.246 178.888 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 27.9 m-85 -110.25 141.66 42.91 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.133 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.555 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 6.5 m-85 -110.34 143.94 39.81 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.684 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 40.7 t -85.78 152.08 3.62 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.344 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -54.49 -23.27 26.91 Favored Glycine 0 CA--C 1.52 0.359 0 C-N-CA 121.409 -0.424 . . . . 0.0 113.389 -179.648 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 10.0 mm -82.64 32.32 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-O 121.379 0.609 . . . . 0.0 110.942 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.3 46.55 57.27 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 115.613 -0.721 . . . . 0.0 114.334 178.667 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 6.2 t -150.52 133.84 8.75 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 117.381 0.591 . . . . 0.0 111.23 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 11.2 Cg_exo -70.57 142.37 44.18 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 123.021 2.48 . . . . 0.0 111.821 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.42 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.4 tp -124.25 29.94 2.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 122.26 1.029 . . . . 0.0 110.178 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.42 ' OG ' ' HB2' ' A' ' 8' ' ' GLU . 9.8 p 179.63 149.9 0.32 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.703 179.619 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -144.97 172.24 13.32 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.731 0.301 . . . . 0.0 110.316 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.601 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -160.1 -161.52 0.89 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.652 -0.703 . . . . 0.0 109.859 178.542 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 117.718 -1.601 . . . . 0.0 111.031 179.664 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.263 0 N-CA-C 113.419 0.128 . . . . 0.0 113.419 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 162.68 -137.35 4.77 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.063 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -140.01 141.22 36.34 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.125 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.582 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 175.79 -120.5 0.76 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.413 -179.14 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -126.3 -41.41 1.9 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 42.6 t -88.33 120.53 70.49 Favored Pre-proline 0 C--O 1.22 -0.474 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.266 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -61.32 132.98 43.8 Favored 'Trans proline' 0 CA--C 1.53 0.312 0 C-N-CA 122.892 2.395 . . . . 0.0 113.901 -178.874 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.539 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 91.4 mt-10 -92.57 -74.91 0.5 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.185 178.825 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -117.59 143.55 46.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.103 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -107.23 146.93 30.81 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.241 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.741 HG13 HG22 ' A' ' 13' ' ' ILE . 9.1 p -79.81 165.13 2.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.29 178.811 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.7 41.34 0.54 Allowed Glycine 0 CA--C 1.518 0.254 0 N-CA-C 114.763 0.665 . . . . 0.0 114.763 -178.591 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.741 HG22 HG13 ' A' ' 11' ' ' VAL . 13.0 tt -157.46 28.27 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-O 122.09 0.947 . . . . 0.0 110.192 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.22 53.4 44.94 Favored Glycine 0 CA--C 1.519 0.312 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.727 178.3 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.435 ' O ' HG12 ' A' ' 11' ' ' VAL . 27.8 m -148.94 126.53 5.65 Favored Pre-proline 0 C--N 1.323 -0.574 0 O-C-N 122.39 -0.476 . . . . 0.0 110.391 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 11.5 Cg_exo -70.17 126.38 12.98 Favored 'Trans proline' 0 N--CA 1.465 -0.205 0 C-N-CA 122.408 2.072 . . . . 0.0 111.752 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.3 pt -115.58 31.95 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.52 0.676 . . . . 0.0 110.655 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 11.2 p 179.23 148.31 0.23 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.825 -1.079 . . . . 0.0 109.543 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.582 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 3.7 m-85 -147.43 164.19 34.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.688 0.28 . . . . 0.0 110.736 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.551 ' O ' ' HA3' ' A' ' 4' ' ' GLY . 29.4 m-85 -97.25 163.89 12.72 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.429 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.15 0 CA-C-O 117.751 -1.583 . . . . 0.0 110.998 179.105 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' GLY . . . . . 0.444 ' N ' ' HB2' ' A' ' 18' ' ' SER . . . . . . . . 0 CA--C 1.52 0.388 0 N-CA-C 113.918 0.327 . . . . 0.0 113.918 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -120.38 -134.51 4.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.317 -0.944 . . . . 0.0 113.084 -179.097 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -132.99 52.63 2.07 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.093 0.473 . . . . 0.0 110.776 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -76.08 -121.96 0.16 Allowed Glycine 0 CA--C 1.519 0.317 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.633 179.811 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 44.9 m170 -122.15 -51.7 1.99 Allowed 'General case' 0 C--N 1.326 -0.448 0 O-C-N 122.465 -0.432 . . . . 0.0 111.296 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.566 HG23 ' CD1' ' A' ' 20' ' ' TYR . 4.4 m -89.63 132.88 35.57 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 110.194 -0.299 . . . . 0.0 110.194 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.4 ' HA ' ' O ' ' A' ' 18' ' ' SER . 14.5 Cg_endo -58.03 139.34 90.08 Favored 'Trans proline' 0 CA--C 1.53 0.314 0 C-N-CA 123.513 2.809 . . . . 0.0 114.484 -178.061 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.525 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.7 mt-10 -92.64 -69.97 0.72 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.065 178.907 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -121.82 144.43 48.83 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.292 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.492 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 4.6 m-85 -111.28 145.95 37.87 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.48 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 42.7 t -76.62 153.69 5.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 177.874 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -52.28 -26.6 21.93 Favored Glycine 0 C--O 1.227 -0.333 0 C-N-CA 121.485 -0.388 . . . . 0.0 113.763 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.0 mt -84.32 31.19 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 CA-C-O 121.283 0.563 . . . . 0.0 111.19 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 53.53 51.45 47.97 Favored Glycine 0 CA--C 1.521 0.428 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.842 178.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 26.9 m -144.62 123.74 7.0 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 122.332 -0.511 . . . . 0.0 111.048 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.492 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 39.9 Cg_endo -67.89 136.71 39.27 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.485 2.123 . . . . 0.0 111.916 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.423 ' O ' HG12 ' A' ' 17' ' ' ILE . 15.3 tt -129.93 34.07 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 122.227 1.013 . . . . 0.0 110.42 -179.528 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.444 ' HB2' ' N ' ' A' ' 1' ' ' GLY . 13.1 p 179.76 149.44 0.31 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.825 -1.08 . . . . 0.0 109.637 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -147.58 165.9 28.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.708 0.29 . . . . 0.0 110.386 -179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.566 ' CD1' HG23 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -158.24 -149.08 0.21 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.189 178.818 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.811 0 CA-C-O 118.68 -1.067 . . . . 0.0 110.668 179.883 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 CA-C-O 120.235 -0.203 . . . . 0.0 113.592 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.5 -120.54 1.49 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.81 -179.178 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.44 145.75 44.98 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.692 0.282 . . . . 0.0 110.62 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.21 -124.48 0.86 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.005 -179.651 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 70.5 m80 -133.29 -47.91 0.84 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.457 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 2.5 p -89.47 128.34 51.35 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.863 179.175 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.494 ' HB3' ' HG3' ' A' ' 16' ' ' PRO . 37.8 Cg_exo -58.77 137.89 82.6 Favored 'Trans proline' 0 N--CA 1.473 0.301 0 C-N-CA 123.443 2.762 . . . . 0.0 113.968 -178.37 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.472 ' HG2' ' CD1' ' A' ' 20' ' ' TYR . 91.8 mt-10 -89.73 -73.32 0.52 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.475 178.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -125.35 135.58 52.59 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.672 -179.704 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.486 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.7 m-85 -91.19 156.28 17.97 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.458 178.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.625 HG23 ' H ' ' A' ' 13' ' ' ILE . 35.1 m -120.38 -175.57 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 120.748 0.309 . . . . 0.0 110.854 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.05 -18.58 64.85 Favored Glycine 0 C--O 1.227 -0.305 0 CA-C-N 116.03 -0.532 . . . . 0.0 113.404 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.625 ' H ' HG23 ' A' ' 11' ' ' VAL . 6.0 mt -84.14 19.27 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.542 0.687 . . . . 0.0 111.022 -179.637 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.89 -44.03 0.82 Allowed Glycine 0 CA--C 1.521 0.42 0 CA-C-N 115.396 -0.82 . . . . 0.0 113.852 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.441 ' O ' HG22 ' A' ' 11' ' ' VAL . 10.0 t -88.47 137.58 30.53 Favored Pre-proline 0 C--N 1.32 -0.712 0 CA-C-O 121.097 0.475 . . . . 0.0 111.226 -179.012 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.494 ' HG3' ' HB3' ' A' ' 7' ' ' PRO . 59.7 Cg_endo -72.65 140.68 33.02 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.891 2.394 . . . . 0.0 111.971 179.83 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.2 mt -108.24 38.21 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 122.213 1.006 . . . . 0.0 109.173 179.416 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.8 p -167.9 143.82 3.93 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.381 179.733 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -147.15 174.16 11.84 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.453 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.472 ' CD1' ' HG2' ' A' ' 8' ' ' GLU . 20.6 p90 -158.75 -159.84 0.82 Allowed 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.076 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.899 0 CA-C-O 118.637 -1.09 . . . . 0.0 111.035 179.833 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.32 0 CA-C-O 120.488 -0.062 . . . . 0.0 113.117 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.62 -138.33 4.34 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.183 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.459 ' HA ' ' HB2' ' A' ' 19' ' ' PHE . . . -145.94 141.94 28.25 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.591 0.234 . . . . 0.0 110.415 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.445 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.25 -127.52 1.41 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 121.014 -0.612 . . . . 0.0 111.932 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.482 ' H ' ' C ' ' A' ' 21' ' ' GLY . 45.3 m80 -116.88 -37.16 3.66 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.604 0.24 . . . . 0.0 110.762 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.7 t -88.45 120.18 70.32 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.302 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.07 139.14 45.83 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 122.954 2.436 . . . . 0.0 113.236 -179.329 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -95.34 -75.57 0.52 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.601 179.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.404 ' O ' ' HA ' ' A' ' 16' ' ' PRO . 27.6 m-85 -107.41 140.58 40.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.073 0.463 . . . . 0.0 111.831 -178.731 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.447 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.5 m-85 -115.8 147.7 40.69 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.239 -0.891 . . . . 0.0 109.053 178.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 15' ' ' THR . 29.9 m -86.64 -167.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 C-N-CA 120.992 -0.283 . . . . 0.0 110.92 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -57.56 -42.18 93.91 Favored Glycine 0 C--O 1.227 -0.329 0 C-N-CA 121.387 -0.435 . . . . 0.0 113.64 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 17.6 pt -86.75 32.65 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 120.932 0.396 . . . . 0.0 111.964 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.59 29.13 31.45 Favored Glycine 0 CA--C 1.519 0.33 0 CA-C-N 115.666 -0.697 . . . . 0.0 114.051 178.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.451 ' O ' HG22 ' A' ' 11' ' ' VAL . 18.9 m -102.57 120.21 53.68 Favored Pre-proline 0 C--N 1.321 -0.671 0 CA-C-N 117.003 0.401 . . . . 0.0 110.497 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 72.8 Cg_endo -80.2 124.64 5.49 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.269 1.98 . . . . 0.0 112.691 -179.549 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.0 mt -116.15 39.33 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 122.333 1.063 . . . . 0.0 108.894 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 p -175.92 146.48 0.71 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.451 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.459 ' HB2' ' HA ' ' A' ' 3' ' ' ALA . 56.4 m-85 -131.54 -172.7 2.92 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 10.6 t80 -122.71 -62.66 1.34 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.55 0.691 . . . . 0.0 110.197 -179.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.482 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.442 -0.904 0 CA-C-N 114.596 -1.184 . . . . 0.0 110.233 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.286 0 N-CA-C 113.221 0.048 . . . . 0.0 113.221 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.35 -137.03 3.91 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.112 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.9 138.76 25.8 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.333 -0.247 . . . . 0.0 110.333 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.669 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 173.71 -127.54 1.36 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.255 -179.227 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -118.64 -37.75 3.23 Favored 'General case' 0 C--N 1.328 -0.363 0 O-C-N 122.827 -0.219 . . . . 0.0 111.248 -179.136 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.5 t -88.14 115.22 62.49 Favored Pre-proline 0 C--O 1.222 -0.345 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 -179.306 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.76 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 34.8 Cg_exo -62.57 137.55 64.96 Favored 'Trans proline' 0 N--CA 1.473 0.28 0 C-N-CA 123.423 2.749 . . . . 0.0 114.165 -178.692 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.0 mt-10 -97.13 -72.11 0.65 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.257 178.439 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 27.8 m-85 -116.62 142.53 46.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.667 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -110.73 149.04 31.06 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.84 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 26.9 m -82.87 -167.41 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.688 179.35 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.78 -42.01 96.25 Favored Glycine 0 C--O 1.227 -0.322 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.588 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 18.2 pt -87.5 33.83 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.08 31.28 32.92 Favored Glycine 0 CA--C 1.519 0.335 0 CA-C-N 115.71 -0.677 . . . . 0.0 114.174 178.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 18.0 m -104.77 125.76 33.0 Favored Pre-proline 0 C--N 1.322 -0.588 0 O-C-N 122.539 -0.389 . . . . 0.0 110.135 179.751 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.76 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 31.3 Cg_endo -65.07 125.77 15.24 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.4 2.067 . . . . 0.0 112.226 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.416 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -115.98 29.09 2.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 122.508 1.147 . . . . 0.0 109.581 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.8 p 179.68 150.08 0.33 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 114.249 -1.341 . . . . 0.0 109.725 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.669 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 14.1 m-85 -140.31 171.38 14.23 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -90.78 -56.41 3.19 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.48 0.657 . . . . 0.0 110.349 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.256 1.492 0 CA-C-O 117.56 -1.689 . . . . 0.0 110.001 -179.841 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.38 0 N-CA-C 113.59 0.196 . . . . 0.0 113.59 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -108.27 -134.68 7.34 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.655 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.417 ' HA ' ' HD1' ' A' ' 19' ' ' PHE . . . -145.38 47.89 1.28 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.031 0.443 . . . . 0.0 111.16 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.639 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . -80.41 -126.06 0.64 Allowed Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.931 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 61.6 m80 -111.47 -44.83 3.46 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -178.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.574 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.8 m -89.42 122.92 67.99 Favored Pre-proline 0 C--O 1.221 -0.431 0 CA-C-O 120.744 0.307 . . . . 0.0 110.962 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.662 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 40.1 Cg_exo -58.27 139.55 90.95 Favored 'Trans proline' 0 N--CA 1.474 0.379 0 C-N-CA 123.32 2.68 . . . . 0.0 114.449 -178.312 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.436 ' HG3' ' C ' ' A' ' 19' ' ' PHE . 94.7 mt-10 -95.26 -72.28 0.63 Allowed 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.675 179.078 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -108.17 144.91 34.94 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.541 -179.619 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.532 ' CZ ' ' HB2' ' A' ' 7' ' ' PRO . 4.7 m-85 -123.72 141.74 51.73 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.205 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.487 HG23 HD12 ' A' ' 17' ' ' ILE . 43.8 t -78.2 155.12 5.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -50.99 -30.52 23.08 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.496 -0.383 . . . . 0.0 113.494 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.2 pt -84.41 30.53 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.847 0.356 . . . . 0.0 111.898 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 55.8 50.09 62.82 Favored Glycine 0 CA--C 1.519 0.283 0 CA-C-N 115.926 -0.579 . . . . 0.0 113.64 178.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 15.2 m -133.85 118.0 14.18 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 117.142 0.471 . . . . 0.0 111.311 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.662 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 4.6 Cg_exo -77.05 130.97 11.62 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.988 2.459 . . . . 0.0 111.719 179.572 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.631 HD13 ' H ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -123.88 33.61 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.541 0.686 . . . . 0.0 111.055 179.979 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 p 179.83 152.92 0.47 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.463 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.639 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 8.5 m-85 -144.48 166.92 23.76 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.574 ' HB2' HG23 ' A' ' 6' ' ' VAL . 97.2 m-85 -90.06 -115.72 0.07 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.615 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.102 0 CA-C-O 118.123 -1.376 . . . . 0.0 110.633 178.245 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.226 0 CA-C-O 120.555 -0.025 . . . . 0.0 113.077 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.49 -139.14 4.57 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.976 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.62 140.35 30.09 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.659 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.64 -128.94 1.51 Allowed Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.077 -179.246 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.411 ' H ' ' C ' ' A' ' 21' ' ' GLY . 62.7 m80 -114.65 -43.11 3.18 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 111.59 0.219 . . . . 0.0 111.59 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.607 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.5 m -89.89 117.82 68.42 Favored Pre-proline 0 C--O 1.223 -0.296 0 CA-C-O 120.825 0.345 . . . . 0.0 110.757 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.468 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 26.8 Cg_exo -63.61 139.61 70.71 Favored 'Trans proline' 0 CA--C 1.53 0.296 0 C-N-CA 123.506 2.804 . . . . 0.0 114.236 -178.301 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.433 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 93.2 mt-10 -91.67 -72.41 0.59 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.425 178.584 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -112.67 139.93 47.87 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.266 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.528 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 4.5 m-85 -111.41 143.82 41.61 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.192 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.9 t -85.43 151.12 3.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 178.373 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -53.58 -24.53 24.91 Favored Glycine 0 C--O 1.226 -0.404 0 C-N-CA 121.499 -0.381 . . . . 0.0 113.539 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.3 mt -82.22 32.61 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-O 121.182 0.515 . . . . 0.0 111.092 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.0 47.55 54.06 Favored Glycine 0 CA--C 1.52 0.368 0 CA-C-N 115.699 -0.682 . . . . 0.0 114.237 178.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.2 t -150.62 129.58 6.27 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 117.359 0.58 . . . . 0.0 111.43 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 85.5 Cg_endo -85.64 131.63 4.0 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.918 2.412 . . . . 0.0 112.493 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -115.47 35.92 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.355 0.598 . . . . 0.0 110.959 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.5 p -176.2 148.66 0.8 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.189 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.659 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 11.9 m-85 -141.34 172.13 13.11 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.607 ' HB2' HG23 ' A' ' 6' ' ' VAL . 93.7 m-85 -95.02 -56.79 2.63 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.554 0.692 . . . . 0.0 110.008 179.753 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.411 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.441 -1.006 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.261 0 CA-C-O 120.313 -0.159 . . . . 0.0 113.305 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.15 -118.0 1.04 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.446 -179.303 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.52 145.09 45.58 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.632 0.253 . . . . 0.0 110.528 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.27 -131.82 1.67 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 121.033 -0.603 . . . . 0.0 111.632 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -123.18 -48.5 1.98 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.069 0.435 . . . . 0.0 110.457 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.487 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 41.8 t -89.96 130.04 44.01 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.253 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -60.74 137.98 76.54 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 123.154 2.569 . . . . 0.0 113.798 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.752 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 90.9 mt-10 -89.09 -73.95 0.49 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.622 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -124.43 143.29 50.71 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.022 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.552 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.0 OUTLIER -104.9 148.39 26.73 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.552 179.167 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 15' ' ' THR . 35.9 m -92.46 178.87 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 116.561 -0.29 . . . . 0.0 110.543 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -60.28 -26.2 63.6 Favored Glycine 0 N--CA 1.453 -0.218 0 CA-C-N 116.087 -0.506 . . . . 0.0 113.54 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.416 ' H ' HG23 ' A' ' 11' ' ' VAL . 9.6 mm -84.06 31.48 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.064 0.459 . . . . 0.0 110.958 -179.765 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 46.0 43.39 12.84 Favored Glycine 0 N--CA 1.46 0.297 0 CA-C-N 115.575 -0.739 . . . . 0.0 113.782 179.156 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.539 ' O ' HG22 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -143.23 135.39 13.23 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-O 120.795 0.331 . . . . 0.0 111.287 -179.261 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 71.7 Cg_endo -84.49 127.35 3.79 Favored 'Trans proline' 0 N--CA 1.454 -0.818 0 C-N-CA 122.562 2.174 . . . . 0.0 112.322 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.6 mt -115.77 39.97 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 122.216 1.007 . . . . 0.0 108.857 179.129 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.9 p -171.58 144.58 1.91 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.841 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -147.32 173.42 12.61 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.752 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -153.61 169.64 22.76 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.216 0.532 . . . . 0.0 111.398 178.741 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.949 0 CA-C-N 114.648 -1.16 . . . . 0.0 112.529 -179.963 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.244 0 CA-C-O 120.541 -0.033 . . . . 0.0 113.074 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.9 -138.33 4.46 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.988 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.34 140.78 32.22 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.328 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.693 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.11 -132.86 2.37 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.459 -179.152 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.461 ' H ' ' C ' ' A' ' 21' ' ' GLY . 23.8 m170 -109.23 -47.34 3.43 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.571 0.224 . . . . 0.0 111.352 -178.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.544 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.45 120.72 69.66 Favored Pre-proline 0 C--O 1.225 -0.233 0 CA-C-O 120.804 0.335 . . . . 0.0 111.206 -179.218 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.607 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 24.7 Cg_exo -64.17 138.98 64.24 Favored 'Trans proline' 0 CA--C 1.529 0.247 0 C-N-CA 123.601 2.868 . . . . 0.0 114.288 -178.584 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.446 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 94.4 mt-10 -91.63 -68.93 0.76 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.568 178.054 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -128.54 142.74 50.97 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.998 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.579 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.5 m-85 -98.07 150.13 21.74 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.369 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.587 HG13 ' H ' ' A' ' 13' ' ' ILE . 9.1 p -88.89 165.41 2.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.206 178.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -55.85 -24.21 40.65 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 121.568 -0.348 . . . . 0.0 113.854 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.587 ' H ' HG13 ' A' ' 11' ' ' VAL . 5.0 mt -82.41 33.32 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 120.938 0.399 . . . . 0.0 111.333 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 47.5 43.11 20.38 Favored Glycine 0 CA--C 1.521 0.426 0 CA-C-N 115.827 -0.624 . . . . 0.0 114.027 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.476 ' O ' HG12 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -146.92 140.73 15.28 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.902 0.351 . . . . 0.0 111.045 -179.472 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.607 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 35.6 Cg_endo -66.28 126.38 15.57 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.29 1.993 . . . . 0.0 111.824 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.43 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -114.53 31.07 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 122.243 1.021 . . . . 0.0 110.027 -179.606 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 25.2 p 179.63 149.13 0.29 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.12 179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.693 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 11.3 m-85 -142.72 172.0 13.28 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.544 ' HB2' HG23 ' A' ' 6' ' ' VAL . 93.6 m-85 -95.6 -58.35 2.14 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.363 0.601 . . . . 0.0 110.42 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.461 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.253 1.316 0 CA-C-O 117.414 -1.77 . . . . 0.0 110.064 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.301 0 N-CA-C 113.214 0.045 . . . . 0.0 113.214 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.28 -139.29 4.49 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.005 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.91 140.01 29.49 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.662 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.43 -129.24 1.57 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.054 -179.245 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.41 ' H ' ' C ' ' A' ' 21' ' ' GLY . 62.8 m80 -114.6 -43.03 3.2 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.481 0.178 . . . . 0.0 111.481 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.608 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.71 117.31 68.02 Favored Pre-proline 0 C--N 1.33 -0.274 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.826 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.478 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 24.6 Cg_exo -64.09 140.44 71.93 Favored 'Trans proline' 0 CA--C 1.529 0.271 0 C-N-CA 123.518 2.812 . . . . 0.0 114.258 -178.391 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.438 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 94.2 mt-10 -91.91 -70.93 0.67 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.447 178.733 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -116.19 142.4 46.87 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.551 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.55 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 3.7 m-85 -114.06 145.41 41.63 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.405 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 42.3 t -82.94 152.92 3.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -54.41 -23.65 27.66 Favored Glycine 0 C--O 1.226 -0.347 0 C-N-CA 121.383 -0.437 . . . . 0.0 113.245 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.2 mt -83.11 32.26 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 CA-C-O 121.209 0.528 . . . . 0.0 111.091 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 51.93 50.14 45.74 Favored Glycine 0 CA--C 1.52 0.348 0 CA-C-N 115.632 -0.713 . . . . 0.0 114.323 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.2 t -150.54 129.44 6.23 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 117.437 0.619 . . . . 0.0 111.345 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 71.7 Cg_endo -80.26 134.8 10.45 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.807 2.338 . . . . 0.0 112.629 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.0 pp -119.14 33.19 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.254 0.549 . . . . 0.0 111.547 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 p -179.22 150.76 0.46 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.094 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.662 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.3 m-85 -140.78 172.17 13.08 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.476 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.608 ' HB2' HG23 ' A' ' 6' ' ' VAL . 95.2 m-85 -95.61 -56.68 2.61 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.509 0.671 . . . . 0.0 110.086 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.41 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.441 -0.978 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.257 0 CA-C-O 120.475 -0.07 . . . . 0.0 113.108 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.95 -136.15 3.71 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.965 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -144.6 140.75 28.94 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 179.286 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.7 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.33 -132.67 2.45 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.668 -179.156 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.48 ' H ' ' C ' ' A' ' 21' ' ' GLY . 20.4 m170 -110.03 -43.74 3.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.534 0.207 . . . . 0.0 111.352 -178.703 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 40.7 t -88.2 118.96 70.15 Favored Pre-proline 0 C--O 1.223 -0.334 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.728 -178.774 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.545 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 31.8 Cg_endo -64.41 138.23 59.29 Favored 'Trans proline' 0 CA--C 1.528 0.225 0 C-N-CA 123.208 2.606 . . . . 0.0 114.234 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.412 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 92.2 mt-10 -95.67 -71.66 0.66 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.516 -0.766 . . . . 0.0 110.372 178.729 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -117.9 142.35 47.43 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.687 -179.611 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -111.95 136.94 50.61 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 43.4 t -145.33 137.69 20.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 120.966 0.412 . . . . 0.0 110.932 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.69 -68.4 0.23 Allowed Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.133 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.3 pt -156.16 46.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 114.78 -0.71 . . . . 0.0 109.736 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.38 18.23 79.98 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -178.59 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.456 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 0.7 OUTLIER -89.41 125.81 60.41 Favored Pre-proline 0 N--CA 1.447 -0.595 0 CA-C-N 115.113 -0.544 . . . . 0.0 110.623 179.975 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.545 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 17.9 Cg_exo -66.66 125.64 14.14 Favored 'Trans proline' 0 N--CA 1.463 -0.28 0 C-N-CA 122.778 2.319 . . . . 0.0 112.33 -179.422 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.411 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -118.34 27.88 3.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 122.714 1.245 . . . . 0.0 109.376 179.343 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.4 p 179.57 150.28 0.33 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 113.899 -1.5 . . . . 0.0 109.475 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.7 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.5 m-85 -142.18 172.22 12.99 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.412 ' CZ ' ' HG2' ' A' ' 8' ' ' GLU . 93.6 m-85 -92.82 -59.46 2.05 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.461 0.648 . . . . 0.0 110.444 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.48 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.253 1.328 0 CA-C-O 117.244 -1.864 . . . . 0.0 109.987 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.281 0 N-CA-C 112.969 -0.052 . . . . 0.0 112.969 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.93 -141.95 5.62 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.93 -0.652 . . . . 0.0 111.714 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.73 46.24 1.02 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.133 0.492 . . . . 0.0 111.095 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.599 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . -81.83 -127.33 0.94 Allowed Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.668 -0.696 . . . . 0.0 112.815 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.1 m-70 -114.31 -43.37 3.21 Favored 'General case' 0 C--N 1.327 -0.402 0 O-C-N 122.444 -0.445 . . . . 0.0 111.89 -178.676 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.543 HG13 ' HB2' ' A' ' 20' ' ' TYR . 2.4 p -89.37 124.76 63.71 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 120.788 0.328 . . . . 0.0 110.682 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.53 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 50.8 Cg_exo -56.36 138.8 85.1 Favored 'Trans proline' 0 N--CA 1.474 0.367 0 C-N-CA 123.53 2.82 . . . . 0.0 114.467 -178.341 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.419 ' HG2' ' CE1' ' A' ' 20' ' ' TYR . 89.8 mt-10 -98.5 -72.88 0.64 Allowed 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.55 178.714 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -118.84 140.8 49.37 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.085 -179.432 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.47 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 5.0 m-85 -108.74 145.68 34.72 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.389 -0.823 . . . . 0.0 108.973 179.295 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.0 p -165.44 151.06 2.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.172 0.511 . . . . 0.0 111.435 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.22 -62.17 0.57 Allowed Glycine 0 CA--C 1.505 -0.553 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.678 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.1 pt -155.75 41.7 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 114.828 -0.686 . . . . 0.0 109.71 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.51 13.18 82.02 Favored Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.645 -179.187 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.8 p -89.66 129.89 45.21 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.688 -0.256 . . . . 0.0 110.88 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.53 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 56.2 Cg_endo -74.14 122.51 7.65 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.238 1.959 . . . . 0.0 112.069 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 16.9 mm -113.51 37.19 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 122.182 0.991 . . . . 0.0 109.028 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 25.1 p 179.85 148.25 0.28 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.566 -1.197 . . . . 0.0 109.789 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.599 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 9.1 m-85 -141.04 167.53 21.96 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.535 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.543 ' HB2' HG13 ' A' ' 6' ' ' VAL . 94.1 m-85 -84.37 -114.54 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.453 0 CA-C-O 117.998 -1.445 . . . . 0.0 111.023 178.857 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.338 0 CA-C-O 120.437 -0.091 . . . . 0.0 113.247 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.66 -137.08 4.15 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.144 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.85 140.12 26.82 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.675 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.53 -128.23 1.51 Allowed Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.344 -179.255 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -115.06 -40.63 3.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.672 0.236 . . . . 0.0 111.493 -178.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.8 t -88.54 115.75 64.27 Favored Pre-proline 0 C--O 1.221 -0.401 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.302 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -64.25 140.03 68.87 Favored 'Trans proline' 0 CA--C 1.532 0.388 0 C-N-CA 123.208 2.605 . . . . 0.0 114.133 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -97.36 -74.4 0.57 Allowed 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.689 179.095 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.0 m-85 -105.3 142.6 34.79 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.457 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.499 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 5.8 m-85 -120.45 143.01 48.73 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.402 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.447 ' CG2' HD12 ' A' ' 17' ' ' ILE . 38.4 t -84.18 153.77 3.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -52.32 -28.02 26.24 Favored Glycine 0 C--O 1.228 -0.252 0 C-N-CA 121.551 -0.357 . . . . 0.0 113.683 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.646 HG13 HG22 ' A' ' 15' ' ' THR . 24.9 pt -82.94 31.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 55.25 52.62 46.15 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 114.926 0.73 . . . . 0.0 114.926 177.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.646 HG22 HG13 ' A' ' 13' ' ' ILE . 9.5 t -150.71 129.24 6.06 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 117.703 0.752 . . . . 0.0 111.198 179.089 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.499 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 85.5 Cg_endo -85.46 130.44 3.86 Favored 'Trans proline' 0 N--CA 1.459 -0.501 0 C-N-CA 122.803 2.336 . . . . 0.0 112.704 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.759 HD13 ' H ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -112.95 33.26 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.457 0.646 . . . . 0.0 110.932 179.839 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.6 p -176.98 150.24 0.75 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.157 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.675 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 15.9 m-85 -141.18 173.0 11.91 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -91.05 -56.67 3.08 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.396 0.617 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.343 0 CA-C-O 117.648 -1.64 . . . . 0.0 110.144 -179.792 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.41 0 N-CA-C 113.347 0.099 . . . . 0.0 113.347 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.59 -143.14 7.57 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.869 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.4 48.4 1.56 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.134 0.492 . . . . 0.0 110.865 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.75 -124.5 0.38 Allowed Glycine 0 CA--C 1.519 0.306 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.41 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.411 ' HD1' ' C ' ' A' ' 21' ' ' GLY . 67.8 m80 -121.87 -43.84 2.34 Favored 'General case' 0 C--N 1.328 -0.364 0 O-C-N 122.457 -0.437 . . . . 0.0 111.596 -179.55 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.408 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 25.4 t -88.94 128.79 50.73 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -57.7 136.43 75.52 Favored 'Trans proline' 0 CA--C 1.529 0.256 0 C-N-CA 123.186 2.591 . . . . 0.0 113.677 -178.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.649 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 94.1 mt-10 -93.4 -73.81 0.55 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.523 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -124.27 142.02 51.6 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.926 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.433 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.5 m-85 -107.24 136.95 46.2 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.306 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.5 m -153.64 -177.48 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.687 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.59 -50.38 2.5 Favored Glycine 0 C--O 1.227 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 113.01 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.408 HG13 ' O ' ' A' ' 13' ' ' ILE . 10.9 tp -170.91 37.75 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-O 122.364 1.078 . . . . 0.0 109.419 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.09 13.41 83.38 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.674 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.409 HG23 HD11 ' A' ' 17' ' ' ILE . 9.0 t -96.81 136.6 21.58 Favored Pre-proline 0 C--N 1.325 -0.461 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 45.5 Cg_endo -71.35 122.88 9.07 Favored 'Trans proline' 0 N--CA 1.462 -0.34 0 C-N-CA 122.289 1.993 . . . . 0.0 112.272 -179.244 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.409 HD11 HG23 ' A' ' 15' ' ' THR . 20.9 mm -114.42 37.85 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 122.298 1.047 . . . . 0.0 108.834 179.343 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 17.1 p -179.65 145.77 0.24 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.446 -1.252 . . . . 0.0 109.702 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -147.01 166.94 25.3 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.328 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.649 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -145.87 170.6 16.26 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.292 178.013 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.411 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.25 1.141 0 CA-C-O 118.552 -1.138 . . . . 0.0 111.963 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.404 0 N-CA-C 113.382 0.113 . . . . 0.0 113.382 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.7 -142.8 7.34 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.845 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.68 48.34 1.53 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.169 0.509 . . . . 0.0 110.755 179.618 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.69 -124.34 0.37 Allowed Glycine 0 N--CA 1.451 -0.329 0 CA-C-N 115.553 -0.749 . . . . 0.0 112.391 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.417 ' HD1' ' C ' ' A' ' 21' ' ' GLY . 67.4 m80 -122.33 -43.58 2.3 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 122.515 -0.403 . . . . 0.0 111.509 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.403 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 25.7 t -89.0 127.95 53.79 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.714 -0.221 . . . . 0.0 110.405 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.516 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 52.7 Cg_exo -56.17 136.03 73.07 Favored 'Trans proline' 0 CA--C 1.53 0.287 0 C-N-CA 123.229 2.619 . . . . 0.0 113.717 -179.065 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.648 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 94.1 mt-10 -93.72 -74.25 0.54 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.626 179.265 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -122.78 141.03 52.26 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.846 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.428 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.2 m-85 -108.06 136.52 47.61 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.431 179.407 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -153.83 -178.3 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 O-C-N 123.282 0.364 . . . . 0.0 110.555 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.92 -50.39 2.62 Favored Glycine 0 C--N 1.332 0.306 0 CA-C-N 116.076 -0.511 . . . . 0.0 113.053 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 13' ' ' ILE . 15.3 tt -170.99 38.31 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-O 122.349 1.071 . . . . 0.0 109.353 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.32 14.13 82.85 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.098 -0.955 . . . . 0.0 112.687 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.0 t -97.31 135.82 21.66 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.516 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 50.8 Cg_endo -72.1 123.5 9.3 Favored 'Trans proline' 0 N--CA 1.46 -0.463 0 C-N-CA 122.19 1.926 . . . . 0.0 112.404 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 20.8 mm -113.06 37.35 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 122.276 1.036 . . . . 0.0 108.754 179.329 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 p -179.89 146.37 0.24 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 114.365 -1.289 . . . . 0.0 109.612 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -146.95 166.45 26.74 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.259 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.648 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -145.04 170.67 15.74 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.421 178.054 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.417 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.242 0.625 0 CA-C-O 119.019 -0.879 . . . . 0.0 111.951 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.435 0 CA-C-O 120.272 -0.182 . . . . 0.0 113.553 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -122.81 -127.15 3.25 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.865 -179.151 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -134.86 143.33 46.94 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.68 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 176.43 -133.94 2.45 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.34 -179.346 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.453 ' H ' ' C ' ' A' ' 21' ' ' GLY . 23.7 m170 -109.31 -46.92 3.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.664 0.268 . . . . 0.0 111.201 -178.835 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.536 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.49 122.54 68.25 Favored Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.187 -179.232 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.18 139.98 69.02 Favored 'Trans proline' 0 N--CA 1.472 0.243 0 C-N-CA 123.427 2.751 . . . . 0.0 114.312 -178.629 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.409 ' HG3' ' C ' ' A' ' 19' ' ' PHE . 92.6 mt-10 -92.47 -71.3 0.65 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.347 178.603 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 53.1 m-85 -128.43 142.64 51.04 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.598 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.595 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.2 m-85 -98.23 149.91 22.08 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.053 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.705 HG13 HG22 ' A' ' 13' ' ' ILE . 6.6 p -87.96 172.62 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.643 179.201 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.563 ' H ' HG22 ' A' ' 11' ' ' VAL . . . -71.94 41.37 0.71 Allowed Glycine 0 C--O 1.229 -0.203 0 N-CA-C 115.056 0.782 . . . . 0.0 115.056 -178.494 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.705 HG22 HG13 ' A' ' 11' ' ' VAL . 10.7 tp -154.21 28.99 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-O 122.169 0.985 . . . . 0.0 110.441 178.291 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 60.04 43.76 97.91 Favored Glycine 0 CA--C 1.521 0.411 0 CA-C-N 114.673 -1.149 . . . . 0.0 115.141 177.505 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.1 t -151.27 137.03 10.9 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-N 117.726 0.763 . . . . 0.0 110.435 178.571 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.595 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 72.3 Cg_endo -77.71 127.01 8.5 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.725 2.283 . . . . 0.0 112.921 -179.069 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 17.6 mm -114.28 38.03 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 122.016 0.912 . . . . 0.0 108.964 179.246 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.7 p -177.96 147.73 0.48 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.029 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.68 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.8 m-85 -144.34 171.85 13.76 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.536 ' HB2' HG23 ' A' ' 6' ' ' VAL . 90.5 m-85 -96.08 -58.82 1.98 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.303 0.573 . . . . 0.0 110.626 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.453 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.252 1.252 0 CA-C-O 117.459 -1.745 . . . . 0.0 110.003 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.332 0 CA-C-O 120.221 -0.211 . . . . 0.0 113.403 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -139.57 -120.97 1.82 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.717 -179.273 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -126.07 143.81 50.97 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.723 ' HA3' ' O ' ' A' ' 20' ' ' TYR . . . -179.99 -125.45 0.96 Allowed Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.551 -179.438 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 30.4 m80 -118.99 -57.54 2.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.85 0.325 . . . . 0.0 111.575 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.528 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 47.3 t -88.6 128.84 51.2 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-O 120.888 0.375 . . . . 0.0 110.345 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -61.01 140.91 92.59 Favored 'Trans proline' 0 CA--C 1.53 0.285 0 C-N-CA 123.523 2.815 . . . . 0.0 114.495 -178.446 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.772 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.2 mt-10 -91.14 -70.83 0.66 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.205 178.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 42.9 m-85 -124.48 144.47 50.08 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.901 -179.611 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.622 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.0 OUTLIER -107.88 149.48 28.23 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.823 179.645 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 15' ' ' THR . 27.2 m -92.66 175.53 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.2 178.615 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.35 -21.79 60.32 Favored Glycine 0 C--O 1.228 -0.247 0 CA-C-N 116.09 -0.505 . . . . 0.0 113.436 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.417 ' H ' HG23 ' A' ' 11' ' ' VAL . 4.7 mt -83.02 28.92 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 121.185 0.517 . . . . 0.0 111.328 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 49.28 44.38 34.77 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 115.559 -0.746 . . . . 0.0 114.162 178.733 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.435 ' O ' HG22 ' A' ' 11' ' ' VAL . 7.8 t -150.67 140.42 13.84 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 117.115 0.457 . . . . 0.0 110.849 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.622 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 51.3 Cg_endo -70.18 140.53 41.32 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.79 2.327 . . . . 0.0 112.194 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.407 ' O ' HG12 ' A' ' 17' ' ' ILE . 14.7 tt -123.44 30.29 2.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 122.302 1.048 . . . . 0.0 109.713 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.1 p -179.15 151.48 0.5 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.479 -1.237 . . . . 0.0 110.071 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.494 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 10.3 m-85 -146.26 171.35 15.1 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.165 -0.679 . . . . 0.0 109.165 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.772 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.2 OUTLIER -139.99 -120.91 0.12 Allowed 'General case' 0 C--N 1.325 -0.483 0 O-C-N 123.045 0.216 . . . . 0.0 110.698 178.78 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.419 ' N ' ' HD1' ' A' ' 20' ' ' TYR . . . . . . . . 0 C--O 1.245 0.811 0 CA-C-O 118.516 -1.158 . . . . 0.0 112.569 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.289 0 CA-C-O 120.573 -0.015 . . . . 0.0 113.133 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 178.9 -137.59 3.26 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.063 -0.589 . . . . 0.0 111.776 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.75 137.77 25.36 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.35 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.642 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.45 -129.24 1.57 Allowed Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.369 -179.293 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 15.1 m-70 -118.57 -36.53 3.48 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.572 0.186 . . . . 0.0 111.204 -179.175 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.7 t -88.1 117.04 67.97 Favored Pre-proline 0 C--N 1.33 -0.26 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 -179.281 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -62.68 134.66 48.47 Favored 'Trans proline' 0 N--CA 1.471 0.189 0 C-N-CA 123.2 2.6 . . . . 0.0 113.845 -178.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -90.62 -72.24 0.58 Allowed 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.667 178.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -128.36 144.47 51.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.856 -179.61 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -109.56 135.03 51.21 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 66.9 t -147.76 145.5 18.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.963 0.411 . . . . 0.0 111.159 -179.411 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.73 -60.82 0.74 Allowed Glycine 0 CA--C 1.503 -0.683 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.906 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 8.2 pt -152.31 40.07 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-O 121.15 0.5 . . . . 0.0 110.445 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.06 23.85 74.53 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.262 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.8 t -102.64 133.73 20.3 Favored Pre-proline 0 C--N 1.325 -0.479 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -76.73 116.7 4.32 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.233 1.955 . . . . 0.0 112.751 -178.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.82 HD13 ' H ' ' A' ' 17' ' ' ILE . 0.2 OUTLIER -103.2 30.23 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 121.964 0.888 . . . . 0.0 109.72 179.047 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 p -175.88 146.77 0.74 Allowed 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 114.353 -1.294 . . . . 0.0 109.9 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.642 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 22.6 m-85 -136.97 173.24 11.91 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -91.45 -56.72 3.02 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.358 0.599 . . . . 0.0 110.417 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.414 0 CA-C-O 117.564 -1.687 . . . . 0.0 110.092 -179.714 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.235 0 N-CA-C 113.755 0.262 . . . . 0.0 113.755 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 164.7 -137.82 4.93 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.178 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -130.66 141.94 50.43 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 179.142 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.4 ' H ' ' HB2' ' A' ' 19' ' ' PHE . . . -179.75 -127.62 1.13 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.101 -179.451 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 35.3 m170 -125.94 -43.66 1.82 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.553 0.216 . . . . 0.0 111.1 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.22 127.45 55.22 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -63.0 137.3 61.4 Favored 'Trans proline' 0 CA--C 1.529 0.246 0 C-N-CA 123.017 2.478 . . . . 0.0 113.807 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.611 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.2 mt-10 -89.67 -73.25 0.52 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.885 179.271 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -121.93 143.66 49.33 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.158 -179.211 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.431 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 3.3 m-85 -110.88 149.01 31.22 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.706 179.442 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.7 m -83.84 -167.56 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.589 179.095 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.65 -41.36 95.66 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 121.251 -0.499 . . . . 0.0 113.506 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 18.8 pt -87.67 33.27 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.766 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.27 32.47 36.78 Favored Glycine 0 CA--C 1.52 0.352 0 CA-C-N 115.71 -0.677 . . . . 0.0 114.224 178.781 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.1 m -105.5 121.61 45.55 Favored Pre-proline 0 C--N 1.322 -0.622 0 O-C-N 122.476 -0.426 . . . . 0.0 110.361 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 56.2 Cg_endo -73.05 125.54 10.45 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.338 2.025 . . . . 0.0 112.373 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 pt -113.79 34.29 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.45 0.643 . . . . 0.0 110.444 179.725 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.0 p -179.71 147.96 0.31 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.749 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.4 ' HB2' ' H ' ' A' ' 4' ' ' GLY . 26.0 m-85 -144.29 174.37 10.96 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 -179.714 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.611 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -159.82 -160.54 0.82 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.083 178.557 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.046 0 CA-C-O 117.706 -1.608 . . . . 0.0 110.981 179.718 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 113.723 0.249 . . . . 0.0 113.723 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.92 -118.54 1.02 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.376 -0.916 . . . . 0.0 112.833 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.4 144.2 46.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.813 0.34 . . . . 0.0 110.559 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.46 -122.9 0.8 Allowed Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.892 -179.634 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -137.21 -43.19 0.56 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.661 0.267 . . . . 0.0 110.645 179.8 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.21 127.36 55.57 Favored Pre-proline 0 C--N 1.328 -0.353 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -62.7 135.99 55.55 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.979 2.453 . . . . 0.0 113.988 -178.487 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.601 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 90.0 mt-10 -91.43 -75.87 0.46 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.246 178.888 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 27.9 m-85 -110.25 141.66 42.91 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.133 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.555 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 6.5 m-85 -110.34 143.94 39.81 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.684 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 40.7 t -85.78 152.08 3.62 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.344 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -54.49 -23.27 26.91 Favored Glycine 0 CA--C 1.52 0.359 0 C-N-CA 121.409 -0.424 . . . . 0.0 113.389 -179.648 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 10.0 mm -82.64 32.32 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-O 121.379 0.609 . . . . 0.0 110.942 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.3 46.55 57.27 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 115.613 -0.721 . . . . 0.0 114.334 178.667 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 6.2 t -150.52 133.84 8.75 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 117.381 0.591 . . . . 0.0 111.23 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 11.2 Cg_exo -70.57 142.37 44.18 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 123.021 2.48 . . . . 0.0 111.821 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.42 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.4 tp -124.25 29.94 2.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 122.26 1.029 . . . . 0.0 110.178 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.42 ' OG ' ' HB2' ' A' ' 8' ' ' GLU . 9.8 p 179.63 149.9 0.32 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.703 179.619 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -144.97 172.24 13.32 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.731 0.301 . . . . 0.0 110.316 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.601 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -160.1 -161.52 0.89 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.652 -0.703 . . . . 0.0 109.859 178.542 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 117.718 -1.601 . . . . 0.0 111.031 179.664 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.263 0 N-CA-C 113.419 0.128 . . . . 0.0 113.419 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 162.68 -137.35 4.77 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.063 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -140.01 141.22 36.34 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.125 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.582 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 175.79 -120.5 0.76 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.413 -179.14 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -126.3 -41.41 1.9 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 42.6 t -88.33 120.53 70.49 Favored Pre-proline 0 C--O 1.22 -0.474 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.266 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -61.32 132.98 43.8 Favored 'Trans proline' 0 CA--C 1.53 0.312 0 C-N-CA 122.892 2.395 . . . . 0.0 113.901 -178.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.539 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 91.4 mt-10 -92.57 -74.91 0.5 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.185 178.825 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -117.59 143.55 46.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.103 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -107.23 146.93 30.81 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.241 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.741 HG13 HG22 ' A' ' 13' ' ' ILE . 9.1 p -79.81 165.13 2.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.29 178.811 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.7 41.34 0.54 Allowed Glycine 0 CA--C 1.518 0.254 0 N-CA-C 114.763 0.665 . . . . 0.0 114.763 -178.591 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.741 HG22 HG13 ' A' ' 11' ' ' VAL . 13.0 tt -157.46 28.27 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-O 122.09 0.947 . . . . 0.0 110.192 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.22 53.4 44.94 Favored Glycine 0 CA--C 1.519 0.312 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.727 178.3 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.435 ' O ' HG12 ' A' ' 11' ' ' VAL . 27.8 m -148.94 126.53 5.65 Favored Pre-proline 0 C--N 1.323 -0.574 0 O-C-N 122.39 -0.476 . . . . 0.0 110.391 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 11.5 Cg_exo -70.17 126.38 12.98 Favored 'Trans proline' 0 N--CA 1.465 -0.205 0 C-N-CA 122.408 2.072 . . . . 0.0 111.752 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.3 pt -115.58 31.95 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.52 0.676 . . . . 0.0 110.655 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 11.2 p 179.23 148.31 0.23 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.825 -1.079 . . . . 0.0 109.543 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.582 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 3.7 m-85 -147.43 164.19 34.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.688 0.28 . . . . 0.0 110.736 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.551 ' O ' ' HA3' ' A' ' 4' ' ' GLY . 29.4 m-85 -97.25 163.89 12.72 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.429 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.15 0 CA-C-O 117.751 -1.583 . . . . 0.0 110.998 179.105 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.444 ' N ' ' HB2' ' A' ' 18' ' ' SER . . . . . . . . 0 CA--C 1.52 0.388 0 N-CA-C 113.918 0.327 . . . . 0.0 113.918 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -120.38 -134.51 4.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.317 -0.944 . . . . 0.0 113.084 -179.097 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -132.99 52.63 2.07 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.093 0.473 . . . . 0.0 110.776 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -76.08 -121.96 0.16 Allowed Glycine 0 CA--C 1.519 0.317 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.633 179.811 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 44.9 m170 -122.15 -51.7 1.99 Allowed 'General case' 0 C--N 1.326 -0.448 0 O-C-N 122.465 -0.432 . . . . 0.0 111.296 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.566 HG23 ' CD1' ' A' ' 20' ' ' TYR . 4.4 m -89.63 132.88 35.57 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 110.194 -0.299 . . . . 0.0 110.194 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.4 ' HA ' ' O ' ' A' ' 18' ' ' SER . 14.5 Cg_endo -58.03 139.34 90.08 Favored 'Trans proline' 0 CA--C 1.53 0.314 0 C-N-CA 123.513 2.809 . . . . 0.0 114.484 -178.061 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.525 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.7 mt-10 -92.64 -69.97 0.72 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.065 178.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -121.82 144.43 48.83 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.292 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.492 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 4.6 m-85 -111.28 145.95 37.87 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.48 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 42.7 t -76.62 153.69 5.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 177.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -52.28 -26.6 21.93 Favored Glycine 0 C--O 1.227 -0.333 0 C-N-CA 121.485 -0.388 . . . . 0.0 113.763 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.0 mt -84.32 31.19 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 CA-C-O 121.283 0.563 . . . . 0.0 111.19 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 53.53 51.45 47.97 Favored Glycine 0 CA--C 1.521 0.428 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.842 178.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 26.9 m -144.62 123.74 7.0 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 122.332 -0.511 . . . . 0.0 111.048 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.492 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 39.9 Cg_endo -67.89 136.71 39.27 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.485 2.123 . . . . 0.0 111.916 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.423 ' O ' HG12 ' A' ' 17' ' ' ILE . 15.3 tt -129.93 34.07 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 122.227 1.013 . . . . 0.0 110.42 -179.528 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.444 ' HB2' ' N ' ' A' ' 1' ' ' GLY . 13.1 p 179.76 149.44 0.31 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.825 -1.08 . . . . 0.0 109.637 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -147.58 165.9 28.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.708 0.29 . . . . 0.0 110.386 -179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.566 ' CD1' HG23 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -158.24 -149.08 0.21 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.189 178.818 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.811 0 CA-C-O 118.68 -1.067 . . . . 0.0 110.668 179.883 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 CA-C-O 120.235 -0.203 . . . . 0.0 113.592 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.5 -120.54 1.49 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.81 -179.178 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.44 145.75 44.98 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.692 0.282 . . . . 0.0 110.62 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.21 -124.48 0.86 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.005 -179.651 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 70.5 m80 -133.29 -47.91 0.84 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.457 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 2.5 p -89.47 128.34 51.35 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.863 179.175 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.494 ' HB3' ' HG3' ' A' ' 16' ' ' PRO . 37.8 Cg_exo -58.77 137.89 82.6 Favored 'Trans proline' 0 N--CA 1.473 0.301 0 C-N-CA 123.443 2.762 . . . . 0.0 113.968 -178.37 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.472 ' HG2' ' CD1' ' A' ' 20' ' ' TYR . 91.8 mt-10 -89.73 -73.32 0.52 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.475 178.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -125.35 135.58 52.59 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.672 -179.704 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.486 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.7 m-85 -91.19 156.28 17.97 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.458 178.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.625 HG23 ' H ' ' A' ' 13' ' ' ILE . 35.1 m -120.38 -175.57 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 120.748 0.309 . . . . 0.0 110.854 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.05 -18.58 64.85 Favored Glycine 0 C--O 1.227 -0.305 0 CA-C-N 116.03 -0.532 . . . . 0.0 113.404 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.625 ' H ' HG23 ' A' ' 11' ' ' VAL . 6.0 mt -84.14 19.27 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.542 0.687 . . . . 0.0 111.022 -179.637 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.89 -44.03 0.82 Allowed Glycine 0 CA--C 1.521 0.42 0 CA-C-N 115.396 -0.82 . . . . 0.0 113.852 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.441 ' O ' HG22 ' A' ' 11' ' ' VAL . 10.0 t -88.47 137.58 30.53 Favored Pre-proline 0 C--N 1.32 -0.712 0 CA-C-O 121.097 0.475 . . . . 0.0 111.226 -179.012 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.494 ' HG3' ' HB3' ' A' ' 7' ' ' PRO . 59.7 Cg_endo -72.65 140.68 33.02 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.891 2.394 . . . . 0.0 111.971 179.83 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.2 mt -108.24 38.21 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 122.213 1.006 . . . . 0.0 109.173 179.416 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.8 p -167.9 143.82 3.93 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.381 179.733 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -147.15 174.16 11.84 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.453 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.472 ' CD1' ' HG2' ' A' ' 8' ' ' GLU . 20.6 p90 -158.75 -159.84 0.82 Allowed 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.076 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.899 0 CA-C-O 118.637 -1.09 . . . . 0.0 111.035 179.833 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.32 0 CA-C-O 120.488 -0.062 . . . . 0.0 113.117 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.62 -138.33 4.34 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.183 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.459 ' HA ' ' HB2' ' A' ' 19' ' ' PHE . . . -145.94 141.94 28.25 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.591 0.234 . . . . 0.0 110.415 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.445 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.25 -127.52 1.41 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 121.014 -0.612 . . . . 0.0 111.932 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.482 ' H ' ' C ' ' A' ' 21' ' ' GLY . 45.3 m80 -116.88 -37.16 3.66 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.604 0.24 . . . . 0.0 110.762 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.7 t -88.45 120.18 70.32 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.302 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.07 139.14 45.83 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 122.954 2.436 . . . . 0.0 113.236 -179.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -95.34 -75.57 0.52 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.601 179.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.404 ' O ' ' HA ' ' A' ' 16' ' ' PRO . 27.6 m-85 -107.41 140.58 40.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.073 0.463 . . . . 0.0 111.831 -178.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.447 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.5 m-85 -115.8 147.7 40.69 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.239 -0.891 . . . . 0.0 109.053 178.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 15' ' ' THR . 29.9 m -86.64 -167.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 C-N-CA 120.992 -0.283 . . . . 0.0 110.92 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -57.56 -42.18 93.91 Favored Glycine 0 C--O 1.227 -0.329 0 C-N-CA 121.387 -0.435 . . . . 0.0 113.64 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 17.6 pt -86.75 32.65 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 120.932 0.396 . . . . 0.0 111.964 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.59 29.13 31.45 Favored Glycine 0 CA--C 1.519 0.33 0 CA-C-N 115.666 -0.697 . . . . 0.0 114.051 178.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.451 ' O ' HG22 ' A' ' 11' ' ' VAL . 18.9 m -102.57 120.21 53.68 Favored Pre-proline 0 C--N 1.321 -0.671 0 CA-C-N 117.003 0.401 . . . . 0.0 110.497 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 72.8 Cg_endo -80.2 124.64 5.49 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.269 1.98 . . . . 0.0 112.691 -179.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.0 mt -116.15 39.33 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 122.333 1.063 . . . . 0.0 108.894 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 p -175.92 146.48 0.71 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.451 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.459 ' HB2' ' HA ' ' A' ' 3' ' ' ALA . 56.4 m-85 -131.54 -172.7 2.92 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 10.6 t80 -122.71 -62.66 1.34 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.55 0.691 . . . . 0.0 110.197 -179.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.482 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.442 -0.904 0 CA-C-N 114.596 -1.184 . . . . 0.0 110.233 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.286 0 N-CA-C 113.221 0.048 . . . . 0.0 113.221 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.35 -137.03 3.91 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.112 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.9 138.76 25.8 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.333 -0.247 . . . . 0.0 110.333 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.669 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 173.71 -127.54 1.36 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.255 -179.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -118.64 -37.75 3.23 Favored 'General case' 0 C--N 1.328 -0.363 0 O-C-N 122.827 -0.219 . . . . 0.0 111.248 -179.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.5 t -88.14 115.22 62.49 Favored Pre-proline 0 C--O 1.222 -0.345 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 -179.306 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.76 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 34.8 Cg_exo -62.57 137.55 64.96 Favored 'Trans proline' 0 N--CA 1.473 0.28 0 C-N-CA 123.423 2.749 . . . . 0.0 114.165 -178.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.0 mt-10 -97.13 -72.11 0.65 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.257 178.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 27.8 m-85 -116.62 142.53 46.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.667 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -110.73 149.04 31.06 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.84 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 26.9 m -82.87 -167.41 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.688 179.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.78 -42.01 96.25 Favored Glycine 0 C--O 1.227 -0.322 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.588 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 18.2 pt -87.5 33.83 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.08 31.28 32.92 Favored Glycine 0 CA--C 1.519 0.335 0 CA-C-N 115.71 -0.677 . . . . 0.0 114.174 178.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 18.0 m -104.77 125.76 33.0 Favored Pre-proline 0 C--N 1.322 -0.588 0 O-C-N 122.539 -0.389 . . . . 0.0 110.135 179.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.76 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 31.3 Cg_endo -65.07 125.77 15.24 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.4 2.067 . . . . 0.0 112.226 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.416 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -115.98 29.09 2.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 122.508 1.147 . . . . 0.0 109.581 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.8 p 179.68 150.08 0.33 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 114.249 -1.341 . . . . 0.0 109.725 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.669 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 14.1 m-85 -140.31 171.38 14.23 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -90.78 -56.41 3.19 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.48 0.657 . . . . 0.0 110.349 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.256 1.492 0 CA-C-O 117.56 -1.689 . . . . 0.0 110.001 -179.841 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.38 0 N-CA-C 113.59 0.196 . . . . 0.0 113.59 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -108.27 -134.68 7.34 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.655 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.417 ' HA ' ' HD1' ' A' ' 19' ' ' PHE . . . -145.38 47.89 1.28 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.031 0.443 . . . . 0.0 111.16 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.639 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . -80.41 -126.06 0.64 Allowed Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.931 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 61.6 m80 -111.47 -44.83 3.46 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -178.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.574 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.8 m -89.42 122.92 67.99 Favored Pre-proline 0 C--O 1.221 -0.431 0 CA-C-O 120.744 0.307 . . . . 0.0 110.962 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.662 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 40.1 Cg_exo -58.27 139.55 90.95 Favored 'Trans proline' 0 N--CA 1.474 0.379 0 C-N-CA 123.32 2.68 . . . . 0.0 114.449 -178.312 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.436 ' HG3' ' C ' ' A' ' 19' ' ' PHE . 94.7 mt-10 -95.26 -72.28 0.63 Allowed 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.675 179.078 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -108.17 144.91 34.94 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.541 -179.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.532 ' CZ ' ' HB2' ' A' ' 7' ' ' PRO . 4.7 m-85 -123.72 141.74 51.73 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.205 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.487 HG23 HD12 ' A' ' 17' ' ' ILE . 43.8 t -78.2 155.12 5.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -50.99 -30.52 23.08 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.496 -0.383 . . . . 0.0 113.494 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.2 pt -84.41 30.53 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.847 0.356 . . . . 0.0 111.898 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 55.8 50.09 62.82 Favored Glycine 0 CA--C 1.519 0.283 0 CA-C-N 115.926 -0.579 . . . . 0.0 113.64 178.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 15.2 m -133.85 118.0 14.18 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 117.142 0.471 . . . . 0.0 111.311 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.662 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 4.6 Cg_exo -77.05 130.97 11.62 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.988 2.459 . . . . 0.0 111.719 179.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.631 ' H ' HD13 ' A' ' 17' ' ' ILE . 0.2 OUTLIER -123.88 33.61 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.541 0.686 . . . . 0.0 111.055 179.979 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 p 179.83 152.92 0.47 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.463 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.639 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 8.5 m-85 -144.48 166.92 23.76 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.574 ' HB2' HG23 ' A' ' 6' ' ' VAL . 97.2 m-85 -90.06 -115.72 0.07 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.102 0 CA-C-O 118.123 -1.376 . . . . 0.0 110.633 178.245 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.226 0 CA-C-O 120.555 -0.025 . . . . 0.0 113.077 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.49 -139.14 4.57 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.976 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.62 140.35 30.09 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.659 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.64 -128.94 1.51 Allowed Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.077 -179.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.411 ' H ' ' C ' ' A' ' 21' ' ' GLY . 62.7 m80 -114.65 -43.11 3.18 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 111.59 0.219 . . . . 0.0 111.59 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.607 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.5 m -89.89 117.82 68.42 Favored Pre-proline 0 C--O 1.223 -0.296 0 CA-C-O 120.825 0.345 . . . . 0.0 110.757 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.468 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 26.8 Cg_exo -63.61 139.61 70.71 Favored 'Trans proline' 0 CA--C 1.53 0.296 0 C-N-CA 123.506 2.804 . . . . 0.0 114.236 -178.301 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.433 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 93.2 mt-10 -91.67 -72.41 0.59 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.425 178.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -112.67 139.93 47.87 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.266 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.528 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 4.5 m-85 -111.41 143.82 41.61 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.192 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.9 t -85.43 151.12 3.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 178.373 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -53.58 -24.53 24.91 Favored Glycine 0 C--O 1.226 -0.404 0 C-N-CA 121.499 -0.381 . . . . 0.0 113.539 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.3 mt -82.22 32.61 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-O 121.182 0.515 . . . . 0.0 111.092 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.0 47.55 54.06 Favored Glycine 0 CA--C 1.52 0.368 0 CA-C-N 115.699 -0.682 . . . . 0.0 114.237 178.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.2 t -150.62 129.58 6.27 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 117.359 0.58 . . . . 0.0 111.43 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 85.5 Cg_endo -85.64 131.63 4.0 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.918 2.412 . . . . 0.0 112.493 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -115.47 35.92 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.355 0.598 . . . . 0.0 110.959 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.5 p -176.2 148.66 0.8 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.189 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.659 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 11.9 m-85 -141.34 172.13 13.11 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.607 ' HB2' HG23 ' A' ' 6' ' ' VAL . 93.7 m-85 -95.02 -56.79 2.63 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.554 0.692 . . . . 0.0 110.008 179.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.411 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.441 -1.006 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.261 0 CA-C-O 120.313 -0.159 . . . . 0.0 113.305 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.15 -118.0 1.04 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.446 -179.303 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.52 145.09 45.58 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.632 0.253 . . . . 0.0 110.528 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.27 -131.82 1.67 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 121.033 -0.603 . . . . 0.0 111.632 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -123.18 -48.5 1.98 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.069 0.435 . . . . 0.0 110.457 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.487 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 41.8 t -89.96 130.04 44.01 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.253 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -60.74 137.98 76.54 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 123.154 2.569 . . . . 0.0 113.798 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.752 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 90.9 mt-10 -89.09 -73.95 0.49 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.622 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -124.43 143.29 50.71 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.022 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.552 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.0 OUTLIER -104.9 148.39 26.73 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.552 179.167 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 15' ' ' THR . 35.9 m -92.46 178.87 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 116.561 -0.29 . . . . 0.0 110.543 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -60.28 -26.2 63.6 Favored Glycine 0 N--CA 1.453 -0.218 0 CA-C-N 116.087 -0.506 . . . . 0.0 113.54 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.416 ' H ' HG23 ' A' ' 11' ' ' VAL . 9.6 mm -84.06 31.48 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.064 0.459 . . . . 0.0 110.958 -179.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 46.0 43.39 12.84 Favored Glycine 0 N--CA 1.46 0.297 0 CA-C-N 115.575 -0.739 . . . . 0.0 113.782 179.156 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.539 ' O ' HG22 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -143.23 135.39 13.23 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-O 120.795 0.331 . . . . 0.0 111.287 -179.261 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 71.7 Cg_endo -84.49 127.35 3.79 Favored 'Trans proline' 0 N--CA 1.454 -0.818 0 C-N-CA 122.562 2.174 . . . . 0.0 112.322 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.6 mt -115.77 39.97 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 122.216 1.007 . . . . 0.0 108.857 179.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.9 p -171.58 144.58 1.91 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.841 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -147.32 173.42 12.61 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.752 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -153.61 169.64 22.76 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.216 0.532 . . . . 0.0 111.398 178.741 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.949 0 CA-C-N 114.648 -1.16 . . . . 0.0 112.529 -179.963 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.244 0 CA-C-O 120.541 -0.033 . . . . 0.0 113.074 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.9 -138.33 4.46 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.988 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.34 140.78 32.22 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.328 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.693 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.11 -132.86 2.37 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.459 -179.152 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.461 ' H ' ' C ' ' A' ' 21' ' ' GLY . 23.8 m170 -109.23 -47.34 3.43 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.571 0.224 . . . . 0.0 111.352 -178.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.544 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.45 120.72 69.66 Favored Pre-proline 0 C--O 1.225 -0.233 0 CA-C-O 120.804 0.335 . . . . 0.0 111.206 -179.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.607 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 24.7 Cg_exo -64.17 138.98 64.24 Favored 'Trans proline' 0 CA--C 1.529 0.247 0 C-N-CA 123.601 2.868 . . . . 0.0 114.288 -178.584 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.446 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 94.4 mt-10 -91.63 -68.93 0.76 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.568 178.054 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -128.54 142.74 50.97 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.998 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.579 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.5 m-85 -98.07 150.13 21.74 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.369 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.587 HG13 ' H ' ' A' ' 13' ' ' ILE . 9.1 p -88.89 165.41 2.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.206 178.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -55.85 -24.21 40.65 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 121.568 -0.348 . . . . 0.0 113.854 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.587 ' H ' HG13 ' A' ' 11' ' ' VAL . 5.0 mt -82.41 33.32 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 120.938 0.399 . . . . 0.0 111.333 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 47.5 43.11 20.38 Favored Glycine 0 CA--C 1.521 0.426 0 CA-C-N 115.827 -0.624 . . . . 0.0 114.027 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.476 ' O ' HG12 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -146.92 140.73 15.28 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.902 0.351 . . . . 0.0 111.045 -179.472 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.607 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 35.6 Cg_endo -66.28 126.38 15.57 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.29 1.993 . . . . 0.0 111.824 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.43 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -114.53 31.07 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 122.243 1.021 . . . . 0.0 110.027 -179.606 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 25.2 p 179.63 149.13 0.29 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.12 179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.693 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 11.3 m-85 -142.72 172.0 13.28 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.544 ' HB2' HG23 ' A' ' 6' ' ' VAL . 93.6 m-85 -95.6 -58.35 2.14 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.363 0.601 . . . . 0.0 110.42 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.461 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.253 1.316 0 CA-C-O 117.414 -1.77 . . . . 0.0 110.064 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.301 0 N-CA-C 113.214 0.045 . . . . 0.0 113.214 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.28 -139.29 4.49 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.005 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.91 140.01 29.49 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.662 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.43 -129.24 1.57 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.054 -179.245 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.41 ' H ' ' C ' ' A' ' 21' ' ' GLY . 62.8 m80 -114.6 -43.03 3.2 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.481 0.178 . . . . 0.0 111.481 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.608 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.71 117.31 68.02 Favored Pre-proline 0 C--N 1.33 -0.274 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.826 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.478 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 24.6 Cg_exo -64.09 140.44 71.93 Favored 'Trans proline' 0 CA--C 1.529 0.271 0 C-N-CA 123.518 2.812 . . . . 0.0 114.258 -178.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.438 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 94.2 mt-10 -91.91 -70.93 0.67 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.447 178.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -116.19 142.4 46.87 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.551 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.55 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 3.7 m-85 -114.06 145.41 41.63 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.405 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 42.3 t -82.94 152.92 3.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -54.41 -23.65 27.66 Favored Glycine 0 C--O 1.226 -0.347 0 C-N-CA 121.383 -0.437 . . . . 0.0 113.245 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.2 mt -83.11 32.26 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 CA-C-O 121.209 0.528 . . . . 0.0 111.091 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 51.93 50.14 45.74 Favored Glycine 0 CA--C 1.52 0.348 0 CA-C-N 115.632 -0.713 . . . . 0.0 114.323 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.2 t -150.54 129.44 6.23 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 117.437 0.619 . . . . 0.0 111.345 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 71.7 Cg_endo -80.26 134.8 10.45 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.807 2.338 . . . . 0.0 112.629 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.0 pp -119.14 33.19 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.254 0.549 . . . . 0.0 111.547 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 p -179.22 150.76 0.46 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.094 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.662 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.3 m-85 -140.78 172.17 13.08 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.476 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.608 ' HB2' HG23 ' A' ' 6' ' ' VAL . 95.2 m-85 -95.61 -56.68 2.61 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.509 0.671 . . . . 0.0 110.086 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.41 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.441 -0.978 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.257 0 CA-C-O 120.475 -0.07 . . . . 0.0 113.108 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.95 -136.15 3.71 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.965 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -144.6 140.75 28.94 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 179.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.7 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.33 -132.67 2.45 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.668 -179.156 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.48 ' H ' ' C ' ' A' ' 21' ' ' GLY . 20.4 m170 -110.03 -43.74 3.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.534 0.207 . . . . 0.0 111.352 -178.703 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 40.7 t -88.2 118.96 70.15 Favored Pre-proline 0 C--O 1.223 -0.334 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.728 -178.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.545 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 31.8 Cg_endo -64.41 138.23 59.29 Favored 'Trans proline' 0 CA--C 1.528 0.225 0 C-N-CA 123.208 2.606 . . . . 0.0 114.234 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.412 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 92.2 mt-10 -95.67 -71.66 0.66 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.516 -0.766 . . . . 0.0 110.372 178.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -117.9 142.35 47.43 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.687 -179.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -111.95 136.94 50.61 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 43.4 t -145.33 137.69 20.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 120.966 0.412 . . . . 0.0 110.932 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.69 -68.4 0.23 Allowed Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.133 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.3 pt -156.16 46.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 114.78 -0.71 . . . . 0.0 109.736 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.38 18.23 79.98 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -178.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.456 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 0.7 OUTLIER -89.41 125.81 60.41 Favored Pre-proline 0 N--CA 1.447 -0.595 0 CA-C-N 115.113 -0.544 . . . . 0.0 110.623 179.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.545 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 17.9 Cg_exo -66.66 125.64 14.14 Favored 'Trans proline' 0 N--CA 1.463 -0.28 0 C-N-CA 122.778 2.319 . . . . 0.0 112.33 -179.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.411 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -118.34 27.88 3.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 122.714 1.245 . . . . 0.0 109.376 179.343 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.4 p 179.57 150.28 0.33 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 113.899 -1.5 . . . . 0.0 109.475 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.7 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.5 m-85 -142.18 172.22 12.99 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.412 ' CZ ' ' HG2' ' A' ' 8' ' ' GLU . 93.6 m-85 -92.82 -59.46 2.05 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.461 0.648 . . . . 0.0 110.444 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.48 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.253 1.328 0 CA-C-O 117.244 -1.864 . . . . 0.0 109.987 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.281 0 N-CA-C 112.969 -0.052 . . . . 0.0 112.969 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.93 -141.95 5.62 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.93 -0.652 . . . . 0.0 111.714 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.73 46.24 1.02 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.133 0.492 . . . . 0.0 111.095 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.599 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . -81.83 -127.33 0.94 Allowed Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.668 -0.696 . . . . 0.0 112.815 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.1 m-70 -114.31 -43.37 3.21 Favored 'General case' 0 C--N 1.327 -0.402 0 O-C-N 122.444 -0.445 . . . . 0.0 111.89 -178.676 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.543 HG13 ' HB2' ' A' ' 20' ' ' TYR . 2.4 p -89.37 124.76 63.71 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 120.788 0.328 . . . . 0.0 110.682 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.53 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 50.8 Cg_exo -56.36 138.8 85.1 Favored 'Trans proline' 0 N--CA 1.474 0.367 0 C-N-CA 123.53 2.82 . . . . 0.0 114.467 -178.341 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.419 ' HG2' ' CE1' ' A' ' 20' ' ' TYR . 89.8 mt-10 -98.5 -72.88 0.64 Allowed 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.55 178.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -118.84 140.8 49.37 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.085 -179.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.47 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 5.0 m-85 -108.74 145.68 34.72 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.389 -0.823 . . . . 0.0 108.973 179.295 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.0 p -165.44 151.06 2.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.172 0.511 . . . . 0.0 111.435 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.22 -62.17 0.57 Allowed Glycine 0 CA--C 1.505 -0.553 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.678 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.1 pt -155.75 41.7 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 114.828 -0.686 . . . . 0.0 109.71 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.51 13.18 82.02 Favored Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.645 -179.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.8 p -89.66 129.89 45.21 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.688 -0.256 . . . . 0.0 110.88 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.53 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 56.2 Cg_endo -74.14 122.51 7.65 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.238 1.959 . . . . 0.0 112.069 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 16.9 mm -113.51 37.19 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 122.182 0.991 . . . . 0.0 109.028 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 25.1 p 179.85 148.25 0.28 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.566 -1.197 . . . . 0.0 109.789 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.599 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 9.1 m-85 -141.04 167.53 21.96 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.535 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.543 ' HB2' HG13 ' A' ' 6' ' ' VAL . 94.1 m-85 -84.37 -114.54 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.453 0 CA-C-O 117.998 -1.445 . . . . 0.0 111.023 178.857 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.338 0 CA-C-O 120.437 -0.091 . . . . 0.0 113.247 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.66 -137.08 4.15 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.144 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.85 140.12 26.82 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.675 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.53 -128.23 1.51 Allowed Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.344 -179.255 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -115.06 -40.63 3.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.672 0.236 . . . . 0.0 111.493 -178.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.8 t -88.54 115.75 64.27 Favored Pre-proline 0 C--O 1.221 -0.401 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -64.25 140.03 68.87 Favored 'Trans proline' 0 CA--C 1.532 0.388 0 C-N-CA 123.208 2.605 . . . . 0.0 114.133 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -97.36 -74.4 0.57 Allowed 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.689 179.095 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.0 m-85 -105.3 142.6 34.79 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.457 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.499 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 5.8 m-85 -120.45 143.01 48.73 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.402 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.447 ' CG2' HD12 ' A' ' 17' ' ' ILE . 38.4 t -84.18 153.77 3.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -52.32 -28.02 26.24 Favored Glycine 0 C--O 1.228 -0.252 0 C-N-CA 121.551 -0.357 . . . . 0.0 113.683 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.646 HG13 HG22 ' A' ' 15' ' ' THR . 24.9 pt -82.94 31.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 55.25 52.62 46.15 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 114.926 0.73 . . . . 0.0 114.926 177.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.646 HG22 HG13 ' A' ' 13' ' ' ILE . 9.5 t -150.71 129.24 6.06 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 117.703 0.752 . . . . 0.0 111.198 179.089 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.499 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 85.5 Cg_endo -85.46 130.44 3.86 Favored 'Trans proline' 0 N--CA 1.459 -0.501 0 C-N-CA 122.803 2.336 . . . . 0.0 112.704 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.759 ' H ' HD13 ' A' ' 17' ' ' ILE . 0.2 OUTLIER -112.95 33.26 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.457 0.646 . . . . 0.0 110.932 179.839 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.6 p -176.98 150.24 0.75 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.157 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.675 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 15.9 m-85 -141.18 173.0 11.91 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -91.05 -56.67 3.08 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.396 0.617 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.343 0 CA-C-O 117.648 -1.64 . . . . 0.0 110.144 -179.792 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.41 0 N-CA-C 113.347 0.099 . . . . 0.0 113.347 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.59 -143.14 7.57 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.869 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.4 48.4 1.56 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.134 0.492 . . . . 0.0 110.865 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.75 -124.5 0.38 Allowed Glycine 0 CA--C 1.519 0.306 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.41 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.411 ' HD1' ' C ' ' A' ' 21' ' ' GLY . 67.8 m80 -121.87 -43.84 2.34 Favored 'General case' 0 C--N 1.328 -0.364 0 O-C-N 122.457 -0.437 . . . . 0.0 111.596 -179.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.408 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 25.4 t -88.94 128.79 50.73 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -57.7 136.43 75.52 Favored 'Trans proline' 0 CA--C 1.529 0.256 0 C-N-CA 123.186 2.591 . . . . 0.0 113.677 -178.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.649 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 94.1 mt-10 -93.4 -73.81 0.55 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.523 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -124.27 142.02 51.6 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.926 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.433 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.5 m-85 -107.24 136.95 46.2 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.306 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.5 m -153.64 -177.48 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.687 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.59 -50.38 2.5 Favored Glycine 0 C--O 1.227 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 113.01 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.408 ' O ' HG13 ' A' ' 13' ' ' ILE . 10.9 tp -170.91 37.75 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-O 122.364 1.078 . . . . 0.0 109.419 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.09 13.41 83.38 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.674 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.409 HG23 HD11 ' A' ' 17' ' ' ILE . 9.0 t -96.81 136.6 21.58 Favored Pre-proline 0 C--N 1.325 -0.461 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 45.5 Cg_endo -71.35 122.88 9.07 Favored 'Trans proline' 0 N--CA 1.462 -0.34 0 C-N-CA 122.289 1.993 . . . . 0.0 112.272 -179.244 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.409 HD11 HG23 ' A' ' 15' ' ' THR . 20.9 mm -114.42 37.85 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 122.298 1.047 . . . . 0.0 108.834 179.343 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 17.1 p -179.65 145.77 0.24 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.446 -1.252 . . . . 0.0 109.702 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -147.01 166.94 25.3 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.328 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.649 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -145.87 170.6 16.26 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.292 178.013 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.411 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.25 1.141 0 CA-C-O 118.552 -1.138 . . . . 0.0 111.963 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.404 0 N-CA-C 113.382 0.113 . . . . 0.0 113.382 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.7 -142.8 7.34 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.845 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.68 48.34 1.53 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.169 0.509 . . . . 0.0 110.755 179.618 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.69 -124.34 0.37 Allowed Glycine 0 N--CA 1.451 -0.329 0 CA-C-N 115.553 -0.749 . . . . 0.0 112.391 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.417 ' HD1' ' C ' ' A' ' 21' ' ' GLY . 67.4 m80 -122.33 -43.58 2.3 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 122.515 -0.403 . . . . 0.0 111.509 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.403 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 25.7 t -89.0 127.95 53.79 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.714 -0.221 . . . . 0.0 110.405 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.516 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 52.7 Cg_exo -56.17 136.03 73.07 Favored 'Trans proline' 0 CA--C 1.53 0.287 0 C-N-CA 123.229 2.619 . . . . 0.0 113.717 -179.065 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.648 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 94.1 mt-10 -93.72 -74.25 0.54 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.626 179.265 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -122.78 141.03 52.26 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.846 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.428 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.2 m-85 -108.06 136.52 47.61 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.431 179.407 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -153.83 -178.3 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 O-C-N 123.282 0.364 . . . . 0.0 110.555 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.92 -50.39 2.62 Favored Glycine 0 C--N 1.332 0.306 0 CA-C-N 116.076 -0.511 . . . . 0.0 113.053 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.416 ' O ' HG12 ' A' ' 13' ' ' ILE . 15.3 tt -170.99 38.31 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-O 122.349 1.071 . . . . 0.0 109.353 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.32 14.13 82.85 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.098 -0.955 . . . . 0.0 112.687 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.0 t -97.31 135.82 21.66 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.516 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 50.8 Cg_endo -72.1 123.5 9.3 Favored 'Trans proline' 0 N--CA 1.46 -0.463 0 C-N-CA 122.19 1.926 . . . . 0.0 112.404 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 20.8 mm -113.06 37.35 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 122.276 1.036 . . . . 0.0 108.754 179.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 p -179.89 146.37 0.24 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 114.365 -1.289 . . . . 0.0 109.612 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -146.95 166.45 26.74 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.259 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.648 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -145.04 170.67 15.74 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.421 178.054 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.417 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.242 0.625 0 CA-C-O 119.019 -0.879 . . . . 0.0 111.951 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.435 0 CA-C-O 120.272 -0.182 . . . . 0.0 113.553 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -122.81 -127.15 3.25 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.865 -179.151 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -134.86 143.33 46.94 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.68 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 176.43 -133.94 2.45 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.34 -179.346 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.453 ' H ' ' C ' ' A' ' 21' ' ' GLY . 23.7 m170 -109.31 -46.92 3.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.664 0.268 . . . . 0.0 111.201 -178.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.536 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.49 122.54 68.25 Favored Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.187 -179.232 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.18 139.98 69.02 Favored 'Trans proline' 0 N--CA 1.472 0.243 0 C-N-CA 123.427 2.751 . . . . 0.0 114.312 -178.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.409 ' HG3' ' C ' ' A' ' 19' ' ' PHE . 92.6 mt-10 -92.47 -71.3 0.65 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.347 178.603 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 53.1 m-85 -128.43 142.64 51.04 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.598 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.595 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.2 m-85 -98.23 149.91 22.08 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.053 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.705 HG13 HG22 ' A' ' 13' ' ' ILE . 6.6 p -87.96 172.62 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.643 179.201 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.563 ' H ' HG22 ' A' ' 11' ' ' VAL . . . -71.94 41.37 0.71 Allowed Glycine 0 C--O 1.229 -0.203 0 N-CA-C 115.056 0.782 . . . . 0.0 115.056 -178.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.705 HG22 HG13 ' A' ' 11' ' ' VAL . 10.7 tp -154.21 28.99 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-O 122.169 0.985 . . . . 0.0 110.441 178.291 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 60.04 43.76 97.91 Favored Glycine 0 CA--C 1.521 0.411 0 CA-C-N 114.673 -1.149 . . . . 0.0 115.141 177.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.1 t -151.27 137.03 10.9 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-N 117.726 0.763 . . . . 0.0 110.435 178.571 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.595 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 72.3 Cg_endo -77.71 127.01 8.5 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.725 2.283 . . . . 0.0 112.921 -179.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 17.6 mm -114.28 38.03 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 122.016 0.912 . . . . 0.0 108.964 179.246 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.7 p -177.96 147.73 0.48 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.029 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.68 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.8 m-85 -144.34 171.85 13.76 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.536 ' HB2' HG23 ' A' ' 6' ' ' VAL . 90.5 m-85 -96.08 -58.82 1.98 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.303 0.573 . . . . 0.0 110.626 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.453 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.252 1.252 0 CA-C-O 117.459 -1.745 . . . . 0.0 110.003 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.332 0 CA-C-O 120.221 -0.211 . . . . 0.0 113.403 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -139.57 -120.97 1.82 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.717 -179.273 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -126.07 143.81 50.97 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.723 ' HA3' ' O ' ' A' ' 20' ' ' TYR . . . -179.99 -125.45 0.96 Allowed Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.551 -179.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -118.99 -57.54 2.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.85 0.325 . . . . 0.0 111.575 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.528 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 47.3 t -88.6 128.84 51.2 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-O 120.888 0.375 . . . . 0.0 110.345 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -61.01 140.91 92.59 Favored 'Trans proline' 0 CA--C 1.53 0.285 0 C-N-CA 123.523 2.815 . . . . 0.0 114.495 -178.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.772 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.2 mt-10 -91.14 -70.83 0.66 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.205 178.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 42.9 m-85 -124.48 144.47 50.08 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.901 -179.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.622 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.0 OUTLIER -107.88 149.48 28.23 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.823 179.645 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 15' ' ' THR . 27.2 m -92.66 175.53 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.2 178.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.35 -21.79 60.32 Favored Glycine 0 C--O 1.228 -0.247 0 CA-C-N 116.09 -0.505 . . . . 0.0 113.436 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.417 ' H ' HG23 ' A' ' 11' ' ' VAL . 4.7 mt -83.02 28.92 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 121.185 0.517 . . . . 0.0 111.328 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 49.28 44.38 34.77 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 115.559 -0.746 . . . . 0.0 114.162 178.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.435 ' O ' HG22 ' A' ' 11' ' ' VAL . 7.8 t -150.67 140.42 13.84 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 117.115 0.457 . . . . 0.0 110.849 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.622 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 51.3 Cg_endo -70.18 140.53 41.32 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.79 2.327 . . . . 0.0 112.194 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.407 ' O ' HG12 ' A' ' 17' ' ' ILE . 14.7 tt -123.44 30.29 2.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 122.302 1.048 . . . . 0.0 109.713 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.1 p -179.15 151.48 0.5 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.479 -1.237 . . . . 0.0 110.071 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.494 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 10.3 m-85 -146.26 171.35 15.1 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.165 -0.679 . . . . 0.0 109.165 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.772 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.2 OUTLIER -139.99 -120.91 0.12 Allowed 'General case' 0 C--N 1.325 -0.483 0 O-C-N 123.045 0.216 . . . . 0.0 110.698 178.78 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.419 ' N ' ' HD1' ' A' ' 20' ' ' TYR . . . . . . . . 0 C--O 1.245 0.811 0 CA-C-O 118.516 -1.158 . . . . 0.0 112.569 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.289 0 CA-C-O 120.573 -0.015 . . . . 0.0 113.133 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 178.9 -137.59 3.26 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.063 -0.589 . . . . 0.0 111.776 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.75 137.77 25.36 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.642 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.45 -129.24 1.57 Allowed Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.369 -179.293 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 15.1 m-70 -118.57 -36.53 3.48 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.572 0.186 . . . . 0.0 111.204 -179.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.7 t -88.1 117.04 67.97 Favored Pre-proline 0 C--N 1.33 -0.26 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 -179.281 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -62.68 134.66 48.47 Favored 'Trans proline' 0 N--CA 1.471 0.189 0 C-N-CA 123.2 2.6 . . . . 0.0 113.845 -178.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -90.62 -72.24 0.58 Allowed 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.667 178.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -128.36 144.47 51.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.856 -179.61 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -109.56 135.03 51.21 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 66.9 t -147.76 145.5 18.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.963 0.411 . . . . 0.0 111.159 -179.411 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.73 -60.82 0.74 Allowed Glycine 0 CA--C 1.503 -0.683 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.906 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 8.2 pt -152.31 40.07 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-O 121.15 0.5 . . . . 0.0 110.445 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.06 23.85 74.53 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.262 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.8 t -102.64 133.73 20.3 Favored Pre-proline 0 C--N 1.325 -0.479 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -76.73 116.7 4.32 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.233 1.955 . . . . 0.0 112.751 -178.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.82 ' H ' HD13 ' A' ' 17' ' ' ILE . 0.2 OUTLIER -103.2 30.23 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 121.964 0.888 . . . . 0.0 109.72 179.047 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 p -175.88 146.77 0.74 Allowed 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 114.353 -1.294 . . . . 0.0 109.9 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.642 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 22.6 m-85 -136.97 173.24 11.91 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -91.45 -56.72 3.02 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.358 0.599 . . . . 0.0 110.417 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.414 0 CA-C-O 117.564 -1.687 . . . . 0.0 110.092 -179.714 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.235 0 N-CA-C 113.755 0.262 . . . . 0.0 113.755 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 164.7 -137.82 4.93 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.178 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -130.66 141.94 50.43 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 179.142 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.4 ' H ' ' HB2' ' A' ' 19' ' ' PHE . . . -179.75 -127.62 1.13 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.101 -179.451 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 35.3 m170 -125.94 -43.66 1.82 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.553 0.216 . . . . 0.0 111.1 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.22 127.45 55.22 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -63.0 137.3 61.4 Favored 'Trans proline' 0 CA--C 1.529 0.246 0 C-N-CA 123.017 2.478 . . . . 0.0 113.807 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.611 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.2 mt-10 -89.67 -73.25 0.52 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.885 179.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -121.93 143.66 49.33 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.158 -179.211 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.431 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 3.3 m-85 -110.88 149.01 31.22 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.706 179.442 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.7 m -83.84 -167.56 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.589 179.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.65 -41.36 95.66 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 121.251 -0.499 . . . . 0.0 113.506 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 18.8 pt -87.67 33.27 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.27 32.47 36.78 Favored Glycine 0 CA--C 1.52 0.352 0 CA-C-N 115.71 -0.677 . . . . 0.0 114.224 178.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.1 m -105.5 121.61 45.55 Favored Pre-proline 0 C--N 1.322 -0.622 0 O-C-N 122.476 -0.426 . . . . 0.0 110.361 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 56.2 Cg_endo -73.05 125.54 10.45 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.338 2.025 . . . . 0.0 112.373 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 pt -113.79 34.29 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.45 0.643 . . . . 0.0 110.444 179.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.0 p -179.71 147.96 0.31 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.749 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.4 ' HB2' ' H ' ' A' ' 4' ' ' GLY . 26.0 m-85 -144.29 174.37 10.96 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 -179.714 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.611 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -159.82 -160.54 0.82 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.083 178.557 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.046 0 CA-C-O 117.706 -1.608 . . . . 0.0 110.981 179.718 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 113.723 0.249 . . . . 0.0 113.723 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.92 -118.54 1.02 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.376 -0.916 . . . . 0.0 112.833 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.4 144.2 46.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.813 0.34 . . . . 0.0 110.559 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.46 -122.9 0.8 Allowed Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.892 -179.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -137.21 -43.19 0.56 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.661 0.267 . . . . 0.0 110.645 179.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.21 127.36 55.57 Favored Pre-proline 0 C--N 1.328 -0.353 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -62.7 135.99 55.55 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.979 2.453 . . . . 0.0 113.988 -178.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.601 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 90.0 mt-10 -91.43 -75.87 0.46 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.246 178.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 27.9 m-85 -110.25 141.66 42.91 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.133 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.555 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 6.5 m-85 -110.34 143.94 39.81 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.684 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 40.7 t -85.78 152.08 3.62 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -54.49 -23.27 26.91 Favored Glycine 0 CA--C 1.52 0.359 0 C-N-CA 121.409 -0.424 . . . . 0.0 113.389 -179.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 10.0 mm -82.64 32.32 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-O 121.379 0.609 . . . . 0.0 110.942 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.3 46.55 57.27 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 115.613 -0.721 . . . . 0.0 114.334 178.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 6.2 t -150.52 133.84 8.75 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 117.381 0.591 . . . . 0.0 111.23 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 11.2 Cg_exo -70.57 142.37 44.18 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 123.021 2.48 . . . . 0.0 111.821 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.42 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.4 tp -124.25 29.94 2.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 122.26 1.029 . . . . 0.0 110.178 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.42 ' OG ' ' HB2' ' A' ' 8' ' ' GLU . 9.8 p 179.63 149.9 0.32 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.703 179.619 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -144.97 172.24 13.32 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.731 0.301 . . . . 0.0 110.316 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.601 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -160.1 -161.52 0.89 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.652 -0.703 . . . . 0.0 109.859 178.542 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 117.718 -1.601 . . . . 0.0 111.031 179.664 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.263 0 N-CA-C 113.419 0.128 . . . . 0.0 113.419 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 162.68 -137.35 4.77 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.063 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -140.01 141.22 36.34 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.125 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.582 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 175.79 -120.5 0.76 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.413 -179.14 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -126.3 -41.41 1.9 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 42.6 t -88.33 120.53 70.49 Favored Pre-proline 0 C--O 1.22 -0.474 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.266 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -61.32 132.98 43.8 Favored 'Trans proline' 0 CA--C 1.53 0.312 0 C-N-CA 122.892 2.395 . . . . 0.0 113.901 -178.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.539 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 91.4 mt-10 -92.57 -74.91 0.5 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.185 178.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -117.59 143.55 46.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.103 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -107.23 146.93 30.81 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.241 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.741 HG13 HG22 ' A' ' 13' ' ' ILE . 9.1 p -79.81 165.13 2.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.29 178.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.7 41.34 0.54 Allowed Glycine 0 CA--C 1.518 0.254 0 N-CA-C 114.763 0.665 . . . . 0.0 114.763 -178.591 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.741 HG22 HG13 ' A' ' 11' ' ' VAL . 13.0 tt -157.46 28.27 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-O 122.09 0.947 . . . . 0.0 110.192 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.22 53.4 44.94 Favored Glycine 0 CA--C 1.519 0.312 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.727 178.3 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.435 ' O ' HG12 ' A' ' 11' ' ' VAL . 27.8 m -148.94 126.53 5.65 Favored Pre-proline 0 C--N 1.323 -0.574 0 O-C-N 122.39 -0.476 . . . . 0.0 110.391 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 11.5 Cg_exo -70.17 126.38 12.98 Favored 'Trans proline' 0 N--CA 1.465 -0.205 0 C-N-CA 122.408 2.072 . . . . 0.0 111.752 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.3 pt -115.58 31.95 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.52 0.676 . . . . 0.0 110.655 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 11.2 p 179.23 148.31 0.23 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.825 -1.079 . . . . 0.0 109.543 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.582 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 3.7 m-85 -147.43 164.19 34.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.688 0.28 . . . . 0.0 110.736 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.551 ' O ' ' HA3' ' A' ' 4' ' ' GLY . 29.4 m-85 -97.25 163.89 12.72 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.429 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.15 0 CA-C-O 117.751 -1.583 . . . . 0.0 110.998 179.105 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . 0.444 ' N ' ' HB2' ' A' ' 18' ' ' SER . . . . . . . . 0 CA--C 1.52 0.388 0 N-CA-C 113.918 0.327 . . . . 0.0 113.918 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -120.38 -134.51 4.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.317 -0.944 . . . . 0.0 113.084 -179.097 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -132.99 52.63 2.07 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.093 0.473 . . . . 0.0 110.776 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -76.08 -121.96 0.16 Allowed Glycine 0 CA--C 1.519 0.317 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.633 179.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 44.9 m170 -122.15 -51.7 1.99 Allowed 'General case' 0 C--N 1.326 -0.448 0 O-C-N 122.465 -0.432 . . . . 0.0 111.296 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.566 HG23 ' CD1' ' A' ' 20' ' ' TYR . 4.4 m -89.63 132.88 35.57 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 110.194 -0.299 . . . . 0.0 110.194 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.4 ' HA ' ' O ' ' A' ' 18' ' ' SER . 14.5 Cg_endo -58.03 139.34 90.08 Favored 'Trans proline' 0 CA--C 1.53 0.314 0 C-N-CA 123.513 2.809 . . . . 0.0 114.484 -178.061 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.525 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.7 mt-10 -92.64 -69.97 0.72 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.065 178.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -121.82 144.43 48.83 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.292 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.492 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 4.6 m-85 -111.28 145.95 37.87 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.48 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 42.7 t -76.62 153.69 5.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 177.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -52.28 -26.6 21.93 Favored Glycine 0 C--O 1.227 -0.333 0 C-N-CA 121.485 -0.388 . . . . 0.0 113.763 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.0 mt -84.32 31.19 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 CA-C-O 121.283 0.563 . . . . 0.0 111.19 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 53.53 51.45 47.97 Favored Glycine 0 CA--C 1.521 0.428 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.842 178.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 26.9 m -144.62 123.74 7.0 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 122.332 -0.511 . . . . 0.0 111.048 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.492 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 39.9 Cg_endo -67.89 136.71 39.27 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.485 2.123 . . . . 0.0 111.916 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.423 ' O ' HG12 ' A' ' 17' ' ' ILE . 15.3 tt -129.93 34.07 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 122.227 1.013 . . . . 0.0 110.42 -179.528 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.444 ' HB2' ' N ' ' A' ' 1' ' ' GLY . 13.1 p 179.76 149.44 0.31 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.825 -1.08 . . . . 0.0 109.637 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -147.58 165.9 28.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.708 0.29 . . . . 0.0 110.386 -179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.566 ' CD1' HG23 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -158.24 -149.08 0.21 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.189 178.818 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.811 0 CA-C-O 118.68 -1.067 . . . . 0.0 110.668 179.883 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 CA-C-O 120.235 -0.203 . . . . 0.0 113.592 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.5 -120.54 1.49 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.81 -179.178 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.44 145.75 44.98 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.692 0.282 . . . . 0.0 110.62 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.21 -124.48 0.86 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.005 -179.651 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 70.5 m80 -133.29 -47.91 0.84 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.457 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 2.5 p -89.47 128.34 51.35 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.863 179.175 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.494 ' HB3' ' HG3' ' A' ' 16' ' ' PRO . 37.8 Cg_exo -58.77 137.89 82.6 Favored 'Trans proline' 0 N--CA 1.473 0.301 0 C-N-CA 123.443 2.762 . . . . 0.0 113.968 -178.37 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.472 ' HG2' ' CD1' ' A' ' 20' ' ' TYR . 91.8 mt-10 -89.73 -73.32 0.52 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.475 178.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -125.35 135.58 52.59 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.672 -179.704 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.486 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.7 m-85 -91.19 156.28 17.97 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.458 178.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.625 HG23 ' H ' ' A' ' 13' ' ' ILE . 35.1 m -120.38 -175.57 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 120.748 0.309 . . . . 0.0 110.854 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.05 -18.58 64.85 Favored Glycine 0 C--O 1.227 -0.305 0 CA-C-N 116.03 -0.532 . . . . 0.0 113.404 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.625 ' H ' HG23 ' A' ' 11' ' ' VAL . 6.0 mt -84.14 19.27 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.542 0.687 . . . . 0.0 111.022 -179.637 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.89 -44.03 0.82 Allowed Glycine 0 CA--C 1.521 0.42 0 CA-C-N 115.396 -0.82 . . . . 0.0 113.852 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.441 ' O ' HG22 ' A' ' 11' ' ' VAL . 10.0 t -88.47 137.58 30.53 Favored Pre-proline 0 C--N 1.32 -0.712 0 CA-C-O 121.097 0.475 . . . . 0.0 111.226 -179.012 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.494 ' HG3' ' HB3' ' A' ' 7' ' ' PRO . 59.7 Cg_endo -72.65 140.68 33.02 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.891 2.394 . . . . 0.0 111.971 179.83 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.2 mt -108.24 38.21 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 122.213 1.006 . . . . 0.0 109.173 179.416 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.8 p -167.9 143.82 3.93 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.381 179.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -147.15 174.16 11.84 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.453 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.472 ' CD1' ' HG2' ' A' ' 8' ' ' GLU . 20.6 p90 -158.75 -159.84 0.82 Allowed 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.076 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.899 0 CA-C-O 118.637 -1.09 . . . . 0.0 111.035 179.833 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.32 0 CA-C-O 120.488 -0.062 . . . . 0.0 113.117 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.62 -138.33 4.34 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.183 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.459 ' HA ' ' HB2' ' A' ' 19' ' ' PHE . . . -145.94 141.94 28.25 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.591 0.234 . . . . 0.0 110.415 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.445 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.25 -127.52 1.41 Allowed Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 121.014 -0.612 . . . . 0.0 111.932 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.482 ' H ' ' C ' ' A' ' 21' ' ' GLY . 45.3 m80 -116.88 -37.16 3.66 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.604 0.24 . . . . 0.0 110.762 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.7 t -88.45 120.18 70.32 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.302 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.07 139.14 45.83 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 122.954 2.436 . . . . 0.0 113.236 -179.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -95.34 -75.57 0.52 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.601 179.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.404 ' O ' ' HA ' ' A' ' 16' ' ' PRO . 27.6 m-85 -107.41 140.58 40.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.073 0.463 . . . . 0.0 111.831 -178.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.447 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.5 m-85 -115.8 147.7 40.69 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.239 -0.891 . . . . 0.0 109.053 178.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 15' ' ' THR . 29.9 m -86.64 -167.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 C-N-CA 120.992 -0.283 . . . . 0.0 110.92 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -57.56 -42.18 93.91 Favored Glycine 0 C--O 1.227 -0.329 0 C-N-CA 121.387 -0.435 . . . . 0.0 113.64 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 17.6 pt -86.75 32.65 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 120.932 0.396 . . . . 0.0 111.964 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.59 29.13 31.45 Favored Glycine 0 CA--C 1.519 0.33 0 CA-C-N 115.666 -0.697 . . . . 0.0 114.051 178.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.451 ' O ' HG22 ' A' ' 11' ' ' VAL . 18.9 m -102.57 120.21 53.68 Favored Pre-proline 0 C--N 1.321 -0.671 0 CA-C-N 117.003 0.401 . . . . 0.0 110.497 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 72.8 Cg_endo -80.2 124.64 5.49 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.269 1.98 . . . . 0.0 112.691 -179.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.0 mt -116.15 39.33 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 122.333 1.063 . . . . 0.0 108.894 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 p -175.92 146.48 0.71 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.451 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.459 ' HB2' ' HA ' ' A' ' 3' ' ' ALA . 56.4 m-85 -131.54 -172.7 2.92 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 10.6 t80 -122.71 -62.66 1.34 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.55 0.691 . . . . 0.0 110.197 -179.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.482 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.442 -0.904 0 CA-C-N 114.596 -1.184 . . . . 0.0 110.233 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.286 0 N-CA-C 113.221 0.048 . . . . 0.0 113.221 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.35 -137.03 3.91 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.112 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.9 138.76 25.8 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.333 -0.247 . . . . 0.0 110.333 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.669 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 173.71 -127.54 1.36 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.255 -179.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -118.64 -37.75 3.23 Favored 'General case' 0 C--N 1.328 -0.363 0 O-C-N 122.827 -0.219 . . . . 0.0 111.248 -179.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.5 t -88.14 115.22 62.49 Favored Pre-proline 0 C--O 1.222 -0.345 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 -179.306 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.76 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 34.8 Cg_exo -62.57 137.55 64.96 Favored 'Trans proline' 0 N--CA 1.473 0.28 0 C-N-CA 123.423 2.749 . . . . 0.0 114.165 -178.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.0 mt-10 -97.13 -72.11 0.65 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.257 178.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 27.8 m-85 -116.62 142.53 46.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.667 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -110.73 149.04 31.06 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.84 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 26.9 m -82.87 -167.41 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.688 179.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.78 -42.01 96.25 Favored Glycine 0 C--O 1.227 -0.322 0 C-N-CA 121.304 -0.474 . . . . 0.0 113.588 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 18.2 pt -87.5 33.83 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.08 31.28 32.92 Favored Glycine 0 CA--C 1.519 0.335 0 CA-C-N 115.71 -0.677 . . . . 0.0 114.174 178.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 18.0 m -104.77 125.76 33.0 Favored Pre-proline 0 C--N 1.322 -0.588 0 O-C-N 122.539 -0.389 . . . . 0.0 110.135 179.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.76 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 31.3 Cg_endo -65.07 125.77 15.24 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.4 2.067 . . . . 0.0 112.226 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.416 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -115.98 29.09 2.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 122.508 1.147 . . . . 0.0 109.581 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.8 p 179.68 150.08 0.33 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 114.249 -1.341 . . . . 0.0 109.725 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.669 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 14.1 m-85 -140.31 171.38 14.23 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -90.78 -56.41 3.19 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.48 0.657 . . . . 0.0 110.349 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.256 1.492 0 CA-C-O 117.56 -1.689 . . . . 0.0 110.001 -179.841 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.38 0 N-CA-C 113.59 0.196 . . . . 0.0 113.59 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -108.27 -134.68 7.34 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.655 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.417 ' HA ' ' HD1' ' A' ' 19' ' ' PHE . . . -145.38 47.89 1.28 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.031 0.443 . . . . 0.0 111.16 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.639 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . -80.41 -126.06 0.64 Allowed Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.931 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 61.6 m80 -111.47 -44.83 3.46 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -178.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.574 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.8 m -89.42 122.92 67.99 Favored Pre-proline 0 C--O 1.221 -0.431 0 CA-C-O 120.744 0.307 . . . . 0.0 110.962 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.662 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 40.1 Cg_exo -58.27 139.55 90.95 Favored 'Trans proline' 0 N--CA 1.474 0.379 0 C-N-CA 123.32 2.68 . . . . 0.0 114.449 -178.312 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.436 ' HG3' ' C ' ' A' ' 19' ' ' PHE . 94.7 mt-10 -95.26 -72.28 0.63 Allowed 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.675 179.078 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -108.17 144.91 34.94 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.541 -179.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.532 ' CZ ' ' HB2' ' A' ' 7' ' ' PRO . 4.7 m-85 -123.72 141.74 51.73 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.205 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.487 HG23 HD12 ' A' ' 17' ' ' ILE . 43.8 t -78.2 155.12 5.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -50.99 -30.52 23.08 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.496 -0.383 . . . . 0.0 113.494 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.2 pt -84.41 30.53 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.847 0.356 . . . . 0.0 111.898 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 55.8 50.09 62.82 Favored Glycine 0 CA--C 1.519 0.283 0 CA-C-N 115.926 -0.579 . . . . 0.0 113.64 178.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 15.2 m -133.85 118.0 14.18 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 117.142 0.471 . . . . 0.0 111.311 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.662 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 4.6 Cg_exo -77.05 130.97 11.62 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.988 2.459 . . . . 0.0 111.719 179.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.631 ' H ' HD13 ' A' ' 17' ' ' ILE . 0.2 OUTLIER -123.88 33.61 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.541 0.686 . . . . 0.0 111.055 179.979 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 p 179.83 152.92 0.47 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.463 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.639 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 8.5 m-85 -144.48 166.92 23.76 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.574 ' HB2' HG23 ' A' ' 6' ' ' VAL . 97.2 m-85 -90.06 -115.72 0.07 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.102 0 CA-C-O 118.123 -1.376 . . . . 0.0 110.633 178.245 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.226 0 CA-C-O 120.555 -0.025 . . . . 0.0 113.077 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.49 -139.14 4.57 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.817 -0.706 . . . . 0.0 111.976 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.62 140.35 30.09 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.659 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.64 -128.94 1.51 Allowed Glycine 0 N--CA 1.448 -0.562 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.077 -179.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.411 ' H ' ' C ' ' A' ' 21' ' ' GLY . 62.7 m80 -114.65 -43.11 3.18 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 111.59 0.219 . . . . 0.0 111.59 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.607 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.5 m -89.89 117.82 68.42 Favored Pre-proline 0 C--O 1.223 -0.296 0 CA-C-O 120.825 0.345 . . . . 0.0 110.757 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.468 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 26.8 Cg_exo -63.61 139.61 70.71 Favored 'Trans proline' 0 CA--C 1.53 0.296 0 C-N-CA 123.506 2.804 . . . . 0.0 114.236 -178.301 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.433 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 93.2 mt-10 -91.67 -72.41 0.59 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.425 178.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -112.67 139.93 47.87 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.266 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.528 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 4.5 m-85 -111.41 143.82 41.61 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.192 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.9 t -85.43 151.12 3.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 178.373 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -53.58 -24.53 24.91 Favored Glycine 0 C--O 1.226 -0.404 0 C-N-CA 121.499 -0.381 . . . . 0.0 113.539 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.3 mt -82.22 32.61 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.445 0 CA-C-O 121.182 0.515 . . . . 0.0 111.092 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.0 47.55 54.06 Favored Glycine 0 CA--C 1.52 0.368 0 CA-C-N 115.699 -0.682 . . . . 0.0 114.237 178.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.2 t -150.62 129.58 6.27 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 117.359 0.58 . . . . 0.0 111.43 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 85.5 Cg_endo -85.64 131.63 4.0 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.918 2.412 . . . . 0.0 112.493 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -115.47 35.92 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 121.355 0.598 . . . . 0.0 110.959 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.5 p -176.2 148.66 0.8 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.189 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.659 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 11.9 m-85 -141.34 172.13 13.11 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.607 ' HB2' HG23 ' A' ' 6' ' ' VAL . 93.7 m-85 -95.02 -56.79 2.63 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.554 0.692 . . . . 0.0 110.008 179.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.411 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.441 -1.006 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.261 0 CA-C-O 120.313 -0.159 . . . . 0.0 113.305 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.15 -118.0 1.04 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.446 -179.303 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.52 145.09 45.58 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.632 0.253 . . . . 0.0 110.528 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.27 -131.82 1.67 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 121.033 -0.603 . . . . 0.0 111.632 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -123.18 -48.5 1.98 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 117.069 0.435 . . . . 0.0 110.457 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.487 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 41.8 t -89.96 130.04 44.01 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.253 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -60.74 137.98 76.54 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 123.154 2.569 . . . . 0.0 113.798 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.752 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 90.9 mt-10 -89.09 -73.95 0.49 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.622 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -124.43 143.29 50.71 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.022 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.552 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.0 OUTLIER -104.9 148.39 26.73 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.552 179.167 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 15' ' ' THR . 35.9 m -92.46 178.87 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 116.561 -0.29 . . . . 0.0 110.543 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -60.28 -26.2 63.6 Favored Glycine 0 N--CA 1.453 -0.218 0 CA-C-N 116.087 -0.506 . . . . 0.0 113.54 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.416 ' H ' HG23 ' A' ' 11' ' ' VAL . 9.6 mm -84.06 31.48 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.064 0.459 . . . . 0.0 110.958 -179.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 46.0 43.39 12.84 Favored Glycine 0 N--CA 1.46 0.297 0 CA-C-N 115.575 -0.739 . . . . 0.0 113.782 179.156 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.539 ' O ' HG22 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -143.23 135.39 13.23 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-O 120.795 0.331 . . . . 0.0 111.287 -179.261 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 71.7 Cg_endo -84.49 127.35 3.79 Favored 'Trans proline' 0 N--CA 1.454 -0.818 0 C-N-CA 122.562 2.174 . . . . 0.0 112.322 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.6 mt -115.77 39.97 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 122.216 1.007 . . . . 0.0 108.857 179.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.9 p -171.58 144.58 1.91 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.841 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -147.32 173.42 12.61 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.752 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -153.61 169.64 22.76 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.216 0.532 . . . . 0.0 111.398 178.741 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.949 0 CA-C-N 114.648 -1.16 . . . . 0.0 112.529 -179.963 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.244 0 CA-C-O 120.541 -0.033 . . . . 0.0 113.074 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 173.9 -138.33 4.46 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.792 -0.718 . . . . 0.0 111.988 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.34 140.78 32.22 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.328 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.693 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.11 -132.86 2.37 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.459 -179.152 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.461 ' H ' ' C ' ' A' ' 21' ' ' GLY . 23.8 m170 -109.23 -47.34 3.43 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.571 0.224 . . . . 0.0 111.352 -178.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.544 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.45 120.72 69.66 Favored Pre-proline 0 C--O 1.225 -0.233 0 CA-C-O 120.804 0.335 . . . . 0.0 111.206 -179.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.607 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 24.7 Cg_exo -64.17 138.98 64.24 Favored 'Trans proline' 0 CA--C 1.529 0.247 0 C-N-CA 123.601 2.868 . . . . 0.0 114.288 -178.584 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.446 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 94.4 mt-10 -91.63 -68.93 0.76 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.568 178.054 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -128.54 142.74 50.97 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.998 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.579 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.5 m-85 -98.07 150.13 21.74 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.369 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.587 HG13 ' H ' ' A' ' 13' ' ' ILE . 9.1 p -88.89 165.41 2.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.206 178.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -55.85 -24.21 40.65 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 121.568 -0.348 . . . . 0.0 113.854 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.587 ' H ' HG13 ' A' ' 11' ' ' VAL . 5.0 mt -82.41 33.32 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 120.938 0.399 . . . . 0.0 111.333 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 47.5 43.11 20.38 Favored Glycine 0 CA--C 1.521 0.426 0 CA-C-N 115.827 -0.624 . . . . 0.0 114.027 178.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.476 ' O ' HG12 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -146.92 140.73 15.28 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.902 0.351 . . . . 0.0 111.045 -179.472 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.607 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 35.6 Cg_endo -66.28 126.38 15.57 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.29 1.993 . . . . 0.0 111.824 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.43 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -114.53 31.07 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 122.243 1.021 . . . . 0.0 110.027 -179.606 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 25.2 p 179.63 149.13 0.29 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.12 179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.693 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 11.3 m-85 -142.72 172.0 13.28 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.544 ' HB2' HG23 ' A' ' 6' ' ' VAL . 93.6 m-85 -95.6 -58.35 2.14 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.363 0.601 . . . . 0.0 110.42 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.461 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.253 1.316 0 CA-C-O 117.414 -1.77 . . . . 0.0 110.064 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.301 0 N-CA-C 113.214 0.045 . . . . 0.0 113.214 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.28 -139.29 4.49 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.005 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -143.91 140.01 29.49 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.662 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.43 -129.24 1.57 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.054 -179.245 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.41 ' H ' ' C ' ' A' ' 21' ' ' GLY . 62.8 m80 -114.6 -43.03 3.2 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.481 0.178 . . . . 0.0 111.481 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.608 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.71 117.31 68.02 Favored Pre-proline 0 C--N 1.33 -0.274 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.826 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.478 ' HB2' ' CZ ' ' A' ' 10' ' ' PHE . 24.6 Cg_exo -64.09 140.44 71.93 Favored 'Trans proline' 0 CA--C 1.529 0.271 0 C-N-CA 123.518 2.812 . . . . 0.0 114.258 -178.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.438 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 94.2 mt-10 -91.91 -70.93 0.67 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.447 178.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -116.19 142.4 46.87 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.551 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.55 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 3.7 m-85 -114.06 145.41 41.63 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.405 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 42.3 t -82.94 152.92 3.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -54.41 -23.65 27.66 Favored Glycine 0 C--O 1.226 -0.347 0 C-N-CA 121.383 -0.437 . . . . 0.0 113.245 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.2 mt -83.11 32.26 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 CA-C-O 121.209 0.528 . . . . 0.0 111.091 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 51.93 50.14 45.74 Favored Glycine 0 CA--C 1.52 0.348 0 CA-C-N 115.632 -0.713 . . . . 0.0 114.323 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.2 t -150.54 129.44 6.23 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 117.437 0.619 . . . . 0.0 111.345 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 71.7 Cg_endo -80.26 134.8 10.45 Favored 'Trans proline' 0 N--CA 1.463 -0.267 0 C-N-CA 122.807 2.338 . . . . 0.0 112.629 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.0 pp -119.14 33.19 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.254 0.549 . . . . 0.0 111.547 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 p -179.22 150.76 0.46 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.094 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.662 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.3 m-85 -140.78 172.17 13.08 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.476 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.608 ' HB2' HG23 ' A' ' 6' ' ' VAL . 95.2 m-85 -95.61 -56.68 2.61 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.509 0.671 . . . . 0.0 110.086 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.41 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 N--CA 1.441 -0.978 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.257 0 CA-C-O 120.475 -0.07 . . . . 0.0 113.108 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.95 -136.15 3.71 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.965 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -144.6 140.75 28.94 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 179.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.7 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.33 -132.67 2.45 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.668 -179.156 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.48 ' H ' ' C ' ' A' ' 21' ' ' GLY . 20.4 m170 -110.03 -43.74 3.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.534 0.207 . . . . 0.0 111.352 -178.703 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 40.7 t -88.2 118.96 70.15 Favored Pre-proline 0 C--O 1.223 -0.334 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.728 -178.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.545 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 31.8 Cg_endo -64.41 138.23 59.29 Favored 'Trans proline' 0 CA--C 1.528 0.225 0 C-N-CA 123.208 2.606 . . . . 0.0 114.234 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.412 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 92.2 mt-10 -95.67 -71.66 0.66 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.516 -0.766 . . . . 0.0 110.372 178.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -117.9 142.35 47.43 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.687 -179.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -111.95 136.94 50.61 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 43.4 t -145.33 137.69 20.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 120.966 0.412 . . . . 0.0 110.932 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.69 -68.4 0.23 Allowed Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.133 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.3 pt -156.16 46.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 114.78 -0.71 . . . . 0.0 109.736 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.38 18.23 79.98 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -178.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.456 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 0.7 OUTLIER -89.41 125.81 60.41 Favored Pre-proline 0 N--CA 1.447 -0.595 0 CA-C-N 115.113 -0.544 . . . . 0.0 110.623 179.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.545 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 17.9 Cg_exo -66.66 125.64 14.14 Favored 'Trans proline' 0 N--CA 1.463 -0.28 0 C-N-CA 122.778 2.319 . . . . 0.0 112.33 -179.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.411 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.2 tp -118.34 27.88 3.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 122.714 1.245 . . . . 0.0 109.376 179.343 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.4 p 179.57 150.28 0.33 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 113.899 -1.5 . . . . 0.0 109.475 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.7 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.5 m-85 -142.18 172.22 12.99 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.412 ' CZ ' ' HG2' ' A' ' 8' ' ' GLU . 93.6 m-85 -92.82 -59.46 2.05 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.461 0.648 . . . . 0.0 110.444 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.48 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.253 1.328 0 CA-C-O 117.244 -1.864 . . . . 0.0 109.987 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.281 0 N-CA-C 112.969 -0.052 . . . . 0.0 112.969 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 176.93 -141.95 5.62 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.93 -0.652 . . . . 0.0 111.714 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.73 46.24 1.02 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.133 0.492 . . . . 0.0 111.095 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.599 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . -81.83 -127.33 0.94 Allowed Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.668 -0.696 . . . . 0.0 112.815 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.1 m-70 -114.31 -43.37 3.21 Favored 'General case' 0 C--N 1.327 -0.402 0 O-C-N 122.444 -0.445 . . . . 0.0 111.89 -178.676 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.543 HG13 ' HB2' ' A' ' 20' ' ' TYR . 2.4 p -89.37 124.76 63.71 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 120.788 0.328 . . . . 0.0 110.682 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.53 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 50.8 Cg_exo -56.36 138.8 85.1 Favored 'Trans proline' 0 N--CA 1.474 0.367 0 C-N-CA 123.53 2.82 . . . . 0.0 114.467 -178.341 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.419 ' HG2' ' CE1' ' A' ' 20' ' ' TYR . 89.8 mt-10 -98.5 -72.88 0.64 Allowed 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.55 178.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -118.84 140.8 49.37 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.085 -179.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.47 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 5.0 m-85 -108.74 145.68 34.72 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.389 -0.823 . . . . 0.0 108.973 179.295 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.0 p -165.44 151.06 2.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.172 0.511 . . . . 0.0 111.435 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.22 -62.17 0.57 Allowed Glycine 0 CA--C 1.505 -0.553 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.678 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.1 pt -155.75 41.7 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 114.828 -0.686 . . . . 0.0 109.71 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.51 13.18 82.02 Favored Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.645 -179.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.8 p -89.66 129.89 45.21 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.688 -0.256 . . . . 0.0 110.88 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.53 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 56.2 Cg_endo -74.14 122.51 7.65 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.238 1.959 . . . . 0.0 112.069 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 16.9 mm -113.51 37.19 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 122.182 0.991 . . . . 0.0 109.028 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 25.1 p 179.85 148.25 0.28 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.566 -1.197 . . . . 0.0 109.789 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.599 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 9.1 m-85 -141.04 167.53 21.96 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.535 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.543 ' HB2' HG13 ' A' ' 6' ' ' VAL . 94.1 m-85 -84.37 -114.54 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.453 0 CA-C-O 117.998 -1.445 . . . . 0.0 111.023 178.857 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.338 0 CA-C-O 120.437 -0.091 . . . . 0.0 113.247 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.66 -137.08 4.15 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.144 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.85 140.12 26.82 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.675 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 172.53 -128.23 1.51 Allowed Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.344 -179.255 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -115.06 -40.63 3.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.672 0.236 . . . . 0.0 111.493 -178.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.8 t -88.54 115.75 64.27 Favored Pre-proline 0 C--O 1.221 -0.401 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -64.25 140.03 68.87 Favored 'Trans proline' 0 CA--C 1.532 0.388 0 C-N-CA 123.208 2.605 . . . . 0.0 114.133 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -97.36 -74.4 0.57 Allowed 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.689 179.095 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 19.0 m-85 -105.3 142.6 34.79 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.457 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.499 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 5.8 m-85 -120.45 143.01 48.73 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.402 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.447 ' CG2' HD12 ' A' ' 17' ' ' ILE . 38.4 t -84.18 153.77 3.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -52.32 -28.02 26.24 Favored Glycine 0 C--O 1.228 -0.252 0 C-N-CA 121.551 -0.357 . . . . 0.0 113.683 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.646 HG13 HG22 ' A' ' 15' ' ' THR . 24.9 pt -82.94 31.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 55.25 52.62 46.15 Favored Glycine 0 CA--C 1.521 0.45 0 N-CA-C 114.926 0.73 . . . . 0.0 114.926 177.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.646 HG22 HG13 ' A' ' 13' ' ' ILE . 9.5 t -150.71 129.24 6.06 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 117.703 0.752 . . . . 0.0 111.198 179.089 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.499 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 85.5 Cg_endo -85.46 130.44 3.86 Favored 'Trans proline' 0 N--CA 1.459 -0.501 0 C-N-CA 122.803 2.336 . . . . 0.0 112.704 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.759 ' H ' HD13 ' A' ' 17' ' ' ILE . 0.2 OUTLIER -112.95 33.26 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.457 0.646 . . . . 0.0 110.932 179.839 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.6 p -176.98 150.24 0.75 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.157 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.675 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 15.9 m-85 -141.18 173.0 11.91 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -91.05 -56.67 3.08 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.396 0.617 . . . . 0.0 110.288 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.343 0 CA-C-O 117.648 -1.64 . . . . 0.0 110.144 -179.792 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.41 0 N-CA-C 113.347 0.099 . . . . 0.0 113.347 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.59 -143.14 7.57 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.869 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.4 48.4 1.56 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.134 0.492 . . . . 0.0 110.865 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.75 -124.5 0.38 Allowed Glycine 0 CA--C 1.519 0.306 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.41 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.411 ' HD1' ' C ' ' A' ' 21' ' ' GLY . 67.8 m80 -121.87 -43.84 2.34 Favored 'General case' 0 C--N 1.328 -0.364 0 O-C-N 122.457 -0.437 . . . . 0.0 111.596 -179.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.408 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 25.4 t -88.94 128.79 50.73 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -57.7 136.43 75.52 Favored 'Trans proline' 0 CA--C 1.529 0.256 0 C-N-CA 123.186 2.591 . . . . 0.0 113.677 -178.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.649 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 94.1 mt-10 -93.4 -73.81 0.55 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.523 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -124.27 142.02 51.6 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.926 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.433 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.5 m-85 -107.24 136.95 46.2 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.306 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.5 m -153.64 -177.48 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.687 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.59 -50.38 2.5 Favored Glycine 0 C--O 1.227 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 113.01 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.408 ' O ' HG13 ' A' ' 13' ' ' ILE . 10.9 tp -170.91 37.75 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-O 122.364 1.078 . . . . 0.0 109.419 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 78.09 13.41 83.38 Favored Glycine 0 N--CA 1.452 -0.295 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.674 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.409 HG23 HD11 ' A' ' 17' ' ' ILE . 9.0 t -96.81 136.6 21.58 Favored Pre-proline 0 C--N 1.325 -0.461 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 45.5 Cg_endo -71.35 122.88 9.07 Favored 'Trans proline' 0 N--CA 1.462 -0.34 0 C-N-CA 122.289 1.993 . . . . 0.0 112.272 -179.244 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.409 HD11 HG23 ' A' ' 15' ' ' THR . 20.9 mm -114.42 37.85 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 122.298 1.047 . . . . 0.0 108.834 179.343 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 17.1 p -179.65 145.77 0.24 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.446 -1.252 . . . . 0.0 109.702 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 -147.01 166.94 25.3 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.328 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.649 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -145.87 170.6 16.26 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.292 178.013 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.411 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.25 1.141 0 CA-C-O 118.552 -1.138 . . . . 0.0 111.963 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.404 0 N-CA-C 113.382 0.113 . . . . 0.0 113.382 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.7 -142.8 7.34 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.845 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.68 48.34 1.53 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.169 0.509 . . . . 0.0 110.755 179.618 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.69 -124.34 0.37 Allowed Glycine 0 N--CA 1.451 -0.329 0 CA-C-N 115.553 -0.749 . . . . 0.0 112.391 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.417 ' HD1' ' C ' ' A' ' 21' ' ' GLY . 67.4 m80 -122.33 -43.58 2.3 Favored 'General case' 0 C--N 1.325 -0.482 0 O-C-N 122.515 -0.403 . . . . 0.0 111.509 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.403 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 25.7 t -89.0 127.95 53.79 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.714 -0.221 . . . . 0.0 110.405 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.516 ' HB3' ' HB3' ' A' ' 16' ' ' PRO . 52.7 Cg_exo -56.17 136.03 73.07 Favored 'Trans proline' 0 CA--C 1.53 0.287 0 C-N-CA 123.229 2.619 . . . . 0.0 113.717 -179.065 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.648 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 94.1 mt-10 -93.72 -74.25 0.54 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.626 179.265 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -122.78 141.03 52.26 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.846 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.428 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.2 m-85 -108.06 136.52 47.61 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.431 179.407 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -153.83 -178.3 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 O-C-N 123.282 0.364 . . . . 0.0 110.555 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.92 -50.39 2.62 Favored Glycine 0 C--N 1.332 0.306 0 CA-C-N 116.076 -0.511 . . . . 0.0 113.053 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.416 ' O ' HG12 ' A' ' 13' ' ' ILE . 15.3 tt -170.99 38.31 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-O 122.349 1.071 . . . . 0.0 109.353 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.32 14.13 82.85 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.098 -0.955 . . . . 0.0 112.687 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 9.0 t -97.31 135.82 21.66 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.516 ' HB3' ' HB3' ' A' ' 7' ' ' PRO . 50.8 Cg_endo -72.1 123.5 9.3 Favored 'Trans proline' 0 N--CA 1.46 -0.463 0 C-N-CA 122.19 1.926 . . . . 0.0 112.404 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 20.8 mm -113.06 37.35 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 122.276 1.036 . . . . 0.0 108.754 179.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 p -179.89 146.37 0.24 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 114.365 -1.289 . . . . 0.0 109.612 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -146.95 166.45 26.74 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.259 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.648 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.1 OUTLIER -145.04 170.67 15.74 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.421 178.054 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.417 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.242 0.625 0 CA-C-O 119.019 -0.879 . . . . 0.0 111.951 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.435 0 CA-C-O 120.272 -0.182 . . . . 0.0 113.553 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -122.81 -127.15 3.25 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.865 -179.151 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -134.86 143.33 46.94 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.68 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 176.43 -133.94 2.45 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.34 -179.346 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.453 ' H ' ' C ' ' A' ' 21' ' ' GLY . 23.7 m170 -109.31 -46.92 3.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.664 0.268 . . . . 0.0 111.201 -178.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.536 HG23 ' HB2' ' A' ' 20' ' ' TYR . 3.7 m -89.49 122.54 68.25 Favored Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.187 -179.232 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.18 139.98 69.02 Favored 'Trans proline' 0 N--CA 1.472 0.243 0 C-N-CA 123.427 2.751 . . . . 0.0 114.312 -178.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.409 ' HG3' ' C ' ' A' ' 19' ' ' PHE . 92.6 mt-10 -92.47 -71.3 0.65 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.347 178.603 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 53.1 m-85 -128.43 142.64 51.04 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.598 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.595 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.2 m-85 -98.23 149.91 22.08 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.053 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.705 HG13 HG22 ' A' ' 13' ' ' ILE . 6.6 p -87.96 172.62 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.643 179.201 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.563 ' H ' HG22 ' A' ' 11' ' ' VAL . . . -71.94 41.37 0.71 Allowed Glycine 0 C--O 1.229 -0.203 0 N-CA-C 115.056 0.782 . . . . 0.0 115.056 -178.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.705 HG22 HG13 ' A' ' 11' ' ' VAL . 10.7 tp -154.21 28.99 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-O 122.169 0.985 . . . . 0.0 110.441 178.291 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 60.04 43.76 97.91 Favored Glycine 0 CA--C 1.521 0.411 0 CA-C-N 114.673 -1.149 . . . . 0.0 115.141 177.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.1 t -151.27 137.03 10.9 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-N 117.726 0.763 . . . . 0.0 110.435 178.571 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.595 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 72.3 Cg_endo -77.71 127.01 8.5 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.725 2.283 . . . . 0.0 112.921 -179.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 17.6 mm -114.28 38.03 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 122.016 0.912 . . . . 0.0 108.964 179.246 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.7 p -177.96 147.73 0.48 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.029 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.68 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 12.8 m-85 -144.34 171.85 13.76 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.536 ' HB2' HG23 ' A' ' 6' ' ' VAL . 90.5 m-85 -96.08 -58.82 1.98 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.303 0.573 . . . . 0.0 110.626 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.453 ' C ' ' H ' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.252 1.252 0 CA-C-O 117.459 -1.745 . . . . 0.0 110.003 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.332 0 CA-C-O 120.221 -0.211 . . . . 0.0 113.403 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -139.57 -120.97 1.82 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.717 -179.273 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -126.07 143.81 50.97 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.723 ' HA3' ' O ' ' A' ' 20' ' ' TYR . . . -179.99 -125.45 0.96 Allowed Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.551 -179.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -118.99 -57.54 2.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.85 0.325 . . . . 0.0 111.575 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.528 ' HB ' ' CE1' ' A' ' 20' ' ' TYR . 47.3 t -88.6 128.84 51.2 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-O 120.888 0.375 . . . . 0.0 110.345 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -61.01 140.91 92.59 Favored 'Trans proline' 0 CA--C 1.53 0.285 0 C-N-CA 123.523 2.815 . . . . 0.0 114.495 -178.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.772 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.2 mt-10 -91.14 -70.83 0.66 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.205 178.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 42.9 m-85 -124.48 144.47 50.08 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.901 -179.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.622 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.0 OUTLIER -107.88 149.48 28.23 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.823 179.645 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 15' ' ' THR . 27.2 m -92.66 175.53 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.2 178.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.35 -21.79 60.32 Favored Glycine 0 C--O 1.228 -0.247 0 CA-C-N 116.09 -0.505 . . . . 0.0 113.436 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.417 ' H ' HG23 ' A' ' 11' ' ' VAL . 4.7 mt -83.02 28.92 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 121.185 0.517 . . . . 0.0 111.328 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 49.28 44.38 34.77 Favored Glycine 0 CA--C 1.521 0.412 0 CA-C-N 115.559 -0.746 . . . . 0.0 114.162 178.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.435 ' O ' HG22 ' A' ' 11' ' ' VAL . 7.8 t -150.67 140.42 13.84 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 117.115 0.457 . . . . 0.0 110.849 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.622 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 51.3 Cg_endo -70.18 140.53 41.32 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.79 2.327 . . . . 0.0 112.194 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.407 ' O ' HG12 ' A' ' 17' ' ' ILE . 14.7 tt -123.44 30.29 2.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 122.302 1.048 . . . . 0.0 109.713 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.1 p -179.15 151.48 0.5 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.479 -1.237 . . . . 0.0 110.071 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.494 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 10.3 m-85 -146.26 171.35 15.1 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.165 -0.679 . . . . 0.0 109.165 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.772 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.2 OUTLIER -139.99 -120.91 0.12 Allowed 'General case' 0 C--N 1.325 -0.483 0 O-C-N 123.045 0.216 . . . . 0.0 110.698 178.78 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.419 ' N ' ' HD1' ' A' ' 20' ' ' TYR . . . . . . . . 0 C--O 1.245 0.811 0 CA-C-O 118.516 -1.158 . . . . 0.0 112.569 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.289 0 CA-C-O 120.573 -0.015 . . . . 0.0 113.133 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 178.9 -137.59 3.26 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.063 -0.589 . . . . 0.0 111.776 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.75 137.77 25.36 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.642 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 174.45 -129.24 1.57 Allowed Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.369 -179.293 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 15.1 m-70 -118.57 -36.53 3.48 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.572 0.186 . . . . 0.0 111.204 -179.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 38.7 t -88.1 117.04 67.97 Favored Pre-proline 0 C--N 1.33 -0.26 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 -179.281 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -62.68 134.66 48.47 Favored 'Trans proline' 0 N--CA 1.471 0.189 0 C-N-CA 123.2 2.6 . . . . 0.0 113.845 -178.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -90.62 -72.24 0.58 Allowed 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.667 178.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -128.36 144.47 51.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.856 -179.61 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -109.56 135.03 51.21 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 179.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 66.9 t -147.76 145.5 18.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.963 0.411 . . . . 0.0 111.159 -179.411 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.73 -60.82 0.74 Allowed Glycine 0 CA--C 1.503 -0.683 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.906 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 8.2 pt -152.31 40.07 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-O 121.15 0.5 . . . . 0.0 110.445 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.06 23.85 74.53 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.262 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.8 t -102.64 133.73 20.3 Favored Pre-proline 0 C--N 1.325 -0.479 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -76.73 116.7 4.32 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.233 1.955 . . . . 0.0 112.751 -178.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.82 ' H ' HD13 ' A' ' 17' ' ' ILE . 0.2 OUTLIER -103.2 30.23 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 121.964 0.888 . . . . 0.0 109.72 179.047 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 p -175.88 146.77 0.74 Allowed 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 114.353 -1.294 . . . . 0.0 109.9 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.642 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 22.6 m-85 -136.97 173.24 11.91 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -91.45 -56.72 3.02 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.358 0.599 . . . . 0.0 110.417 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.414 0 CA-C-O 117.564 -1.687 . . . . 0.0 110.092 -179.714 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.235 0 N-CA-C 113.755 0.262 . . . . 0.0 113.755 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 164.7 -137.82 4.93 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.178 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -130.66 141.94 50.43 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 179.142 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.4 ' H ' ' HB2' ' A' ' 19' ' ' PHE . . . -179.75 -127.62 1.13 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.101 -179.451 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 35.3 m170 -125.94 -43.66 1.82 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.553 0.216 . . . . 0.0 111.1 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.22 127.45 55.22 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -63.0 137.3 61.4 Favored 'Trans proline' 0 CA--C 1.529 0.246 0 C-N-CA 123.017 2.478 . . . . 0.0 113.807 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.611 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.2 mt-10 -89.67 -73.25 0.52 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.885 179.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -121.93 143.66 49.33 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.158 -179.211 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.431 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 3.3 m-85 -110.88 149.01 31.22 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.706 179.442 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.7 m -83.84 -167.56 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.589 179.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.65 -41.36 95.66 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 121.251 -0.499 . . . . 0.0 113.506 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 18.8 pt -87.67 33.27 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.27 32.47 36.78 Favored Glycine 0 CA--C 1.52 0.352 0 CA-C-N 115.71 -0.677 . . . . 0.0 114.224 178.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.1 m -105.5 121.61 45.55 Favored Pre-proline 0 C--N 1.322 -0.622 0 O-C-N 122.476 -0.426 . . . . 0.0 110.361 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 56.2 Cg_endo -73.05 125.54 10.45 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.338 2.025 . . . . 0.0 112.373 -179.591 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 pt -113.79 34.29 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.45 0.643 . . . . 0.0 110.444 179.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.0 p -179.71 147.96 0.31 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.749 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.4 ' HB2' ' H ' ' A' ' 4' ' ' GLY . 26.0 m-85 -144.29 174.37 10.96 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 -179.714 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.611 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -159.82 -160.54 0.82 Allowed 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.083 178.557 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.046 0 CA-C-O 117.706 -1.608 . . . . 0.0 110.981 179.718 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 113.723 0.249 . . . . 0.0 113.723 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.92 -118.54 1.02 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.376 -0.916 . . . . 0.0 112.833 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.4 144.2 46.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.813 0.34 . . . . 0.0 110.559 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.46 -122.9 0.8 Allowed Glycine 0 N--CA 1.446 -0.64 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.892 -179.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 85.6 m-70 -137.21 -43.19 0.56 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.661 0.267 . . . . 0.0 110.645 179.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -89.21 127.36 55.57 Favored Pre-proline 0 C--N 1.328 -0.353 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -62.7 135.99 55.55 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.979 2.453 . . . . 0.0 113.988 -178.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.601 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 90.0 mt-10 -91.43 -75.87 0.46 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.246 178.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 27.9 m-85 -110.25 141.66 42.91 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.133 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.555 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 6.5 m-85 -110.34 143.94 39.81 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.684 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 40.7 t -85.78 152.08 3.62 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 178.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -54.49 -23.27 26.91 Favored Glycine 0 CA--C 1.52 0.359 0 C-N-CA 121.409 -0.424 . . . . 0.0 113.389 -179.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 10.0 mm -82.64 32.32 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.582 0 CA-C-O 121.379 0.609 . . . . 0.0 110.942 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 52.3 46.55 57.27 Favored Glycine 0 CA--C 1.522 0.5 0 CA-C-N 115.613 -0.721 . . . . 0.0 114.334 178.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 6.2 t -150.52 133.84 8.75 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 117.381 0.591 . . . . 0.0 111.23 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 11.2 Cg_exo -70.57 142.37 44.18 Favored 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 123.021 2.48 . . . . 0.0 111.821 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.42 ' O ' HG13 ' A' ' 17' ' ' ILE . 11.4 tp -124.25 29.94 2.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 122.26 1.029 . . . . 0.0 110.178 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.42 ' OG ' ' HB2' ' A' ' 8' ' ' GLU . 9.8 p 179.63 149.9 0.32 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.703 179.619 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -144.97 172.24 13.32 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.731 0.301 . . . . 0.0 110.316 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.601 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.0 OUTLIER -160.1 -161.52 0.89 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.652 -0.703 . . . . 0.0 109.859 178.542 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.05 0 CA-C-O 117.718 -1.601 . . . . 0.0 111.031 179.664 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.263 0 N-CA-C 113.419 0.128 . . . . 0.0 113.419 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 162.68 -137.35 4.77 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.063 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -140.01 141.22 36.34 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.125 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.582 ' N ' ' HB2' ' A' ' 19' ' ' PHE . . . 175.79 -120.5 0.76 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.413 -179.14 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -126.3 -41.41 1.9 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 42.6 t -88.33 120.53 70.49 Favored Pre-proline 0 C--O 1.22 -0.474 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.266 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -61.32 132.98 43.8 Favored 'Trans proline' 0 CA--C 1.53 0.312 0 C-N-CA 122.892 2.395 . . . . 0.0 113.901 -178.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.539 ' HG2' ' CZ ' ' A' ' 20' ' ' TYR . 91.4 mt-10 -92.57 -74.91 0.5 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.185 178.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -117.59 143.55 46.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.103 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -107.23 146.93 30.81 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.241 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.741 HG13 HG22 ' A' ' 13' ' ' ILE . 9.1 p -79.81 165.13 2.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.29 178.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.7 41.34 0.54 Allowed Glycine 0 CA--C 1.518 0.254 0 N-CA-C 114.763 0.665 . . . . 0.0 114.763 -178.591 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.741 HG22 HG13 ' A' ' 11' ' ' VAL . 13.0 tt -157.46 28.27 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-O 122.09 0.947 . . . . 0.0 110.192 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.22 53.4 44.94 Favored Glycine 0 CA--C 1.519 0.312 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.727 178.3 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.435 ' O ' HG12 ' A' ' 11' ' ' VAL . 27.8 m -148.94 126.53 5.65 Favored Pre-proline 0 C--N 1.323 -0.574 0 O-C-N 122.39 -0.476 . . . . 0.0 110.391 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 15' ' ' THR . 11.5 Cg_exo -70.17 126.38 12.98 Favored 'Trans proline' 0 N--CA 1.465 -0.205 0 C-N-CA 122.408 2.072 . . . . 0.0 111.752 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.3 pt -115.58 31.95 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.52 0.676 . . . . 0.0 110.655 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 11.2 p 179.23 148.31 0.23 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.825 -1.079 . . . . 0.0 109.543 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.582 ' HB2' ' N ' ' A' ' 4' ' ' GLY . 3.7 m-85 -147.43 164.19 34.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.688 0.28 . . . . 0.0 110.736 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.551 ' O ' ' HA3' ' A' ' 4' ' ' GLY . 29.4 m-85 -97.25 163.89 12.72 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.429 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.15 0 CA-C-O 117.751 -1.583 . . . . 0.0 110.998 179.105 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.444 ' N ' ' HB2' ' A' ' 18' ' ' SER . . . . . . . . 0 CA--C 1.52 0.388 0 N-CA-C 113.918 0.327 . . . . 0.0 113.918 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -120.38 -134.51 4.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.317 -0.944 . . . . 0.0 113.084 -179.097 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -132.99 52.63 2.07 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.093 0.473 . . . . 0.0 110.776 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -76.08 -121.96 0.16 Allowed Glycine 0 CA--C 1.519 0.317 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.633 179.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 44.9 m170 -122.15 -51.7 1.99 Allowed 'General case' 0 C--N 1.326 -0.448 0 O-C-N 122.465 -0.432 . . . . 0.0 111.296 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.566 HG23 ' CD1' ' A' ' 20' ' ' TYR . 4.4 m -89.63 132.88 35.57 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 110.194 -0.299 . . . . 0.0 110.194 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.4 ' HA ' ' O ' ' A' ' 18' ' ' SER . 14.5 Cg_endo -58.03 139.34 90.08 Favored 'Trans proline' 0 CA--C 1.53 0.314 0 C-N-CA 123.513 2.809 . . . . 0.0 114.484 -178.061 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.525 ' HG2' ' CD2' ' A' ' 20' ' ' TYR . 91.7 mt-10 -92.64 -69.97 0.72 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.065 178.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -121.82 144.43 48.83 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.292 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.492 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 4.6 m-85 -111.28 145.95 37.87 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.48 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 42.7 t -76.62 153.69 5.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 177.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -52.28 -26.6 21.93 Favored Glycine 0 C--O 1.227 -0.333 0 C-N-CA 121.485 -0.388 . . . . 0.0 113.763 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 5.0 mt -84.32 31.19 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 CA-C-O 121.283 0.563 . . . . 0.0 111.19 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 53.53 51.45 47.97 Favored Glycine 0 CA--C 1.521 0.428 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.842 178.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 26.9 m -144.62 123.74 7.0 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 122.332 -0.511 . . . . 0.0 111.048 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.492 ' HA ' ' HA ' ' A' ' 10' ' ' PHE . 39.9 Cg_endo -67.89 136.71 39.27 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.485 2.123 . . . . 0.0 111.916 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.423 ' O ' HG12 ' A' ' 17' ' ' ILE . 15.3 tt -129.93 34.07 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 122.227 1.013 . . . . 0.0 110.42 -179.528 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.444 ' HB2' ' N ' ' A' ' 1' ' ' GLY . 13.1 p 179.76 149.44 0.31 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.825 -1.08 . . . . 0.0 109.637 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -147.58 165.9 28.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.708 0.29 . . . . 0.0 110.386 -179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.566 ' CD1' HG23 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -158.24 -149.08 0.21 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.189 178.818 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.811 0 CA-C-O 118.68 -1.067 . . . . 0.0 110.668 179.883 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 CA-C-O 120.235 -0.203 . . . . 0.0 113.592 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.5 -120.54 1.49 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.36 -0.924 . . . . 0.0 112.81 -179.178 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -118.44 145.75 44.98 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.692 0.282 . . . . 0.0 110.62 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.21 -124.48 0.86 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.005 -179.651 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 70.5 m80 -133.29 -47.91 0.84 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.457 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 2.5 p -89.47 128.34 51.35 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.863 179.175 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.494 ' HB3' ' HG3' ' A' ' 16' ' ' PRO . 37.8 Cg_exo -58.77 137.89 82.6 Favored 'Trans proline' 0 N--CA 1.473 0.301 0 C-N-CA 123.443 2.762 . . . . 0.0 113.968 -178.37 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.472 ' HG2' ' CD1' ' A' ' 20' ' ' TYR . 91.8 mt-10 -89.73 -73.32 0.52 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.475 178.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -125.35 135.58 52.59 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.672 -179.704 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.486 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 2.7 m-85 -91.19 156.28 17.97 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.458 178.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.625 HG23 ' H ' ' A' ' 13' ' ' ILE . 35.1 m -120.38 -175.57 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 120.748 0.309 . . . . 0.0 110.854 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.05 -18.58 64.85 Favored Glycine 0 C--O 1.227 -0.305 0 CA-C-N 116.03 -0.532 . . . . 0.0 113.404 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.625 ' H ' HG23 ' A' ' 11' ' ' VAL . 6.0 mt -84.14 19.27 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 121.542 0.687 . . . . 0.0 111.022 -179.637 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.89 -44.03 0.82 Allowed Glycine 0 CA--C 1.521 0.42 0 CA-C-N 115.396 -0.82 . . . . 0.0 113.852 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.441 ' O ' HG22 ' A' ' 11' ' ' VAL . 10.0 t -88.47 137.58 30.53 Favored Pre-proline 0 C--N 1.32 -0.712 0 CA-C-O 121.097 0.475 . . . . 0.0 111.226 -179.012 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.494 ' HG3' ' HB3' ' A' ' 7' ' ' PRO . 59.7 Cg_endo -72.65 140.68 33.02 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.891 2.394 . . . . 0.0 111.971 179.83 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.2 mt -108.24 38.21 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 122.213 1.006 . . . . 0.0 109.173 179.416 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 23.8 p -167.9 143.82 3.93 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.381 179.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -147.15 174.16 11.84 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.453 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.472 ' CD1' ' HG2' ' A' ' 8' ' ' GLU . 20.6 p90 -158.75 -159.84 0.82 Allowed 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.076 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.899 0 CA-C-O 118.637 -1.09 . . . . 0.0 111.035 179.833 . . . . . . . . 0 0 . 1 stop_ save_